{\rtf1\deflang1033\deflangfe1033\margl720\margr720\margt360\margb360{\stylesheet{\fs20\lang1033\snext0 Normal;}
{\s1\sb240\keepn{\*\pn \pnlvl1\pndec\pnprev1\pnstart1\pnsp144}\b\f0\fs30\lang1033 \sbasedon0\snext0 heading 1;}
{\s2\sb200\keepn{\*\pn \pnlvl2\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs26\lang1033 \sbasedon0\snext0 heading 2;}
{\s3\sb180\keepn{\*\pn \pnlvl3\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 3;}
{\s4\sb160\keepn{\*\pn \pnlvl4\pnucltr\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 4;}
{\s5\sb140\keepn{\*\pn \pnlvl5\pncltr\pnprev1\pnstart1\pnsp144}\b\f0\fs20\lang1033 \sbasedon0\snext0 heading 5;}
{\s6\tqc\lang1033\sbasedon0\snext6 footer;}
{\*\cs16 \additive\super\sbasedon10 footnote reference;}
{\*\cs18 \additive\sbasedon10 page number;}}
{\fonttbl{\f0\fnil Times New Roman;}{\f1\fnil Courier New}{\f2005\fnil Courier New;}{\f2010\fnil Wingdings;}{\f2020\fnil Webdings;}{\f2\fnil Arial;}{\f3\fnil Arial;}{\f4\fnil LucidaHandwriting;}{\f5\fnil Symbol;}{\f6\fnil Symbol;}{\f7\fnil Ferdsch;}{\f30\fnil Myriad Cn Semibold;}{\f31\fnil Myriad Roman;}{\f50\fnil Courier New;}{\f51\fnil Times New Roman;}{\f52\fnil Arial;}{\f53\fnil Symbol;}{\f54\fnil Wingdings;}{\f55\fnil Wingdings 2;}{\f56\fnil Wingdings 3;}{\f57\fnil Webdings;}{\f58\fnil Arial Narrow;}{\f59\fnil Arial Unicode MS;}{\f60\fnil Cyberbit;}{\f61\fnil Morningstar 1U Light;}{\f62\fnil Calibri;}}
{\*\listtable{\list\listtemplateid1\listsimple1
{\listlevel\levelnfc23\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'00.}{\levelnumbers \'01}\f0\fs16\fi-360\li720}\listid1}
}
{\listoverridetable{\listoverride\listid1\listoverridecount1\ls1}}
{\colortbl;\red0\green0\blue0;\red127\green0\blue0;\red0\green0\blue255;\red127\green127\blue127;\red0\green51\blue153;\red255\green204\blue0;\red255\green255\blue255;\red246\green244\blue236;\red0\green0\blue0;\red255\green17\blue0;\red204\green238\blue255;\red1\green1\blue1;}
{\*\bkmkstart filing_1}{\*\bkmkend filing_1}{\*\bkmkstart doc_1_1}{\*\bkmkend doc_1_1}
\par\pard\plain\fs16\par\pard\plain\cf1\f51\fs20\ql Use these links to rapidly review the document
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001_table_of_contents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "fa48001_index_to_financial_state" }{\*\fldrslt\cf3\f51\fs20\ql Index to Financial Statements}}
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\b\qc As filed with the Securities and Exchange Commission on June\~30, 2014\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\qr Registration No.\~333-195169\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql \~
\par\pard\plain\fs16\par\pard\plain\f0\fs16\par\pard\plain\sa2200\cf1\f52\fs24\b\qc UNITED STATES
\par\pard\plain\fs16\pard\plain\cf1\f52\fs24\b\qc SECURITIES AND EXCHANGE COMMISSION
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc Washington, D.C. 20549\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\b\qc AMENDMENT NO. 3
\par\pard\plain\fs16\pard\plain\cf1\f52\fs20\b\qc TO
\par\pard\plain\fs16\pard\plain\cf1\f52\fs24\b\qc FORM\~S-1
\par\pard\plain\fs16\pard\plain\cf1\f52\fs20\b\qc REGISTRATION STATEMENT
\par\pard\plain\fs16\pard\plain\cf1\f52\fs20\b\qc UNDER
\par\pard\plain\fs16\pard\plain\cf1\f52\fs20\b\qc THE SECURITIES ACT OF\~1933\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs24\b\qc Minerva Neurosciences,\~Inc.
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\qc (Exact name of registrant as specified in its charter)\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16
\par\pard\plain
{\trowd\trqc\clvertalc\cellx3403\clvertalc\cellx3698\clvertalc\cellx7101\clvertalc\cellx7396\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx3403\clvertalc\cellx3698\clvertalc\cellx7101\clvertalc\cellx7396\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\trqc\cellx3403\cellx3698\cellx7101\cellx7396\cellx10799\trrh198
\pard\plain\intbl\cf1\f52\fs16\b\qc Delaware\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2834\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 26-0784194\cell{
{\trowd\trqc\cellx3403\cellx3698\cellx7101\cellx7396\cellx10799\trrh198\row}}}
{\trowd\trqc\cellx3403\cellx3698\cellx7101\cellx7396\cellx10799\trrh396
\pard\plain\intbl\cf1\f52\fs16\qc (State or other jurisdiction of
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\qc incorporation or organization)\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qc (Primary Standard Industrial
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\qc Classification Code Number)\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qc (I.R.S. Employer
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\qc Identification Number)\cell{
{\trowd\trqc\cellx3403\cellx3698\cellx7101\cellx7396\cellx10799\trrh396\row}}}
{\trowd\trqc\cellx10800\trrh1237
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc 245 First Street
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Suite\~1800
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Cambridge, MA 02142
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc (617)\~444-8444
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\qc (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)\cell{
{\trowd\trqc\cellx10800\trrh1237\row}}}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc Rogerio Vivaldi Coelho
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc Chief Executive Officer
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc 245 First Street
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc Suite\~1800
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc Cambridge, MA 02142
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc (617)\~444-8444
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\qc (Name, address, including zip code, and telephone number, including area code, of agent for service)\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\b\i\qc Copies to:
\par\pard\plain
{\trowd\trqc\clvertalc\cellx5248\clvertalc\cellx5552\clvertalc\cellx10800\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx5248\clvertalc\cellx5552\clvertalc\cellx10800\trrh-66\row}}}
{\trowd\trqc\cellx5248\cellx5552\cellx10800\trrh1386
\pard\plain\intbl\cf1\f52\fs16\b\qc David\~W. Pollak
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Denis Segota
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Morgan Lewis\~& Bockius\~LLP
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc 101 Park Avenue
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc New York, NY 10178
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc (212)\~309-6000\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc Nicole Brookshire
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Darren\~K. DeStefano
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Charles\~S. Kim
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Cooley\~LLP
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc 500 Boylston Street, 14th\~Floor
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Boston, MA 02116
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc (617)\~937-2300\cell{
{\trowd\trqc\cellx5248\cellx5552\cellx10800\trrh1386\row}}}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\ql Approximate date of commencement of proposed sale to the public:\plain\cf1\f52\fs16\ql \~\~\~\~As soon as practicable after the effective date of this Registration\plain\cf1\f52\fs16\ql Statement.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule\~415 under the\plain\cf1\f52\fs16\ql Securities Act of 1933, check the following box.\~\plain\cf1\f54\fs16\ql o\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If this Form is filed to register additional securities for an offering pursuant to Rule\~462(b) under the Securities Act, please check the following box\plain\cf1\f52\fs16\ql and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.\~\plain\cf1\f54\fs16\ql o\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If this Form is a post-effective amendment filed pursuant to Rule\~462(c) under the Securities Act, check the following box and list the Securities\plain\cf1\f52\fs16\ql Act registration statement number of the earlier effective registration statement for the same offering.\~\plain\cf1\f54\fs16\ql o\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If this Form is a post-effective amendment filed pursuant to Rule\~462(d) under the Securities Act, check the following box and list the Securities\plain\cf1\f52\fs16\ql Act registration statement number of the earlier effective registration statement for the same offering.\~\plain\cf1\f54\fs16\ql o\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting\plain\cf1\f52\fs16\ql company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule\~12b-2 of the Exchange Act.\plain\cf1\f52\fs16\ql (Check one):
\par\pard\plain
{\trowd\trqc\clvertalc\cellx7295\clvertalc\cellx7535\clvertalc\cellx10255\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7295\clvertalc\cellx7535\clvertalc\cellx10255\trrh-66\row}}}
{\trowd\trqc\cellx7295\cellx7535\cellx10255\trrh198
\pard\plain\intbl\cf1\f52\fs16\ql Large\~accelerated\~filer\~\plain\intbl\cf1\f54\fs16\ql o\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql Accelerated\~filer\~\plain\intbl\cf1\f54\fs16\ql o\cell{
{\trowd\trqc\cellx7295\cellx7535\cellx10255\trrh198\row}}}
{\trowd\trqc\cellx7295\cellx7535\cellx10255\trrh198
\pard\plain\intbl\cf1\f52\fs16\ql Non-accelerated\~filer\~\plain\intbl\cf1\f54\fs16\ql ý\plain\intbl\cf1\f52\fs16\ql (Do not check if a smaller reporting company)\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql Smaller\~reporting\~company\~\plain\intbl\cf1\f54\fs16\ql o\cell{
{\trowd\trqc\cellx7295\cellx7535\cellx10255\trrh198\row}}}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16{\*\bkmkstart part_1_2_1}{\*\bkmkend part_1_2_1}\pard\plain\cf1\f52\fs16\b\qc CALCULATION OF REGISTRATION FEE
\par\pard\plain
{\trowd\trqc\clvertalc\cellx932\clvertalc\cellx1192\clvertalc\cellx4352\clvertalc\cellx4612\clvertalc\cellx7772\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx932\clvertalc\cellx1192\clvertalc\cellx4352\clvertalc\cellx4612\clvertalc\cellx7772\trrh-66\row}}}
{\trowd\trqc\cellx932\cellx1192\clvertalb\cellx4352\clvertalb\cellx4612\clvertalb\cellx7772\trrh198
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\cellx932\cellx1192\clvertalb\cellx4352\clvertalb\cellx4612\clvertalb\cellx7772\trrh198\row}}}
{\trowd\trqc\clbrdrb\brdrdb\brdrcf1\cellx7776\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clbrdrb\brdrdb\brdrcf1\cellx7776\trrh37\row}}}
{\trowd\trqc\clvertalb\cellx932\clvertalb\cellx1192\clvertalb\cellx4352\clvertalb\cellx4612\clvertalb\cellx7772\trrh1237
\pard\plain\intbl\cf1\f52\fs16\b\qc Title of\plain\intbl\cf1\f52\fs16\b\qc Each Class\plain\intbl\cf1\f52\fs16\b\qc of
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Securities\plain\intbl\cf1\f52\fs16\b\qc to be\plain\intbl\cf1\f52\fs16\b\qc Registered
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc Proposed Maximum
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Aggregate
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Offering Price\plain\intbl\cf1\f52\fs12\b\qc (1)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc Amount of
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc Registration Fee\plain\intbl\cf1\f52\fs12\b\qc (2)(3)
\par\pard\plain\intbl\fs16\cell{
{\trowd\trqc\clvertalb\cellx932\clvertalb\cellx1192\clvertalb\cellx4352\clvertalb\cellx4612\clvertalb\cellx7772\trrh1237\row}}}
{\trowd\trqc\clbrdrb\brdrs\brdrcf1\cellx7776\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clbrdrb\brdrs\brdrcf1\cellx7776\trrh37\row}}}
{\trowd\trqc\cellx932\cellx1192\clvertalb\cellx4352\clvertalb\cellx4612\clvertalb\cellx7772\trrh990
\pard\plain\intbl\li176\fi-176\cf1\f52\fs16\ql Common\plain\intbl\li176\cf1\f52\fs16\ql Stock,\plain\intbl\li176\cf1\f52\fs16\ql $0.0001\plain\intbl\li176\cf1\f52\fs16\ql par value\plain\intbl\li176\cf1\f52\fs16\ql per share\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qc $37,636,362\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qc $4,848\cell{
{\trowd\trqc\cellx932\cellx1192\clvertalb\cellx4352\clvertalb\cellx4612\clvertalb\cellx7772\trrh990\row}}}
{\trowd\trqc\clbrdrb\brdrdb\brdrcf1\cellx7776\trrh37
\pard\plain\intbl\li176\fi-176\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clbrdrb\brdrdb\brdrcf1\cellx7776\trrh37\row}}}\pard\plain\li440\ri220\sb220\sa220\cf1\f52\fs12\i\ql (1)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql Estimated solely for the purpose of calculating the registration fee pursuant to Rule\~457(o) under the Securities Act of\plain\li440\ri220\cf1\f52\fs16\ql 1933. Includes the offering price of any additional shares that the underwriters have the option to purchase.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li440\ri220\cf1\f52\fs12\i\ql (2)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql Calculated pursuant to Rule\~457(o) based on an estimate of the proposed maximum aggregate offering price.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li440\ri220\cf1\f52\fs12\i\ql (3)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql The Registrant previously paid an aggregate of $9,696 in connection with this Registration Statement.\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\b\ql The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until\plain\cf1\f52\fs16\b\ql the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective\plain\cf1\f52\fs16\b\ql in accordance with Section\~8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as\plain\cf1\f52\fs16\b\ql the Commission, acting pursuant to said Section\~8(a), may determine.\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf10\f52\fs16\ql The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration\plain\cf10\f52\fs16\ql statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek\plain\cf10\f52\fs16\ql an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.\par\pard\plain\f0\fs16\par\pard\plain\cf10\f52\fs16\qr SUBJECT TO COMPLETION, DATED JUNE\~30, 2014.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql PRELIMINARY PROSPECTUS\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs24\b\qc 5,454,545 Shares\par\qc{\*\shppict{\pict\jpegblip\picw321\pich84\picscalex300\picscaley300\bliptag-515732923
{\*\blipuid 7523af176f0da29d69fcb24c8f1bd3f3}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}}
\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs24\b\qc Common Stock\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\ql We are offering 5,454,545 shares of our common stock. This is our initial public offering and no public market currently exists for our\plain\cf1\f52\fs16\ql common stock. We expect the initial public offering price to be $6.00 per share.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our common stock has been approved for listing on The NASDAQ Global Market under the symbol "NERV." We are an "emerging growth\plain\cf1\f52\fs16\ql company" as defined by the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced\plain\cf1\f52\fs16\ql public company reporting requirements for this prospectus and future filings. Please see "Prospectus Summary\~\u8212? Implications of Being\plain\cf1\f52\fs16\ql an Emerging Growth Company."\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Investing in our common stock involves a high degree of risk. Please read "Risk Factors" beginning on page\~10 of this prospectus.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these\plain\cf1\f52\fs16\b\ql securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1889\clvertalc\cellx2288\clvertalc\cellx2770\clvertalc\cellx4109\clvertalc\cellx4508\clvertalc\cellx4944\clvertalc\cellx6723\clvertalc\cellx7122\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1889\clvertalc\cellx2288\clvertalc\cellx2770\clvertalc\cellx4109\clvertalc\cellx4508\clvertalc\cellx4944\clvertalc\cellx6723\clvertalc\cellx7122\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1889\clvertalb\cellx2288\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4110\clvertalb\cellx4509\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6725\clvertalb\cellx7124\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc PER SHARE\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc TOTAL\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1889\clvertalb\cellx2288\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4110\clvertalb\cellx4509\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6725\clvertalb\cellx7124\trrh248\row}}}
{\trowd\trqc\clvertalb\cellx1889\clvertalb\cellx2288\clvertalb\cellx2770\clvertalb\cellx4109\clvertalb\cellx4508\clvertalb\cellx4944\clvertalb\cellx6723\clvertalb\cellx7122\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Public Offering Price\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx1889\clvertalb\cellx2288\clvertalb\cellx2770\clvertalb\cellx4109\clvertalb\cellx4508\clvertalb\cellx4944\clvertalb\cellx6723\clvertalb\cellx7122\trrh206\row}}}
{\trowd\trqc\clvertalb\cellx1889\clvertalb\cellx2288\clvertalb\cellx2770\clvertalb\cellx4109\clvertalb\cellx4508\clvertalb\cellx4944\clvertalb\cellx6723\clvertalb\cellx7122\trrh413
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Underwriting Discounts\plain\intbl\li198\cf1\f52\fs16\ql and Commissions\plain\intbl\li198\cf1\f52\fs11\ql\super (1)\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx1889\clvertalb\cellx2288\clvertalb\cellx2770\clvertalb\cellx4109\clvertalb\cellx4508\clvertalb\cellx4944\clvertalb\cellx6723\clvertalb\cellx7122\trrh413\row}}}
{\trowd\trqc\clvertalb\cellx1889\clvertalb\cellx2288\clvertalb\cellx2770\clvertalb\cellx4109\clvertalb\cellx4508\clvertalb\cellx4944\clvertalb\cellx6723\clvertalb\cellx7122\trrh619
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Proceeds to Minerva\plain\intbl\li198\cf1\f52\fs16\ql Neurosciences,\~Inc.\plain\intbl\li198\cf1\f52\fs16\ql Before Expenses\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx1889\clvertalb\cellx2288\clvertalb\cellx2770\clvertalb\cellx4109\clvertalb\cellx4508\clvertalb\cellx4944\clvertalb\cellx6723\clvertalb\cellx7122\trrh619\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\li528\ri264\sb264\sa264\cf1\f52\fs12\i\ql (1)\par\pard\plain\li528\ri264\cf1\f52\fs16\ql The underwriters will also be reimbursed for certain expenses incurred in this offering. The table does not reflect additional fees of\plain\li528\ri264\cf1\f52\fs16\ql approximately $280,000 that we will pay the underwriters at the closing of this offering in connection with their advisory services relating\plain\li528\ri264\cf1\f52\fs16\ql to private placements that will be completed concurrently with this offering. See the section of this prospectus titled "Underwriting" for\plain\li528\ri264\cf1\f52\fs16\ql details.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Certain of our existing stockholders have indicated an interest in purchasing up to an aggregate of approximately $16\~million of shares of our\plain\cf1\f52\fs16\ql common stock in this offering at the initial public offering price. However, because indications of interest are not binding agreements or\plain\cf1\f52\fs16\ql commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any of these stockholders. In\plain\cf1\f52\fs16\ql addition, any of these stockholders may determine to purchase more, less or no shares in this offering. The underwriters will receive the\plain\cf1\f52\fs16\ql same underwriting discounts and commissions on any shares purchased by these stockholders as they will on any other shares sold to the\plain\cf1\f52\fs16\ql public in this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Delivery of the shares of common stock is expected to be made on or about\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~, 2014. We have granted the underwriters an\plain\cf1\f52\fs16\ql option for a period of 30\~days to purchase an additional 818,182 shares of our common stock. If the underwriters exercise the option in full,\plain\cf1\f52\fs16\ql the total underwriting discounts and commissions payable by us will be $\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~, and the total proceeds to us, before expenses, will be\plain\cf1\f52\fs16\ql $\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\qc Sole Book-Running Manager\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs24\b\qc Jefferies\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\qc Co-Managers\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs24\b\qc Baird\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~ \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~JMP Securities\par\pard\plain\f0\fs16\par\pard\plain\li396\cf1\f52\fs16\ql \~\~\~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc Prospectus dated\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~ \~\~\~, 2014.\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_bg48001_1_1}{\*\bkmkend gmnh1page_bg48001_1_1}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart bg48001_table_of_contents}{\*\bkmkend bg48001_table_of_contents}{\*\bkmkstart BG48001A_main_toc}{\*\bkmkend BG48001A_main_toc}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\cf1\f52\fs16\b\ql Table of Contents{\*\bkmkstart BG48001_TOC}{\*\bkmkend BG48001_TOC}
\par\pard\plain
{\trowd\trqc\clvertalc\cellx3384\clvertalc\cellx5449\clvertalc\cellx7774\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx3384\clvertalc\cellx5449\clvertalc\cellx7774\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx3384\clvertalb\cellx5449\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7774\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc Page\cell{
{\trowd\trqc\clvertalb\cellx3384\clvertalb\cellx5449\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7774\trrh248\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "ca48001_prospectus_summary" }{\*\fldrslt\cf3\f52\fs16\ql Prospectus Summary}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "ca48001_prospectus_summary" }{\*\fldrslt\cf3\f52\fs16\qr 1}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "co48001_risk_factors" }{\*\fldrslt\cf3\f52\fs16\ql Risk Factors}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "co48001_risk_factors" }{\*\fldrslt\cf3\f52\fs16\qr 10}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh412
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "da48001_special_note_regarding_f" }{\*\fldrslt\cf3\f52\fs16\ql Special Note Regarding Forward-Looking}}\plain\intbl\li198\ul{\field{\*\fldinst HYPERLINK \\l "da48001_special_note_regarding_f" }{\*\fldrslt\cf3\f52\fs16\ql Statements}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "da48001_special_note_regarding_f" }{\*\fldrslt\cf3\f52\fs16\qr 51}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh412\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "da48001_use_of_proceeds" }{\*\fldrslt\cf3\f52\fs16\ql Use of Proceeds}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "da48001_use_of_proceeds" }{\*\fldrslt\cf3\f52\fs16\qr 53}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "da48001_dividend_policy" }{\*\fldrslt\cf3\f52\fs16\ql Dividend Policy}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "da48001_dividend_policy" }{\*\fldrslt\cf3\f52\fs16\qr 54}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "dc48001_capitalization" }{\*\fldrslt\cf3\f52\fs16\ql Capitalization}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "dc48001_capitalization" }{\*\fldrslt\cf3\f52\fs16\qr 55}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "dc48001_dilution" }{\*\fldrslt\cf3\f52\fs16\ql Dilution}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "dc48001_dilution" }{\*\fldrslt\cf3\f52\fs16\qr 57}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "de48001_selected_historical_fina" }{\*\fldrslt\cf3\f52\fs16\ql Selected Historical Financial Data}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "de48001_selected_historical_fina" }{\*\fldrslt\cf3\f52\fs16\qr 60}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh412
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "dg48001_unaudited_pro_forma_co__" }{\*\fldrslt\cf3\f52\fs16\ql Unaudited Pro Forma Condensed}}\plain\intbl\li198\ul{\field{\*\fldinst HYPERLINK \\l "dg48001_unaudited_pro_forma_co__" }{\*\fldrslt\cf3\f52\fs16\ql Combined Financial Statements}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "dg48001_unaudited_pro_forma_co__" }{\*\fldrslt\cf3\f52\fs16\qr 62}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh412\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh619
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "dm48001_management_s_discussion_" }{\*\fldrslt\cf3\f52\fs16\ql Management's Discussion and Analysis of}}\plain\intbl\li198\ul{\field{\*\fldinst HYPERLINK \\l "dm48001_management_s_discussion_" }{\*\fldrslt\cf3\f52\fs16\ql Financial Condition and Results of}}\plain\intbl\li198\ul{\field{\*\fldinst HYPERLINK \\l "dm48001_management_s_discussion_" }{\*\fldrslt\cf3\f52\fs16\ql Operations}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "dm48001_management_s_discussion_" }{\*\fldrslt\cf3\f52\fs16\qr 66}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh619\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "ds48001_business" }{\*\fldrslt\cf3\f52\fs16\ql Business}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "ds48001_business" }{\*\fldrslt\cf3\f52\fs16\qr 92}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "eg48001_management" }{\*\fldrslt\cf3\f52\fs16\ql Management}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "eg48001_management" }{\*\fldrslt\cf3\f52\fs16\qr 145}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "ei48001_executive_and_director_c" }{\*\fldrslt\cf3\f52\fs16\ql Executive and Director Compensation}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "ei48001_executive_and_director_c" }{\*\fldrslt\cf3\f52\fs16\qr 152}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh413
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "ek48001_certain_relationships_an" }{\*\fldrslt\cf3\f52\fs16\ql Certain Relationships and Related Party}}\plain\intbl\li198\ul{\field{\*\fldinst HYPERLINK \\l "ek48001_certain_relationships_an" }{\*\fldrslt\cf3\f52\fs16\ql Transactions}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "ek48001_certain_relationships_an" }{\*\fldrslt\cf3\f52\fs16\qr 162}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh413\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "em48001_principal_stockholders" }{\*\fldrslt\cf3\f52\fs16\ql Principal Stockholders}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "em48001_principal_stockholders" }{\*\fldrslt\cf3\f52\fs16\qr 167}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "em48001_description_of_capital_s" }{\*\fldrslt\cf3\f52\fs16\ql Description of Capital Stock}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "em48001_description_of_capital_s" }{\*\fldrslt\cf3\f52\fs16\qr 170}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "eo48001_shares_eligible_for_futu" }{\*\fldrslt\cf3\f52\fs16\ql Shares Eligible for Future Sale}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "eo48001_shares_eligible_for_futu" }{\*\fldrslt\cf3\f52\fs16\qr 175}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh619
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "eo48001_material_u_s__federal_in" }{\*\fldrslt\cf3\f52\fs16\ql Material U.S. Federal Income Tax}}\plain\intbl\li198\ul{\field{\*\fldinst HYPERLINK \\l "eo48001_material_u_s__federal_in" }{\*\fldrslt\cf3\f52\fs16\ql Considerations for Non-U.S. Holders of}}\plain\intbl\li198\ul{\field{\*\fldinst HYPERLINK \\l "eo48001_material_u_s__federal_in" }{\*\fldrslt\cf3\f52\fs16\ql Common Stock}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "eo48001_material_u_s__federal_in" }{\*\fldrslt\cf3\f52\fs16\qr 177}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh619\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "eq48001_underwriting" }{\*\fldrslt\cf3\f52\fs16\ql Underwriting}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "eq48001_underwriting" }{\*\fldrslt\cf3\f52\fs16\qr 181}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "eq48001_legal_matters" }{\*\fldrslt\cf3\f52\fs16\ql Legal Matters}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "eq48001_legal_matters" }{\*\fldrslt\cf3\f52\fs16\qr 190}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "eq48001_experts" }{\*\fldrslt\cf3\f52\fs16\ql Experts}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "eq48001_experts" }{\*\fldrslt\cf3\f52\fs16\qr 190}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "eq48001_where_you_can_find_addit" }{\*\fldrslt\cf3\f52\fs16\ql Where You Can Find Additional Information}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "eq48001_where_you_can_find_addit" }{\*\fldrslt\cf3\f52\fs16\qr 191}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206
\pard\plain\intbl\li198\fi-198\ul{\field{\*\fldinst HYPERLINK \\l "lk1" }{\*\fldrslt\cf3\f52\fs16\ql Index to Financial Statements}}\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "lk1" }{\*\fldrslt\cf3\f52\fs16\qr F-1}}\cell{
{\trowd\trqc\cellx3384\cellx5449\clvertalb\cellx7774\trrh206\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\sa220\cf1\f52\fs16\ql Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those\plain\cf1\f52\fs16\ql contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and\plain\cf1\f52\fs16\ql can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the\plain\cf1\f52\fs16\ql shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information\plain\cf1\f52\fs16\ql contained in this prospectus is current only as of its date.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Through and including\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~, 2014 (the 25th\~day after the date of this prospectus), all dealers effecting transactions in\plain\cf1\f52\fs16\b\ql these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a\plain\cf1\f52\fs16\b\ql dealer's obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Persons who come into possession of this prospectus and any such free writing prospectus in jurisdictions outside the United States are\plain\cf1\f52\fs16\ql required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such\plain\cf1\f52\fs16\ql free writing prospectus applicable to that jurisdiction.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc i\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_ca48001_1_1}{\*\bkmkend gmnh1page_ca48001_1_1}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql \~
\par\pard\plain\fs16{\*\bkmkstart ca48001_prospectus_summary}{\*\bkmkend ca48001_prospectus_summary}{\*\bkmkstart toc_ca48001_1}{\*\bkmkend toc_ca48001_1}
\par\pard\plain\fs16{\*\bkmkstart item_1_3_1}{\*\bkmkend item_1_3_1}\pard\plain\li264\ri264\sb264\cf1\f52\fs16\b\qc PROSPECTUS SUMMARY
\par\pard\plain\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\i\ql The following summary highlights information contained elsewhere in this prospectus and is qualified in its entirety by the more\plain\li264\ri264\cf1\f52\fs16\i\ql detailed information and financial statements included elsewhere in this prospectus. This summary does not contain all of the\plain\li264\ri264\cf1\f52\fs16\i\ql information you should consider before investing in our common stock. Before you decide to invest in our common stock, you should\plain\li264\ri264\cf1\f52\fs16\i\ql read and carefully consider the following summary together with the entire prospectus, including the financial statements and the\plain\li264\ri264\cf1\f52\fs16\i\ql related notes thereto appearing elsewhere in this prospectus and the matters discussed in the sections in this prospectus entitled\plain\li264\ri264\cf1\f52\fs16\i\ql "Risk Factors," "Selected Historical Financial Data," "Unaudited Pro Forma Condensed Combined Financial Statements" and\plain\li264\ri264\cf1\f52\fs16\i\ql "Management's Discussion and Analysis of Financial Condition and Results of Operations." Some of the statements in this prospectus\plain\li264\ri264\cf1\f52\fs16\i\ql constitute forward-looking statements that involve risks and uncertainties. See "Special Note Regarding Forward-Looking Statements."\plain\li264\ri264\cf1\f52\fs16\i\ql Our actual results could differ materially from those anticipated in such forward-looking statements as a result of certain factors,\plain\li264\ri264\sa22\cf1\f52\fs16\i\ql including those discussed in the "Risk Factors" and other sections of this prospectus.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\b\ql Company Overview\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product\plain\li264\ri264\cf1\f52\fs16\ql candidates to treat patients suffering from central nervous system, or CNS, diseases. Leveraging our domain expertise, we have\plain\li264\ri264\cf1\f52\fs16\ql acquired or in-licensed four development-stage proprietary compounds that we believe have innovative mechanisms of action with\plain\li264\ri264\cf1\f52\fs16\ql potentially positive therapeutic profiles. Our lead product candidates are MIN-101, a compound we are developing for the treatment of\plain\li264\ri264\cf1\f52\fs16\ql patients with schizophrenia, and MIN-117, a compound for the potential treatment of patients suffering from major depressive\plain\li264\ri264\cf1\f52\fs16\ql disorder, or MDD. In addition, our portfolio includes MIN-202, a compound we are co-developing for the treatment of patients\plain\li264\ri264\cf1\f52\fs16\ql suffering from primary and secondary insomnia, and MIN-301, a compound we are developing for the treatment of patients suffering\plain\li264\ri264\cf1\f52\fs16\ql from Parkinson's disease. We believe our innovative product candidates have significant potential to transform the lives of a large\plain\li264\ri264\cf1\f52\fs16\ql number of affected patients and their families who are currently not well-served by available therapies in each of their respective\plain\li264\ri264\sa22\cf1\f52\fs16\ql indications.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql We plan to develop and, if approved by the applicable regulatory authorities, commercialize our product candidates for the\plain\li264\ri264\cf1\f52\fs16\ql neuropsychiatric pharmaceutical market, which represents a significant portion of the broader CNS therapeutic area. Neuropsychiatry\plain\li264\ri264\cf1\f52\fs16\ql is a medical subspecialty devoted to understanding and treating cognitive, emotional, behavioral and perceptual symptoms resulting\plain\li264\ri264\cf1\f52\fs16\ql from circuit-specific brain dysfunction and includes the study of the diseases we are presently targeting, namely schizophrenia, MDD,\plain\li264\ri264\cf1\f52\fs16\ql insomnia and Parkinson's disease. These neuropsychiatric diseases affect large numbers of individuals with family members also\plain\li264\ri264\cf1\f52\fs16\ql bearing significant burdens. According to Datamonitor, an independent market research firm, 4.7\~million people suffer from\plain\li264\ri264\cf1\f52\fs16\ql schizophrenia, 32\~million suffer from MDD, 53\~million suffer from insomnia and more than 2.4\~million suffer from Parkinson's disease in\plain\li264\ri264\sa22\cf1\f52\fs16\ql the United States, Japan and the five major European Union markets of France, Germany, Italy, Spain and the United Kingdom.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql While there are numerous available therapies in the market for the treatment of the neuropsychiatric diseases we are targeting, each\plain\li264\ri264\cf1\f52\fs16\ql of these therapies has significant limitations in addressing the needs of patients. We have pursued the development of our product\plain\li264\ri264\cf1\f52\fs16\ql candidates based on our deep knowledge of the pathophysiology of neuropsychiatric diseases, the pharmacology of our portfolio of\plain\li264\ri264\cf1\f52\fs16\ql compounds and the limitations of current therapies. We believe our product candidates each represent a differentiated treatment\plain\li264\ri264\sa22\cf1\f52\fs16\ql option that could overcome the limitations of current therapies and address the unmet needs of patients and their families.\par\pard\plain\f0\fs16\par\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 1\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_ca48001_1_2}{\*\bkmkend gmnh1page_ca48001_1_2}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\qc\li264\ri264\sb264\sa22{\*\shppict{\pict\jpegblip\picw619\pich348\picscalex375\picscaley375\bliptag-515732923
{\*\blipuid 7523af176f0da29d69fcb24c8f1bd3f3}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}}
\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\ql Our product candidates include:\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\b\i\ql MIN-101\plain\li264\ri264\cf1\f52\fs16\ql , an innovative molecule behaving as an antagonist of 5-HT2A and sigma2 receptors, which we are\plain\li264\ri264\cf1\f52\fs16\ql developing for the treatment of patients with schizophrenia. Most current therapies are geared primarily towards\plain\li264\ri264\cf1\f52\fs16\ql treating positive symptoms, such as hallucinations, delusions, and thought and movement disorders. However,\plain\li264\ri264\cf1\f52\fs16\ql positive symptoms are often experienced only periodically in an individual with schizophrenia while negative\plain\li264\ri264\cf1\f52\fs16\ql symptoms, such as mood flatness, lack of pleasure in daily life, or decreased ability to initiate and maintain social\plain\li264\ri264\cf1\f52\fs16\ql interaction, persist chronically throughout an individual's lifetime and increase with severity over time. According to\plain\li264\ri264\cf1\f52\fs16\ql Datamonitor, in 2012 within the United States and the five major European Union markets, 4.2\~million patients\plain\li264\ri264\cf1\f52\fs16\ql suffered from schizophrenia, leading to a $3.9\~billion drug market, with 48% of patients predominantly suffering\plain\li264\ri264\cf1\f52\fs16\ql from negative symptoms. Unlike current therapies, we believe, at its anticipated dose and dosing schedule,\plain\li264\ri264\cf1\f52\fs16\ql MIN-101, due to its particular pharmacological profile, has the potential to address negative symptoms as well as\plain\li264\ri264\cf1\f52\fs16\ql the positive and cognitive symptoms of the disease, sleep disorders, and overall psychopathology, without many of\plain\li264\ri264\cf1\f52\fs16\ql the typical side effects associated with existing therapies. If approved, we believe MIN-101 would be a\plain\li264\ri264\cf1\f52\fs16\ql first-in-class compound for the treatment of negative symptoms. We intend to seek approval for MIN-101 initially\plain\li264\ri264\cf1\f52\fs16\ql as a first line monotherapy and also plan to study its use as an adjunctive therapy. We believe that MIN-101 could\plain\li264\ri264\cf1\f52\fs16\ql address the existing treated population and those who are not being treated successfully with the currently\plain\li264\ri264\cf1\f52\fs16\ql available therapies. In a Phase\~IIa clinical trial, a statistically significant improvement of negative symptoms and a\plain\li264\ri264\cf1\f52\fs16\ql non-statistically significant trend toward the improvement of positive and cognitive symptoms and overall\plain\li264\ri264\cf1\f52\fs16\ql psychopathology was observed after three months of administration of MIN-101 in a twice-a-day formulation. The\plain\li264\ri264\cf1\f52\fs16\ql trial also showed that MIN-101 could have sleep promoting effects in contrast to currently available therapies and\plain\li264\ri264\cf1\f52\fs16\ql had no negative impact on sleep as measured by polysomnography. We plan to initiate a small clinical trial in the\plain\li264\ri264\cf1\f52\fs16\ql second quarter of 2014 to confirm prior Phase\~I results, using a once a day formulation, in preparation for\plain\li264\ri264\cf1\f52\fs16\ql conducting a Phase\~IIb clinical trial of MIN-101 in Europe in the fourth quarter of 2014.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\b\i\ql MIN-117\plain\li264\ri264\cf1\f52\fs16\ql , an innovative molecule behaving mainly as an antagonist on 5-HT1A receptors and as an inhibitor of\plain\li264\ri264\cf1\f52\fs16\ql both serotonin and dopamine reuptake, which we are developing for the treatment of patients with MDD. MDD is\plain\li264\ri264\cf1\f52\fs16\ql the most prominent subtype and a severe form of depression, with 6% of MDD patients committing suicide.\plain\li264\ri264\cf1\f52\fs16\ql According to Datamonitor, it is estimated that up to 30% of\par\pard\plain\f0\fs16\par\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 2\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_ca48001_1_3}{\*\bkmkend gmnh1page_ca48001_1_3}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql people will experience an episode of MDD at some point in their life, and there are currently 30\~million cases in\plain\li264\ri264\cf1\f52\fs16\ql the United States and the five major European Union markets. Datamonitor estimated that sales of drugs for\plain\li264\ri264\cf1\f52\fs16\ql depression totaled $5.2\~billion across the United States and the five major European Union markets in 2012. We\plain\li264\ri264\cf1\f52\fs16\ql believe that existing therapies do not address all of the needs of the MDD patient population and a large number\plain\li264\ri264\cf1\f52\fs16\ql of patients fail to respond or only partially respond to existing treatment options. Due to their mechanisms of\plain\li264\ri264\cf1\f52\fs16\ql action, some current treatment options take up to four weeks to have a noticeable effect, which can expose\plain\li264\ri264\cf1\f52\fs16\ql patients to a period of vulnerability during which they are at most risk of committing suicide. In addition, currently\plain\li264\ri264\cf1\f52\fs16\ql available therapies have several side effects, including cognitive impairment, sexual dysfunction and sleep\plain\li264\ri264\cf1\f52\fs16\ql disorders, that lead many patients to discontinue therapy. We believe that the results of two Phase\~I clinical trials\plain\li264\ri264\cf1\f52\fs16\ql of MIN-117 in healthy subjects that explored doses higher than the anticipated therapeutic dose, and pre-clinical\plain\li264\ri264\cf1\f52\fs16\ql studies suggest that many of the typical side effects commonly experienced by patients taking existing\plain\li264\ri264\cf1\f52\fs16\ql pharmaceutical treatments for MDD may not be associated with MIN-117 at therapeutic dose levels. Based on a\plain\li264\ri264\cf1\f52\fs16\ql Phase\~I clinical trial, MIN-117 may have a positive effect on sleep, a potential biomarker for drug efficacy for MDD,\plain\li264\ri264\cf1\f52\fs16\ql suggesting the utility of further study for the treatment of MDD. Subject to the receipt of additional financing, we\plain\li264\ri264\cf1\f52\fs16\ql plan to conduct additional clinical trials of MIN-117. We also plan to explore the potential for a collaboration for the\plain\li264\ri264\sa22\cf1\f52\fs16\ql future clinical development and commercialization of MIN-117 for the treatment of MDD.\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\b\i\ql MIN-202,\plain\li264\ri264\cf1\f52\fs16\ql an innovative molecule acting as a selective orexin\~2 receptor antagonist, which we are co-developing\plain\li264\ri264\cf1\f52\fs16\ql for the treatment of patients with insomnia. Insomnia can be the primary condition for patients or a secondary\plain\li264\ri264\cf1\f52\fs16\ql symptom of another medical or psychiatric condition, such as MDD or schizophrenia. Datamonitor estimated sales\plain\li264\ri264\cf1\f52\fs16\ql of drugs for insomnia totaled $2.7\~billion across the United States, Japan and five major European Union markets\plain\li264\ri264\cf1\f52\fs16\ql in 2012. We intend to evaluate MIN-202 as a treatment in primary insomnia as well as secondary insomnia as an\plain\li264\ri264\cf1\f52\fs16\ql adjunctive therapy with an antidepressant for the treatment of mood disorders. Unlike many current therapies that\plain\li264\ri264\cf1\f52\fs16\ql activate sleep-promoting neurotransmitters, MIN-202 is specifically targeted towards inhibiting the activity of the\plain\li264\ri264\cf1\f52\fs16\ql neurons that promote wakefulness. We believe this approach is likely to result in better preservation of\plain\li264\ri264\cf1\f52\fs16\ql physiological and restorative sleep with improved safety and tolerability than currently available therapies that can\plain\li264\ri264\cf1\f52\fs16\ql cause daytime sedation and cognitive impairment. The results of a Phase\~I single ascending dose trial for MIN-202\plain\li264\ri264\cf1\f52\fs16\ql suggested a relationship which supports a rapid induction and promotion of sleepiness. We are co-developing\plain\li264\ri264\cf1\f52\fs16\ql MIN-202 with Janssen Pharmaceutica N.V., a Johnson\~& Johnson company, or Janssen. Pursuant to our\plain\li264\ri264\cf1\f52\fs16\ql agreement with Janssen, upon the completion of this offering, we will own the exclusive rights to develop and\plain\li264\ri264\cf1\f52\fs16\ql commercialize the compound in the European Union, subject to royalty payments to Janssen, and have royalty\plain\li264\ri264\cf1\f52\fs16\ql rights for any sales outside the European Union. In conjunction with Janssen, we plan to conduct two Phase\~Ib\plain\li264\ri264\cf1\f52\fs16\ql clinical trials of MIN-202 in 2014 in Europe, the first of which has been submitted to the necessary regulatory and\plain\li264\ri264\cf1\f52\fs16\ql ethical approval authorities in the European Union so that subject enrollment may begin.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\b\i\ql MIN-301\plain\li264\ri264\cf1\f52\fs16\ql , a soluble recombinant form of the Neuregulin-1\plain\li264\ri264\cf1\f53\fs16\ql b\plain\li264\ri264\cf1\f52\fs16\ql 1, or NRG-1\plain\li264\ri264\cf1\f53\fs16\ql b\plain\li264\ri264\cf1\f52\fs16\ql 1, protein, which we are developing for\plain\li264\ri264\cf1\f52\fs16\ql the treatment of patients with Parkinson's disease. We believe MIN-301 has the potential to slow the onset of, and\plain\li264\ri264\cf1\f52\fs16\ql restore the brain functions damaged by, Parkinson's disease. According to Datamonitor, there were nearly 800,000\plain\li264\ri264\cf1\f52\fs16\ql cases in the United States, and Parkinson's disease was identified as the 14th\~leading cause of death by the\plain\li264\ri264\cf1\f52\fs16\ql Centers for Disease Control and Prevention in 2011. According to Decision Resources, approximately $2.3\~billion of\plain\li264\ri264\cf1\f52\fs16\ql drug sales were related to Parkinson's disease in the United States, Japan and the five major European Union\plain\li264\ri264\cf1\f52\fs16\ql markets in 2012. Current treatments for Parkinson's disease improve the symptoms of patients, but none have\plain\li264\ri264\cf1\f52\fs16\ql been proven to delay the onset of the disease, slow or prevent the progression of the disease or reverse its\plain\li264\ri264\cf1\f52\fs16\ql effects. Due to MIN-301's novel mechanism of action that targets the cause of neurological deficits, we believe it\plain\li264\ri264\cf1\f52\fs16\ql has the potential to address these unmet needs of patients and, if approved for marketing, may be used as an\plain\li264\ri264\cf1\f52\fs16\ql early-stage monotherapy as well as a complementary therapy to existing treatments. Currently, we are conducting\plain\li264\ri264\cf1\f52\fs16\ql material scale-up for Investigational New Drug (IND)-enabling studies. We will need to obtain additional funding to\plain\li264\ri264\cf1\f52\fs16\ql initiate human trials of MIN-301.\par\pard\plain\f0\fs16\par\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 3\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_ca48001_1_4}{\*\bkmkend gmnh1page_ca48001_1_4}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\b\ql Our Strategy\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql Our strategy is to develop and, if approved by the applicable regulatory authorities, commercialize products with transformative\plain\li264\ri264\cf1\f52\fs16\ql potential addressing critical unmet medical needs in the neuropsychiatric therapeutic area. Pursuing our strategy will be based on the\plain\li264\ri264\cf1\f52\fs16\ql following principles: unwavering commitment to neuropsychiatric patients and community; scientific rigor applied to drug development\plain\li264\ri264\cf1\f52\fs16\ql and the clinical trial process; leveraging patient and caregiver insights to drive scientific advancements; and integrity. Key elements of\plain\li264\ri264\sa22\cf1\f52\fs16\ql our strategy are:\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Advance the clinical development and obtain regulatory approval of our current product candidates.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current\plain\li264\ri264\cf1\f52\fs16\ql product candidate portfolio.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Serve the patient community with a cost-effective commercial infrastructure upon any approval of a product\plain\li264\ri264\cf1\f52\fs16\ql candidate.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Leverage our management team's expertise and current intellectual property portfolio to identify and explore\plain\li264\ri264\cf1\f52\fs16\ql additional indications relating to our current portfolio of compounds and to acquire additional product candidates.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\b\ql Risks Associated with our Business\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are\plain\li264\ri264\sa22\cf1\f52\fs16\ql discussed more fully in the "Risk Factors" section of this prospectus. These risks include the following:\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql We have incurred significant losses since our inception. We expect to continue to incur losses over the next\plain\li264\ri264\cf1\f52\fs16\ql several years and may never achieve or maintain profitability, which, among other things, raises doubt about our\plain\li264\ri264\cf1\f52\fs16\ql ability to continue as a going concern.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql We will require additional capital to finance our operations, which may not be available to us on acceptable terms,\plain\li264\ri264\cf1\f52\fs16\ql or at all. As a result, we may not complete the development and commercialization of our product candidates or\plain\li264\ri264\cf1\f52\fs16\ql develop new product candidates.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql We are heavily dependent on the success of our two lead product candidates and we cannot give any assurance\plain\li264\ri264\cf1\f52\fs16\ql that any of our product candidates will receive regulatory approval in a timely manner or at all, which is necessary\plain\li264\ri264\cf1\f52\fs16\ql before they can be commercialized.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Our clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which could\plain\li264\ri264\cf1\f52\fs16\ql prevent or delay regulatory approval and commercialization, and also increase costs.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql If we experience delays in clinical testing, we will be delayed in commercializing our product candidates, our costs\plain\li264\ri264\cf1\f52\fs16\ql may increase and our business may be harmed.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql If we are unable to enroll subjects in clinical trials, we will be unable to complete these trials on a timely basis or\plain\li264\ri264\cf1\f52\fs16\ql at all.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql We are in the process of combining several corporate entities and assets into our company, which will increase our\plain\li264\ri264\cf1\f52\fs16\ql infrastructure and reporting burden.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql We have no experience in advancing product candidates beyond Phase\~IIa, which makes it difficult to assess our\plain\li264\ri264\cf1\f52\fs16\ql ability to develop and commercialize our product candidates.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize\plain\li264\ri264\cf1\f52\fs16\ql on product candidates or indications that may be more profitable or for which there is a greater likelihood of\plain\li264\ri264\cf1\f52\fs16\ql success.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql We face substantial competition, which may result in others discovering, developing or commercializing products\plain\li264\ri264\cf1\f52\fs16\ql before or more successfully than us.\par\pard\plain\f0\fs16\par\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 4\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_ca48001_1_5}{\*\bkmkend gmnh1page_ca48001_1_5}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql If the market opportunities for any product that we or our collaborators develop are smaller than we believe they\plain\li264\ri264\cf1\f52\fs16\ql are, our revenue may be adversely affected and our business may suffer.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql We have identified material weaknesses and significant deficiencies in our internal control over financial reporting,\plain\li264\ri264\cf1\f52\fs16\ql which increases the risk of material misstatements in our future financial statements.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\b\ql Corporate Information\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql We were incorporated under the name Cyrenaic Pharmaceuticals,\~Inc. under the laws of the State of Delaware on April\~23, 2007. In\plain\li264\ri264\cf1\f52\fs16\ql November 2013, we merged with Sonkei Pharmaceuticals,\~Inc. and the combined company was renamed Minerva Neurosciences,\~Inc.\plain\li264\ri264\cf1\f52\fs16\ql As a result of the merger, or the Sonkei Merger, we have the rights to develop, sell and import MIN-101 and MIN-117 globally,\plain\li264\ri264\cf1\f52\fs16\ql excluding most of Asia, pursuant to license agreements with Mitsubishi Tanabe Pharma Corporation. We further expanded our product\plain\li264\ri264\cf1\f52\fs16\ql candidate portfolio in February 2014 by acquiring the shares of Mind-NRG\~SA, or Mind-NRG, which has exclusive rights to develop\plain\li264\ri264\cf1\f52\fs16\ql and commercialize MIN-301, or the Mind-NRG Acquisition. In addition, in February 2014, we entered into a co-development and\plain\li264\ri264\cf1\f52\fs16\ql license agreement with Janssen for European Union development and commercialization rights to MIN-202, which is subject to the\plain\li264\ri264\sa22\cf1\f52\fs16\ql completion of this offering.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql Our principal executive offices are located at 245 First Street, Suite\~1800, Cambridge, MA 02142 and our phone number is\plain\li264\ri264\cf1\f52\fs16\ql (617)\~444-8444. Our website address is www.minervaneurosciences.com. The information contained on our website is not\plain\li264\ri264\cf1\f52\fs16\ql incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed\plain\li264\ri264\sa22\cf1\f52\fs16\ql through, our website as part of this prospectus or in deciding whether to purchase our common stock.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\b\ql Implications of Being an Emerging Growth Company\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql As a company with less than $1\~billion in revenue during our last fiscal year, we qualify as an "emerging growth company" as defined\plain\li264\ri264\cf1\f52\fs16\ql in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we\plain\li264\ri264\cf1\f52\fs16\ql are permitted and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies\plain\li264\ri264\sa22\cf1\f52\fs16\ql that are not emerging growth companies. These exemptions include:\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Being permitted to provide only two years of audited financial statements, in addition to any required unaudited\plain\li264\ri264\cf1\f52\fs16\ql interim financial statements, with correspondingly reduced "Management's Discussion and Analysis of Financial\plain\li264\ri264\cf1\f52\fs16\ql Condition and Results of Operations" disclosure;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Not being required to comply with the auditor attestation requirements in the assessment of our internal control\plain\li264\ri264\cf1\f52\fs16\ql over financial reporting;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Not being required to comply with any requirement that may be adopted by the Public Company Accounting\plain\li264\ri264\cf1\f52\fs16\ql Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional\plain\li264\ri264\cf1\f52\fs16\ql information about the audit and the financial statements;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Reduced disclosure obligations regarding executive compensation; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql Exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and\plain\li264\ri264\cf1\f52\fs16\ql shareholder approval of any golden parachute payments not previously approved.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth\plain\li264\ri264\cf1\f52\fs16\ql company. We would cease to be an emerging growth company if we have more than $1\~billion in annual revenue, have more than\plain\li264\ri264\cf1\f52\fs16\ql $700\~million in market value of our capital stock held by non-affiliates or issue more than $1\~billion of non-convertible debt over a\plain\li264\ri264\cf1\f52\fs16\ql three-year period. We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of\plain\li264\ri264\cf1\f52\fs16\ql some reduced reporting burdens in this prospectus. Accordingly, the information contained herein may be different than the\plain\li264\ri264\sa22\cf1\f52\fs16\ql information you receive from other public companies in which you hold stock.\par\pard\plain\f0\fs16\par\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 5\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cc48001_1_6}{\*\bkmkend gmnh1page_cc48001_1_6}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql \~
\par\pard\plain\fs16{\*\bkmkstart cc48001_the_offering}{\*\bkmkend cc48001_the_offering}{\*\bkmkstart toc_cc48001_1}{\*\bkmkend toc_cc48001_1}
\par\pard\plain\fs16\pard\plain\li264\ri264\sb264\cf1\f52\fs16\b\qc The Offering
\par\pard\plain\fs16
\par\pard\plain
{\trowd\trqc\clvertalc\cellx4360\clvertalc\cellx4720\clvertalc\cellx10280\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx4360\clvertalc\cellx4720\clvertalc\cellx10280\trrh-66\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Common stock offered by us\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql 5,454,545\~shares\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh206\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh476
\pard\plain\intbl\li198\sb264\fi-198\cf1\f52\fs16\ql Common stock to be outstanding after this offering\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\sb264\cf1\f52\fs16\ql 18,278,084\~shares\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh476\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh889
\pard\plain\intbl\li198\sb264\fi-198\cf1\f52\fs16\ql Option to purchase additional shares\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\sb264\cf1\f52\fs16\ql We have granted the underwriters an option for a period of 30\~days\plain\intbl\cf1\f52\fs16\ql from the date of this prospectus to purchase up to 818,182 additional\plain\intbl\cf1\f52\fs16\ql shares of our common stock.\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh889\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh1095
\pard\plain\intbl\li198\sb264\fi-198\cf1\f52\fs16\ql Use of proceeds\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\sb264\cf1\f52\fs16\ql We estimate that our net proceeds from this offering will be\plain\intbl\cf1\f52\fs16\ql approximately $26.9\~million, assuming an initial public offering price of\plain\intbl\cf1\f52\fs16\ql $6.00\~per share, after deducting estimated underwriting discounts and\plain\intbl\cf1\f52\fs16\ql commissions and estimated offering expenses payable by us.\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh1095\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh1508
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\sb264\cf1\f52\fs16\ql We expect to use the net proceeds from this offering to fund part of the\plain\intbl\cf1\f52\fs16\ql continued clinical development of MIN-101 and MIN-202 and\plain\intbl\cf1\f52\fs16\ql pre-clinical development of MIN-301. We intend to use the remaining\plain\intbl\cf1\f52\fs16\ql net proceeds from this offering to satisfy certain contractual obligations\plain\intbl\cf1\f52\fs16\ql and for working capital and other general corporate purposes. See "Use\plain\intbl\cf1\f52\fs16\ql of Proceeds" for additional information.\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh1508\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh889
\pard\plain\intbl\li198\sb264\fi-198\cf1\f52\fs16\ql Risk factors\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\sb264\cf1\f52\fs16\ql See "Risk Factors" beginning on page\~10 and the other information\plain\intbl\cf1\f52\fs16\ql included in this prospectus for a discussion of factors you should\plain\intbl\cf1\f52\fs16\ql carefully consider before deciding to invest in our common stock.\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh889\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh476
\pard\plain\intbl\li198\sb264\fi-198\cf1\f52\fs16\ql NASDAQ Global Market symbol\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\sb264\cf1\f52\fs16\ql "NERV"\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh476\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh2539
\pard\plain\intbl\li198\sb264\fi-198\cf1\f52\fs16\ql Directed share program\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\sb264\cf1\f52\fs16\ql At our request, the underwriters have reserved up to 272,727 shares of\plain\intbl\cf1\f52\fs16\ql our common stock offered by this prospectus for sale, at the initial\plain\intbl\cf1\f52\fs16\ql public offering price, to our directors and officers and certain other\plain\intbl\cf1\f52\fs16\ql parties related to us. Shares purchased by our directors and officers will\plain\intbl\cf1\f52\fs16\ql be subject to the 180-day lock-up restriction described in the\plain\intbl\cf1\f52\fs16\ql "Underwriting" section of this prospectus. The number of shares of\plain\intbl\cf1\f52\fs16\ql common stock available for sale to the general public will be reduced to\plain\intbl\cf1\f52\fs16\ql the extent these individuals purchase such reserved shares. Any\plain\intbl\cf1\f52\fs16\ql reserved shares that are not so purchased will be offered by the\plain\intbl\cf1\f52\fs16\ql underwriters to the general public on the same basis as the other\plain\intbl\cf1\f52\fs16\ql shares offered by this prospectus.\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh2539\row}}}
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh2126
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\sb264\cf1\f52\fs16\ql Separate from the directed share program, certain of our existing\plain\intbl\cf1\f52\fs16\ql stockholders have indicated an interest in purchasing up to an\plain\intbl\cf1\f52\fs16\ql aggregate of approximately $16\~million of shares of our common stock\plain\intbl\cf1\f52\fs16\ql in this offering at the initial public offering price. However, because\plain\intbl\cf1\f52\fs16\ql indications of interest are not binding agreements or commitments to\plain\intbl\cf1\f52\fs16\ql purchase, the underwriters may determine to sell more, less or no\plain\intbl\cf1\f52\fs16\ql shares in this offering to any of these stockholders. In addition, any of\plain\intbl\cf1\f52\fs16\ql these stockholders may determine to purchase more, less or no shares\plain\intbl\cf1\f52\fs16\ql in this offering.\cell{
{\trowd\trqc\cellx4360\cellx4720\clvertalb\cellx10280\trrh2126\row}}}\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 6\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cc48001_1_7}{\*\bkmkend gmnh1page_cc48001_1_7}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql The number of shares of our common stock outstanding immediately after this offering is based on (i)\~8,520,925 shares of common\plain\li264\ri264\cf1\f52\fs16\ql stock outstanding as of June\~10, 2014, (ii)\~the shares to be issued in this offering and (iii)\~an estimated 4,302,614 shares to be issued\plain\li264\ri264\sa22\cf1\f52\fs16\ql in a series of transactions that we expect to occur concurrently with and/or upon completion of this offering, but excludes:\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql 646,759\~shares of common stock issuable upon the exercise of options outstanding as of June\~10, 2014, with an\plain\li264\ri264\cf1\f52\fs16\ql exercise price of $9.49\~per share; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql 2,896,995\~shares of common stock reserved for future issuance under our Amended and Restated 2013 Equity\plain\li264\ri264\cf1\f52\fs16\ql Incentive Plan, as well as any automatic increases in the number of shares of our common stock reserved for\plain\li264\ri264\cf1\f52\fs16\ql future issuance under the plan.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\ql Unless otherwise indicated, all information in this prospectus:\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql assumes no exercise by the underwriters of their option to purchase up to 818,182 shares of our common stock in\plain\li264\ri264\cf1\f52\fs16\ql this offering;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql reflects the conversion of outstanding convertible promissory notes in principal amounts of $1.3\~million issued in\plain\li264\ri264\cf1\f52\fs16\ql November 2013 and \u8364?0.5\~million (or $0.7\~million, as converted) assumed in connection with the Sonkei\plain\li264\ri264\cf1\f52\fs16\ql Merger in November 2013, collectively referred to as the 2013 Notes, including accrued interest thereon, into an\plain\li264\ri264\cf1\f52\fs16\ql aggregate of 351,595 shares of common stock upon the closing of this offering, at the initial public offering price;\plain\li264\ri264\cf1\f52\fs16\ql for purposes of this prospectus, assuming an initial public offering price of $6.00 per share, and a closing date of\plain\li264\ri264\cf1\f52\fs16\ql June\~30, 2014;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql assumes the sale of $19.7\~million of our common stock to Johnson\~& Johnson Development Corporation, or JJDC,\plain\li264\ri264\cf1\f52\fs16\ql an affiliate of Janssen, or 3,284,353 shares, in a private placement concurrent with the closing of this offering at\plain\li264\ri264\cf1\f52\fs16\ql the initial public offering price; for purposes of this prospectus, assuming an initial public offering price of $6.00 per\plain\li264\ri264\cf1\f52\fs16\ql share, and our subsequent upfront payment of $22.0\~million to Janssen in connection with the co-development and\plain\li264\ri264\cf1\f52\fs16\ql license agreement that will become effective upon the closing of this offering, collectively referred to as the\plain\li264\ri264\cf1\f52\fs16\ql Janssen Transactions;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql assumes the sale of $4.0\~million of our common stock to certain former shareholders of Mind-NRG, or 666,666\plain\li264\ri264\cf1\f52\fs16\ql shares, in a private placement concurrent with the closing of this offering, at the initial public offering price; for\plain\li264\ri264\cf1\f52\fs16\ql purposes of this prospectus, assuming an initial public offering price of $6.00 per share;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql assumes no exercise of outstanding options after June\~10, 2014;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql except where otherwise noted, reflects the acquisition of the license to intellectual property rights to MIN-202 under\plain\li264\ri264\cf1\f52\fs16\ql the co-development and license agreement with Janssen, which will become effective upon the closing of this\plain\li264\ri264\cf1\f52\fs16\ql offering; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li264\ri264\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\li264\ri264\cf1\f52\fs16\ql gives effect to the 1-for-3.5 reverse stock split of our common stock effected on June\~9, 2014.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql Except as otherwise noted, all amounts referred to in this prospectus as "$\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~, as converted" shall mean the U.S. dollar amount\plain\li264\ri264\sa22\cf1\f52\fs16\ql applying the conversion rate from the Euro as of March\~31, 2014 which was 1.3652.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql Certain of our existing stockholders have indicated an interest in purchasing up to an aggregate of approximately $16\~million of shares\plain\li264\ri264\cf1\f52\fs16\ql of our common stock in this offering at the initial public offering price. However, because indications of interest are not binding\plain\li264\ri264\cf1\f52\fs16\ql agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any of\plain\li264\ri264\sa22\cf1\f52\fs16\ql these stockholders. In addition, any of these stockholders may determine to purchase more, less or no shares in this offering.\par\pard\plain\f0\fs16\par\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 7\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_ce48001_1_8}{\*\bkmkend gmnh1page_ce48001_1_8}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql \~
\par\pard\plain\fs16{\*\bkmkstart ce48001_summary_historical_finan}{\*\bkmkend ce48001_summary_historical_finan}{\*\bkmkstart toc_ce48001_1}{\*\bkmkend toc_ce48001_1}
\par\pard\plain\fs16\pard\plain\li264\ri264\sb264\cf1\f52\fs16\b\qc Summary Historical Financial Data
\par\pard\plain\fs16\par\pard\plain\li264\ri264\sb264\sa22\cf1\f52\fs16\ql The following tables summarize our historical financial data and our pro forma condensed combined financial information and should\plain\li264\ri264\cf1\f52\fs16\ql be read together with "Selected Historical Financial Data," Unaudited Pro Forma Condensed Combined Financial Statements,"\plain\li264\ri264\cf1\f52\fs16\ql "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the historical financial statements and\plain\li264\ri264\sa22\cf1\f52\fs16\ql related notes, each of which are included elsewhere in this prospectus.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql We have derived our statements of operations data for the two years ended December\~31, 2012 and 2013 from our audited financial\plain\li264\ri264\cf1\f52\fs16\ql statements included elsewhere in this prospectus. We have derived our statements of operations data for the three months ended\plain\li264\ri264\cf1\f52\fs16\ql March\~31, 2013 and 2014 and the summary balance sheet data as of March\~31, 2014 from our unaudited interim financial statements\plain\li264\ri264\cf1\f52\fs16\ql included elsewhere in this prospectus. The summary historical results set forth below are not necessarily indicative of results to be\plain\li264\ri264\sa22\cf1\f52\fs16\ql expected for any future period.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql The unaudited pro forma condensed combined statements of operations data for the year ended December\~31, 2013 includes our\plain\li264\ri264\cf1\f52\fs16\ql historical results of operations, after giving pro forma effect to the Sonkei Merger and the Mind-NRG Acquisition, as if they occurred\plain\li264\ri264\cf1\f52\fs16\ql on January\~1, 2013. The unaudited pro forma condensed combined statements of operations data for the three months ended\plain\li264\ri264\cf1\f52\fs16\ql March\~31, 2014 includes our historical results of operations, after giving pro forma effect to the Mind-NRG Acquisition, as if it\plain\li264\ri264\cf1\f52\fs16\ql occurred on January\~1, 2013. The unaudited supplemental pro forma condensed balance sheet data as of March\~31, 2014 gives pro\plain\li264\ri264\cf1\f52\fs16\ql forma effect to (i)\~the repayment of $0.5\~million of debt incurred in connection with the Mind-NRG Acquisition, plus all accrued interest\plain\li264\ri264\cf1\f52\fs16\ql thereon payable to certain stockholders in April 2014, (ii)\~the incurrence of a $0.6\~million loan payable to certain of our stockholders\plain\li264\ri264\cf1\f52\fs16\ql and their affiliates in April, or the April Bridge Loan, and (iii)\~the incurrence of a $1.0\~million loan payable to certain of our\plain\li264\ri264\cf1\f52\fs16\ql stockholders and their affiliates in May, or the May Bridge Loan. As of June\~10, 2014, we have drawn down $0.5\~million under the\plain\li264\ri264\sa22\cf1\f52\fs16\ql May Bridge Loan, however, we expect to draw down the remaining $0.5\~million prior to the closing of this offering.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql The summary unaudited pro forma as adjusted condensed combined balance sheet data gives pro forma effect to (i)\~the conversion\plain\li264\ri264\cf1\f52\fs16\ql of the 2013 Notes, including accrued interest thereon, into an aggregate of 351,595 shares of common stock upon the closing of this\plain\li264\ri264\cf1\f52\fs16\ql offering at an assumed initial public offering price of $6.00 per share and an assumed closing date of June\~30, 2014, (ii)\~the\plain\li264\ri264\cf1\f52\fs16\ql repayment of the April Bridge Loan plus all accrued interest thereon, in connection with the closing of this offering, assuming a\plain\li264\ri264\cf1\f52\fs16\ql closing date of June\~30, 2014, (iii)\~the repayment of $1.0\~million relating to the May Bridge Loan plus all accrued interest, in\plain\li264\ri264\cf1\f52\fs16\ql connection with the closing of this offering, assuming a closing date of June\~30, 2014, (iv)\~the payment of a \u8364?0.5\~million (or\plain\li264\ri264\cf1\f52\fs16\ql $0.7\~million, as converted) license payment with respect to MIN-301 to ProteoSys SA, or ProteoSys, that is payable in connection\plain\li264\ri264\cf1\f52\fs16\ql with the closing of this offering, or the ProteoSys License Fee, (v)\~the purchase of 3,284,353 shares of our common stock by JJDC in\plain\li264\ri264\cf1\f52\fs16\ql a private placement concurrent with the closing of this offering at an assumed price of $6.00 per share, the assumed initial public\plain\li264\ri264\cf1\f52\fs16\ql offering price set forth on the cover page of this prospectus, for an aggregate of $19.7\~million, and our subsequent payment of\plain\li264\ri264\cf1\f52\fs16\ql $22.0\~million to Janssen, pursuant to the co-development and license agreement with Janssen, (vi)\~the purchase of 666,666 shares of\plain\li264\ri264\cf1\f52\fs16\ql our common stock by certain former stockholders of Mind-NRG in a private placement concurrent with the closing of this offering at\plain\li264\ri264\cf1\f52\fs16\ql an assumed price of $6.00 per share, the assumed initial public offering price set forth on the cover page of this prospectus, for an\plain\li264\ri264\cf1\f52\fs16\ql aggregate of $4.0\~million, and (vii)\~the sale of 5,454,545 shares of common stock in this offering at an assumed initial public offering\plain\li264\ri264\sa22\cf1\f52\fs16\ql price of $6.00 per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses.\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql The summary unaudited pro forma condensed combined financial data is for informational purposes only and does not purport to\plain\li264\ri264\sa22\cf1\f52\fs16\ql represent what our results of operations would have been if the Sonkei Merger or\par\pard\plain\f0\fs16\par\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 8\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_ce48001_1_9}{\*\bkmkend gmnh1page_ce48001_1_9}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\li264\ri264\sb264\cf1\f52\fs16\ql Mind-NRG Acquisition had occurred as of those dates or what those results will be for future periods. We cannot assure you that the\plain\li264\ri264\cf1\f52\fs16\ql assumptions used by our management, which they believe are reasonable, for preparation of the summary unaudited pro forma\plain\li264\ri264\sa22\cf1\f52\fs16\ql condensed combined financial data will prove to be correct.\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx580\clvertalc\cellx812\clvertalc\cellx1044\clvertalc\cellx1276\clvertalc\cellx1508\clvertalc\cellx1740\clvertalc\cellx1972\clvertalc\cellx2204\clvertalc\cellx2436\clvertalc\cellx2668\clvertalc\cellx2900\clvertalc\cellx3132\clvertalc\cellx3364\clvertalc\cellx3596\clvertalc\cellx3828\clvertalc\cellx4060\clvertalc\cellx4292\clvertalc\cellx4524\clvertalc\cellx4756\clvertalc\cellx4988\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx580\clvertalc\cellx812\clvertalc\cellx1044\clvertalc\cellx1276\clvertalc\cellx1508\clvertalc\cellx1740\clvertalc\cellx1972\clvertalc\cellx2204\clvertalc\cellx2436\clvertalc\cellx2668\clvertalc\cellx2900\clvertalc\cellx3132\clvertalc\cellx3364\clvertalc\cellx3596\clvertalc\cellx3828\clvertalc\cellx4060\clvertalc\cellx4292\clvertalc\cellx4524\clvertalc\cellx4756\clvertalc\cellx4988\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx580\clvertalb\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1974\clvertalb\cellx2206\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2670\clvertalb\cellx2902\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4064\clvertalb\cellx4296\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4760\clvertalb\cellx4992\trrh235
\pard\plain\intbl\cf1\f52\fs4\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc YEARS ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc DECEMBER 31,\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc PRO FORMA FOR
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc YEAR ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc DECEMBER\~31,\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc THREE MONTHS
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc MARCH\~31,\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc PRO FORMA FOR
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc THREE MONTHS
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc MARCH\~31,\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx580\clvertalb\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1974\clvertalb\cellx2206\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2670\clvertalb\cellx2902\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4064\clvertalb\cellx4296\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4760\clvertalb\cellx4992\trrh235\row}}}
{\trowd\trqc\clvertalb\cellx580\clvertalb\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1276\clvertalb\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1972\clvertalb\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2668\clvertalb\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3364\clvertalb\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4060\clvertalb\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4756\clvertalb\cellx4988\trrh74
\pard\plain\intbl\cf1\f52\fs4\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc 2012\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc 2014\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc 2014\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx580\clvertalb\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1276\clvertalb\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1972\clvertalb\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2668\clvertalb\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3364\clvertalb\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4060\clvertalb\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4756\clvertalb\cellx4988\trrh74\row}}}
{\trowd\trqc\clvertalb\cellx580\clvertalb\cellx812\clvertalb\cellx4763\clvertalb\cellx4995\trrh74
\pard\plain\intbl\cf1\f52\fs4\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc (in thousands, except share and per share data)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx580\clvertalb\cellx812\clvertalb\cellx4763\clvertalb\cellx4995\trrh74\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh118
\pard\plain\intbl\li176\fi-44\cf1\f52\fs4\b\ql Statement of Operations\plain\intbl\li176\cf1\f52\fs4\b\ql Data:\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh118\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh59
\pard\plain\intbl\li352\fi-44\cf1\f52\fs4\ql Expenses:\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh59\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh118
\pard\plain\intbl\li528\fi-44\cf1\f52\fs4\ql Research and\plain\intbl\li528\cf1\f52\fs4\ql development\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 550\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 708\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 2,297\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 104\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 586\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 737\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh118\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh118
\pard\plain\intbl\li528\fi-44\cf1\f52\fs4\ql General and\plain\intbl\li528\cf1\f52\fs4\ql administrative\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 1,031\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 2,467\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 3,179\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 167\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 2,037\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 2,339\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh118\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh11
\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh11\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh74
\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh74\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh59
\pard\plain\intbl\li528\fi-44\cf1\f52\fs4\ql Total expenses\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 1,581\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 3,175\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 5,476\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 271\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 2,623\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 3,076\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh59\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh177
\pard\plain\intbl\li352\fi-44\cf1\f52\fs4\ql Foreign exchange\plain\intbl\li352\cf1\f52\fs4\ql (gains)/losses and\plain\intbl\li352\cf1\f52\fs4\ql other, net\~\~\~\~\~\~\~\~\~\~\~\~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 1\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 29\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr (7\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 7\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 7\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh177\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh118
\pard\plain\intbl\li352\fi-44\cf1\f52\fs4\ql Interest expense\plain\intbl\li352\cf1\f52\fs4\ql (income), net\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 58\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 72\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 308\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 308\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh118\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh11
\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh11\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh74
\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh74\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh59
\pard\plain\intbl\li528\fi-44\cf1\f52\fs4\ql Net loss\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (1,582\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (3,262\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (5,541\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (271\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (2,938\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (3,391\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh59\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh11
\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh11\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh74
\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh74\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh74
\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs5\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh74\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh11
\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh11\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh59
\pard\plain\intbl\li198\fi-44\cf1\f52\fs4\b\ql Per Share Data:\plain\intbl\li198\cf1\f52\fs3\b\ql (1)\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh59\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh177
\pard\plain\intbl\li352\fi-44\cf1\f52\fs4\ql Net loss per\plain\intbl\li352\cf1\f52\fs4\ql share\~\u8212? basic\plain\intbl\li352\cf1\f52\fs4\ql and diluted\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (0.47\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (0.78\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (0.75\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (0.08\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (0.43\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (0.45\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx580\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx812\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1044\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1276\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1508\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1740\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2204\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2436\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2668\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2900\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3364\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3596\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3828\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4060\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4292\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4524\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4756\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4988\trrh177\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh177
\pard\plain\intbl\li352\fi-44\cf1\f52\fs4\ql Weighted average shares\plain\intbl\li352\cf1\f52\fs4\ql outstanding\~\u8212?\plain\intbl\li352\cf1\f52\fs4\ql basic and diluted\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 3,386,914\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 4,186,104\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 7,396,760\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 3,562,454\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 6,902,910\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 7,594,321\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx580\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1044\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1276\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1508\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1740\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2204\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2436\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2668\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2900\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3364\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3828\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4060\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4292\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4524\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4756\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4988\trrh177\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\li440\ri220\sb220\sa220\cf1\f52\fs12\i\ql (1)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql Per share data excludes 926,604 shares of common stock held by one of our stockholders that are not considered outstanding\plain\li440\ri220\cf1\f52\fs16\ql for accounting purposes for the periods presented. See "Management's Discussion and Analysis\~\u8212? Share Repurchase in\plain\li440\ri220\cf1\f52\fs16\ql Settlement of Nonrecourse Notes."\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1183\clvertalc\cellx1842\clvertalc\cellx2568\clvertalc\cellx3227\clvertalc\cellx3886\clvertalc\cellx4612\clvertalc\cellx5271\clvertalc\cellx5930\clvertalc\cellx6656\clvertalc\cellx7315\clvertalc\cellx7974\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1183\clvertalc\cellx1842\clvertalc\cellx2568\clvertalc\cellx3227\clvertalc\cellx3886\clvertalc\cellx4612\clvertalc\cellx5271\clvertalc\cellx5930\clvertalc\cellx6656\clvertalc\cellx7315\clvertalc\cellx7974\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1183\clvertalb\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7319\clvertalb\cellx7978\trrh209
\pard\plain\intbl\cf1\f52\fs13\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs13\b\qc MARCH\~31, 2014\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1183\clvertalb\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7319\clvertalb\cellx7978\trrh209\row}}}
{\trowd\trqc\clvertalb\cellx1183\clvertalb\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3228\clvertalb\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5273\clvertalb\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7318\clvertalb\cellx7977\trrh334
\pard\plain\intbl\cf1\f52\fs13\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs13\b\qc ACTUAL\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs13\b\qc SUPPLEMENTAL
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc PRO FORMA\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs13\b\qc PRO FORMA
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc AS ADJUSTED\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1183\clvertalb\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3228\clvertalb\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5273\clvertalb\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7318\clvertalb\cellx7977\trrh334\row}}}
{\trowd\trqc\clvertalb\cellx1183\clvertalb\cellx1842\clvertalb\cellx7319\clvertalb\cellx7978\trrh209
\pard\plain\intbl\cf1\f52\fs13\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs13\b\qc (in thousands)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1183\clvertalb\cellx1842\clvertalb\cellx7319\clvertalb\cellx7978\trrh209\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh334
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\b\ql Balance Sheet\plain\intbl\li176\cf1\f52\fs13\b\ql Data:\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh334\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh334
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\ql Cash and cash\plain\intbl\li176\cf1\f52\fs13\ql equivalents\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 2,141\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 3,234\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 29,508\cell\pard\plain\intbl\cf1\f52\fs10\ql (1)\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh334\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh501
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\ql In-process\plain\intbl\li176\cf1\f52\fs13\ql research and\plain\intbl\li176\cf1\f52\fs13\ql development\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 34,200\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 34,200\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 34,200\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh501\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh167
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\ql Goodwill\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 15,104\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 15,104\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 15,104\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh167\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh501
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\ql Other current and\plain\intbl\li176\cf1\f52\fs13\ql long-term\plain\intbl\li176\cf1\f52\fs13\ql assets\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 1,693\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 1,693\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 77\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh501\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209
\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh167
\pard\plain\intbl\li352\fi-132\cf1\f52\fs13\ql Total assets\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 53,138\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 54,231\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 78,889\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh167\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh668
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\ql Accounts payable,\plain\intbl\li176\cf1\f52\fs13\ql accrued\plain\intbl\li176\cf1\f52\fs13\ql expenses and\plain\intbl\li176\cf1\f52\fs13\ql other liabilities\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 4,551\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 4,551\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 2,180\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh668\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh668
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\ql Convertible\plain\intbl\li176\cf1\f52\fs13\ql promissory\plain\intbl\li176\cf1\f52\fs13\ql notes, net of\plain\intbl\li176\cf1\f52\fs13\ql discount\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 333\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 333\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh668\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh167
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\ql Loans payable\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 500\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 1,600\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh167\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh334
\pard\plain\intbl\li176\fi-132\cf1\f52\fs13\ql Deferred tax\plain\intbl\li176\cf1\f52\fs13\ql liability\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 13,669\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 13,669\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 13,669\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh334\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209
\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh167
\pard\plain\intbl\li352\fi-132\cf1\f52\fs13\ql Total liabilities\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 19,053\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 20,153\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 15,849\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh167\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh501
\pard\plain\intbl\li352\fi-132\cf1\f52\fs13\ql Total\plain\intbl\li352\cf1\f52\fs13\ql stockholders'\plain\intbl\li352\cf1\f52\fs13\ql equity\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 34,085\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 34,078\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 63,040\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh501\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209
\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh668
\pard\plain\intbl\li352\fi-132\cf1\f52\fs13\ql Total liabilities\plain\intbl\li352\cf1\f52\fs13\ql and\plain\intbl\li352\cf1\f52\fs13\ql stockholders'\plain\intbl\li352\cf1\f52\fs13\ql equity\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 53,138\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 54,231\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 78,889\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1183\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1842\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2568\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3227\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3886\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4612\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5930\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7315\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7974\trrh668\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209
\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209
\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs16\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2568\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3227\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3886\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4612\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5271\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5930\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7315\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7974\trrh209\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1183\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1842\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3228\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3887\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5273\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5932\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7318\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7977\trrh31\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\li440\ri220\sb220\sa220\cf1\f52\fs12\i\ql (1)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql Pro forma as adjusted cash and cash equivalents includes the net proceeds of $26.9\~million from the sale of shares in this\plain\li440\ri220\cf1\f52\fs16\ql offering, plus proceeds from the concurrent private placement transactions of $23.7\~million, less the $22\~million payment to\plain\li440\ri220\cf1\f52\fs16\ql Janssen pursuant to the co-development and license agreement with Janssen, the payment of the ProteoSys License fee of\plain\li440\ri220\cf1\f52\fs16\ql approximately $0.7\~million and the repayment of $1.6\~million in loans, assuming $0.5\~million to be drawn down prior to the closing\plain\li440\ri220\cf1\f52\fs16\ql of this offering.\par\pard\plain\f0\fs16\par\pard\plain\brdrb\brdrs\li264\ri264\sb264\sa22\cf1\f52\fs2\ql \~\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 9\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_co48001_1_10}{\*\bkmkend gmnh1page_co48001_1_10}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart co48001_risk_factors}{\*\bkmkend co48001_risk_factors}{\*\bkmkstart toc_co48001_1}{\*\bkmkend toc_co48001_1}
\par\pard\plain\fs16{\*\bkmkstart item_1_3_2}{\*\bkmkend item_1_3_2}\pard\plain\cf1\f52\fs16\b\qc RISK FACTORS
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\i\ql Investing in our common stock involves a high degree of risk. Before you invest in our common stock, you should carefully consider the\plain\cf1\f52\fs16\i\ql following risks, as well as general economic and business risks, and all of the other information contained in this prospectus. Any of the\plain\cf1\f52\fs16\i\ql following risks could have a material adverse effect on our business, operating results and financial condition and cause the trading price of\plain\cf1\f52\fs16\i\ql our common stock to decline, which would cause you to lose all or part of your investment. When determining whether to invest, you should\plain\cf1\f52\fs16\i\ql also refer to the other information contained in this prospectus, including our financial statements and the related notes thereto.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Risks Related to Our Financial Position and Capital Requirements\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We have incurred significant losses since our inception. We expect to continue to incur losses over the next several years and\plain\cf1\f52\fs16\b\i\ql may never achieve or maintain profitability.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We are a clinical development-stage biopharmaceutical company. In November 2013, we merged with Sonkei Pharmaceuticals,\~Inc., or\plain\cf1\f52\fs16\ql Sonkei, and, in February 2014, we acquired Mind-NRG, which were also clinical development-stage biopharmaceutical companies.\plain\cf1\f52\fs16\ql Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and\plain\cf1\f52\fs16\ql significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory\plain\cf1\f52\fs16\ql approval or become commercially viable. As an early stage company, we have limited experience and have not yet demonstrated an ability\plain\cf1\f52\fs16\ql to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields,\plain\cf1\f52\fs16\ql particularly the biopharmaceutical area. We have no products approved for commercial sale and have not generated any revenue from\plain\cf1\f52\fs16\ql product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We are not profitable and have incurred losses in each period since our inception in 2007. For the year ended December\~31, 2013, we\plain\cf1\f52\fs16\ql reported a net loss of $3.3\~million and a combined pro forma net loss of $5.5\~million, after giving effect to the Sonkei Merger and the\plain\cf1\f52\fs16\ql Mind-NRG Acquisition as if such transactions occurred on January\~1, 2013. For the three months ended March\~31, 2014, we reported a net\plain\cf1\f52\fs16\ql loss of $2.9\~million and a combined pro forma net loss of $3.4\~million after giving effect to the Mind-NRG Acquisition as if it occurred on\plain\cf1\f52\fs16\ql January\~1, 2013. For a description of the combined pro forma adjustments described above, see "Unaudited Pro Forma Condensed\plain\cf1\f52\fs16\ql Combined Financial Statements." As of March\~31, 2014, we had an accumulated deficit of $20.8\~million.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our\plain\cf1\f52\fs16\ql research and development of, and seek regulatory approvals for, our product candidates. If any of our product candidates fail in clinical trials\plain\cf1\f52\fs16\ql or do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never\plain\cf1\f52\fs16\ql generate revenue or become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in\plain\cf1\f52\fs16\ql subsequent periods. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may\plain\cf1\f52\fs16\ql adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our\plain\cf1\f52\fs16\ql ability to generate revenues. Our prior losses and expected future losses have had and will continue to have an adverse effect on our\plain\cf1\f52\fs16\ql stockholders' equity and working capital.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a\plain\cf1\f52\fs16\b\i\ql result, we may not complete the development and commercialization of our product candidates or develop new product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our operations and the historic operations of Sonkei and Mind-NRG have consumed substantial amounts of cash since inception. We\plain\cf1\f52\fs16\ql expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we\plain\cf1\f52\fs16\ql advance our product candidates into clinical trials.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 10\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_co48001_1_11}{\*\bkmkend gmnh1page_co48001_1_11}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As of March\~31, 2014, we had cash and cash equivalents of $2.1\~million. We believe that the net proceeds from this offering, the Janssen\plain\cf1\f52\fs16\ql Transactions, the concurrent private placement to the former Mind-NRG shareholders and our existing cash and cash equivalents, will fund\plain\cf1\f52\fs16\ql our projected operating requirements through 2015. In particular, we expect these funds will allow us to complete our planned Phase\~II\plain\cf1\f52\fs16\ql clinical development for one of our two lead product candidates, MIN-101, as well as to complete the planned Phase\~Ib clinical development\plain\cf1\f52\fs16\ql of MIN-202 with Janssen and pre-clinical development of MIN-301. However, circumstances may cause us to consume capital more rapidly\plain\cf1\f52\fs16\ql than we currently anticipate. We will require significant additional capital to fund the development of one of our two lead product candidates,\plain\cf1\f52\fs16\ql MIN-117, and to fund future clinical trials of our other product candidate, and to obtain regulatory approval for, and to commercialize, our\plain\cf1\f52\fs16\ql product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our future funding requirements, both short and long-term, will depend on many factors, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the initiation, progress, timing, costs and results of pre-clinical and clinical studies for our product candidates and future\plain\cf1\f52\fs16\ql product candidates we may develop;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the outcome, timing and cost of seeking and obtaining regulatory approvals from the EMA, FDA and comparable foreign\plain\cf1\f52\fs16\ql regulatory authorities, including the potential for such authorities to require that we perform more studies than those that\plain\cf1\f52\fs16\ql we currently expect;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the cost to establish, maintain, expand and defend the scope of our intellectual property portfolio, including the amount\plain\cf1\f52\fs16\ql and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing,\plain\cf1\f52\fs16\ql filing, prosecution, defense and enforcement of any patents or other intellectual property rights;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the effect of competing technological and market developments;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql market acceptance of any approved product candidates;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; and\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the cost of establishing sales, marketing and distribution capabilities for our product candidates for which we may receive\plain\cf1\f52\fs16\ql regulatory approval and that we determine to commercialize ourselves or in collaboration with our partners.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql When we need to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities,\plain\cf1\f52\fs16\ql which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future\plain\cf1\f52\fs16\ql financing will be available in sufficient amounts or on terms acceptable to us, if at all. Further, the evolving and volatile global economic\plain\cf1\f52\fs16\ql climate and global financial market conditions could limit our ability to raise funding and otherwise adversely impact our business or those of\plain\cf1\f52\fs16\ql our collaborators and providers. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us we may have\plain\cf1\f52\fs16\ql to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. Any of\plain\cf1\f52\fs16\ql these events could significantly harm our business, financial condition and prospects.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern, and as a result, our\plain\cf1\f52\fs16\ql independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the\plain\cf1\f52\fs16\ql year ended December\~31, 2013 with respect to this uncertainty. Our ability to continue as a going concern could materially limit our ability to\plain\cf1\f52\fs16\ql raise additional funds through the issuance of new debt or equity securities or otherwise. Future reports on our financial statements may\plain\cf1\f52\fs16\ql include an explanatory paragraph with respect to our ability to continue as a going concern. We are a development stage company and\plain\cf1\f52\fs16\ql have not generated revenues or been profitable since inception, and it is possible we will never achieve profitability. None of our product\plain\cf1\f52\fs16\ql candidates can be marketed until governmental approvals have been obtained. Accordingly, there is no current source of revenues much\plain\cf1\f52\fs16\ql less profits, to sustain our present activities, and no revenues will likely be available until, and unless, our product candidates are approved\plain\cf1\f52\fs16\ql by the EMA, FDA or comparable regulatory agencies in\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 11\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_co48001_1_12}{\*\bkmkend gmnh1page_co48001_1_12}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql other countries and successfully marketed, either by us or a partner, an outcome which may not occur. If we successfully complete this\plain\cf1\f52\fs16\ql offering, based upon our currently expected level of operating expenditures, we expect to be able to fund our operations to 2015. This period\plain\cf1\f52\fs16\ql could be shortened if there are any significant increases in planned spending on development programs or more rapid progress of\plain\cf1\f52\fs16\ql development programs than anticipated. There is no assurance that other financing will be available when needed to allow us to continue as\plain\cf1\f52\fs16\ql a going concern. The perception that we may not be able to continue as a going concern may cause others to choose not to deal with us\plain\cf1\f52\fs16\ql due to concerns about our ability to meet our contractual obligations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We plan to use potential future operating losses and our federal and state net operating loss, or NOL, carryforwards to offset\plain\cf1\f52\fs16\b\i\ql taxable income from revenue generated from operations or corporate collaborations. However, our ability to use existing NOL\plain\cf1\f52\fs16\b\i\ql carryforwards would likely be limited as a result of issuance of equity securities.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As of December\~31, 2013, we had approximately $16.0\~million of federal net operating carryforwards. These federal NOL carryforwards will\plain\cf1\f52\fs16\ql begin to expire at various dates beginning in 2027, if not utilized. We plan to use our operating losses to offset any potential future taxable\plain\cf1\f52\fs16\ql income generated from operations or collaborations. To the extent we generate taxable income, we plan to use our existing NOL\plain\cf1\f52\fs16\ql carryforwards and future losses to offset income that would otherwise be taxable. However, under the Tax Reform Act of 1986, the amount\plain\cf1\f52\fs16\ql of benefits from our NOL carryforwards may be impaired or limited if we incur a cumulative ownership change of more than 50%, as\plain\cf1\f52\fs16\ql interpreted by the U.S. Internal Revenue Service, over a three year period. We have not performed a detailed analysis to determine whether\plain\cf1\f52\fs16\ql an ownership change occurred upon consummation of the merger between us and Sonkei or upon the acquisition of Mind-NRG or will occur\plain\cf1\f52\fs16\ql in connection with this offering or in connection with the shares to be issued to JJDC or shareholders of Mind-NRG in concurrent private\plain\cf1\f52\fs16\ql placements in connection with this offering. However, as a result of these three transactions and this offering, it is likely that an ownership\plain\cf1\f52\fs16\ql change would occur or has occurred, and such ownership change could also be triggered by subsequent sales of securities by us or our\plain\cf1\f52\fs16\ql stockholders. Therefore, it is likely that some or all of our existing NOL carryforwards would be limited by the provisions of Section\~382 of\plain\cf1\f52\fs16\ql the U.S. Internal Revenue Code of 1986, as amended. Further, state NOL carryforwards may be similarly limited. We had approximately\plain\cf1\f52\fs16\ql $11.0\~million of state net operating carryforwards at December\~31, 2013. It is also possible that future changes in ownership could similarly\plain\cf1\f52\fs16\ql limit our ability to utilize NOL carryforwards. It is possible that all of our existing NOL carryforwards would be disallowed. Any such\plain\cf1\f52\fs16\ql disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation and any increased liabilities could\plain\cf1\f52\fs16\ql adversely affect our business, results of operations, financial condition and cash flow.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Risks Related to Our Business and Industry\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We are heavily dependent on the success of our two lead product candidates and we cannot give any assurance that any of our\plain\cf1\f52\fs16\b\i\ql product candidates will receive regulatory approval in a timely manner or at all, which is necessary before they can be\plain\cf1\f52\fs16\b\i\ql commercialized.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have invested a significant portion of our efforts and financial resources in the licensing and development of our two lead product\plain\cf1\f52\fs16\ql candidates: (i)\~MIN-101 for the treatment of schizophrenia and (ii)\~MIN-117 for the treatment of major depressive disorder, or MDD. We plan\plain\cf1\f52\fs16\ql to use the substantial majority of our net proceeds from this offering to fund a Phase\~IIb clinical trial of MIN-101 in Europe. In order to\plain\cf1\f52\fs16\ql develop MIN-117, we will need to obtain additional financing. We may never successfully develop, obtain regulatory approval for, and then\plain\cf1\f52\fs16\ql successfully commercialize MIN-101 or MIN-117.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The regulatory approval process is expensive and the time required to obtain approval from the EMA, FDA or other regulatory authorities in\plain\cf1\f52\fs16\ql other jurisdictions to sell any product is uncertain and may take years. See the section entitled "Business\~\u8212? Government Regulation\plain\cf1\f52\fs16\ql and Product Approval" for a discussion of the process for regulatory approval from the EMA and FDA.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 12\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_co48001_1_13}{\*\bkmkend gmnh1page_co48001_1_13}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We currently hold no Investigational New Drug, or IND, approvals in the United States, and as a result do not intend to initiate human\plain\cf1\f52\fs16\ql clinical trials of our product candidates (with the exception of MIN-301) in the United States until 2015 or later. Whether regulatory approval\plain\cf1\f52\fs16\ql will be granted is unpredictable and depends upon numerous factors, including the substantial discretion of the regulatory authorities.\plain\cf1\f52\fs16\ql Moreover, the filing of a marketing application, including a New Drug Application, or NDA, requires a payment of a significant user fee upon\plain\cf1\f52\fs16\ql submission. The filing of marketing applications for our product candidates may be delayed due to our lack of financial resources to pay\plain\cf1\f52\fs16\ql such user fee.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Initially, we plan to conduct clinical trials in Europe. Applications to commence clinical trials in the European Union are to member state\plain\cf1\f52\fs16\ql regulatory authorities. Good Clinical Practice (in the EU under ICH 1997), or GCP, as incorporated into the EU Clinical Trials Directive\plain\cf1\f52\fs16\ql 2001/20 and national implementing regulations sets out most issues in the conduct of trials but national divergences exist especially in\plain\cf1\f52\fs16\ql relation to insurance and compensation, which will require a thorough understanding of the specific procedures and requirements for the\plain\cf1\f52\fs16\ql specific member states in which we chose to conduct the clinical trials. Clinical trials in the European Union also require an ethics committee\plain\cf1\f52\fs16\ql or institutional review board opinion, and there is often inconsistency as to ethics committee decisions. The ethics committee may ask\plain\cf1\f52\fs16\ql questions, may require re-writing or amending the protocol, any and all of which would require more time and expense. Even after\plain\cf1\f52\fs16\ql re-submission to the relevant ethics committee, the application may still ultimately be rejected. After clinical trial authorization, we may be\plain\cf1\f52\fs16\ql inspected for compliance with GCP by inspectors from the national regulatory authorities. If the inspections provide warnings or require\plain\cf1\f52\fs16\ql changes this will incur further delays and cost and we may be restricted from completing the trials.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If, following submission, our NDA or marketing authorization application is not accepted for substantive review or approval, the EMA, FDA or\plain\cf1\f52\fs16\ql other comparable foreign regulatory authorities may require that we conduct additional clinical or pre-clinical trials, provide additional data,\plain\cf1\f52\fs16\ql manufacture additional validation batches or develop additional analytical tests methods before they will reconsider our application. If the\plain\cf1\f52\fs16\ql EMA, FDA or other comparable foreign regulatory authorities requires additional studies or data, we would incur increased costs and delays\plain\cf1\f52\fs16\ql in the marketing approval process, which may require us to expend more resources than we have available. In addition, the EMA, FDA or\plain\cf1\f52\fs16\ql other comparable foreign regulatory authorities may not consider sufficient any additional required trials, data or information that we perform\plain\cf1\f52\fs16\ql and complete or generate, or we may decide to abandon the program.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Moreover, policies, regulations, or the type and amount of pre-clinical and clinical data necessary to gain approval may change during the\plain\cf1\f52\fs16\ql course of a product candidate's clinical development and may vary among jurisdictions. It is possible that none of our existing product\plain\cf1\f52\fs16\ql candidates or any of our future product candidates will ever obtain regulatory approval, even if we expend substantial time and resources\plain\cf1\f52\fs16\ql seeking such approval.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our product candidates could fail to receive regulatory approval for many reasons, including the following:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the EMA, FDA or other regulatory authorities may disagree with the design or implementation of our clinical trials. We\plain\cf1\f52\fs16\ql have not yet consulted with the EMA or the FDA on the design and conduct of the clinical trials that have already been\plain\cf1\f52\fs16\ql conducted and which we intend to conduct. Thus, the EMA, FDA and other comparable foreign authorities may not agree\plain\cf1\f52\fs16\ql with the design or implementation of these trials. We intend to seek guidance from the EMA in relation to the EU clinical\plain\cf1\f52\fs16\ql trial program and the FDA on the design and conduct of clinical trials of our compounds when we initiate a clinical\plain\cf1\f52\fs16\ql program in the United States in the future;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql we may be unable to demonstrate to the satisfaction of the EMA, FDA or other regulatory authorities that a product\plain\cf1\f52\fs16\ql candidate is safe and effective for its proposed indication;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the results of clinical trials may not meet the level of statistical significance required by the EMA, FDA or other regulatory\plain\cf1\f52\fs16\ql authorities for approval;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks;\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 13\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_co48001_1_14}{\*\bkmkend gmnh1page_co48001_1_14}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the EMA, FDA or other regulatory authorities may disagree with our interpretation of data from pre-clinical studies or\plain\cf1\f52\fs16\ql clinical trials;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA\plain\cf1\f52\fs16\ql or other submission or to obtain regulatory approval in the United States or elsewhere;\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the EMA, FDA or other regulatory authorities may fail to approve the manufacturing processes or facilities of third-party\plain\cf1\f52\fs16\ql manufacturers with which we contract for clinical and commercial supplies; and\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the approval policies or regulations of the EMA, FDA or other regulatory authorities outside of the United States may\plain\cf1\f52\fs16\ql significantly change in a manner rendering our clinical data insufficient for approval.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Even if we obtain approval for a particular product, regulatory authorities may approve any of our product candidates for fewer or more\plain\cf1\f52\fs16\ql limited indications, including more limited patient populations, than we request, may require that contraindications, warnings, or precautions\plain\cf1\f52\fs16\ql be included in the product labeling, including a black box warning, may grant approval contingent on the performance of costly\plain\cf1\f52\fs16\ql post-marketing clinical trials or other post-market requirements, including risk evaluation and mitigation strategies, or REMS, or may approve\plain\cf1\f52\fs16\ql a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that\plain\cf1\f52\fs16\ql product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The clinical trials related to our product candidates have been limited to six Phase\~I trials completed between 2002 and 2004 for MIN-101, a\plain\cf1\f52\fs16\ql Phase\~IIa trial for MIN-101 completed in 2009, two Phase\~I trials for MIN-117 completed between 2005 and 2009, and a Phase\~I trial for\plain\cf1\f52\fs16\ql MIN-202 in 2011. Each of our product candidates has also undergone pre-clinical studies. The results of pre-clinical studies and early\plain\cf1\f52\fs16\ql clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Interpretation of results from early,\plain\cf1\f52\fs16\ql usually smaller, studies that suggest positive trends in some subjects, requires caution. Results from later stages of clinical trials enrolling\plain\cf1\f52\fs16\ql more subjects may fail to show the desired safety and efficacy results or otherwise fail to be consistent with the results of earlier trials of the\plain\cf1\f52\fs16\ql same product candidates. Later clinical trial results may not replicate earlier clinical trials for a variety of reasons, including differences in trial\plain\cf1\f52\fs16\ql design, different trial endpoints (or lack of trial endpoints in exploratory studies), subject population, number of subjects, subject selection\plain\cf1\f52\fs16\ql criteria, trial duration, drug dosage and formulation and lack of statistical power in the earlier studies. A number of companies in the\plain\cf1\f52\fs16\ql pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or\plain\cf1\f52\fs16\ql unacceptable safety profiles, notwithstanding promising results in earlier trials.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql The results of clinical trials conducted at sites outside the United States may not be accepted by the FDA and the results of\plain\cf1\f52\fs16\b\i\ql clinical trials conducted at sites in the United States may not be accepted by international regulatory authorities.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We plan to conduct our clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the\plain\cf1\f52\fs16\ql United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be\plain\cf1\f52\fs16\ql well-designed and conducted and performed by qualified investigators in accordance with ethical principles such as institutional review\plain\cf1\f52\fs16\ql board, or IRB, or ethics committee approval and informed consent. The study population must also adequately represent the U.S. population,\plain\cf1\f52\fs16\ql and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful.\plain\cf1\f52\fs16\ql Generally, the subject population for any clinical trials conducted outside of the United States must be representative of the U.S. population.\plain\cf1\f52\fs16\ql In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its\plain\cf1\f52\fs16\ql determination that the trials were conducted consistent with all applicable U.S. laws and regulations. There can be no assurance the FDA\plain\cf1\f52\fs16\ql will accept data from trials conducted outside of the United States as adequate support of a marketing application and it is not unusual for\plain\cf1\f52\fs16\ql the FDA to require some Phase\~III clinical trial data to be generated in the United States. If the FDA does not accept the data from our\plain\cf1\f52\fs16\ql international clinical trials, it would likely result in the need for additional trials in the United States, which would be costly and\plain\cf1\f52\fs16\ql time-consuming and could delay or permanently halt the development of one or more of our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 14\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cq48001_1_15}{\*\bkmkend gmnh1page_cq48001_1_15}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If we experience delays in clinical testing, we will be delayed in commercializing our product candidates, our costs may increase\plain\cf1\f52\fs16\b\i\ql and our business may be harmed.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We do not know whether our clinical trials will need to be restructured or will be completed on schedule, or at all. Our product development\plain\cf1\f52\fs16\ql costs will increase if we experience delays in clinical testing. Significant clinical trial delays also could shorten any periods during which we\plain\cf1\f52\fs16\ql may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do,\plain\cf1\f52\fs16\ql which would impair our ability to successfully commercialize our product candidates and may harm our business, results of operations and\plain\cf1\f52\fs16\ql prospects.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The commencement and completion of clinical development can be delayed or halted for a number of reasons, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql difficulties obtaining regulatory approval to commence a clinical trial or complying with conditions imposed by a regulatory\plain\cf1\f52\fs16\ql authority regarding the scope or term of a clinical trial;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql delays in reaching or failure to reach agreement on acceptable terms with prospective clinical research organizations, or\plain\cf1\f52\fs16\ql CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among\plain\cf1\f52\fs16\ql different CROs and trial sites;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql deviations from the trial protocol by clinical trial sites and investigators, or failing to conduct the trial in accordance with\plain\cf1\f52\fs16\ql regulatory requirements;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql failure of our third parties, such as CROs, to satisfy their contractual duties or meet expected deadlines;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql insufficient or inadequate supply or quantity of product material for use in trials due to delays in the importation and\plain\cf1\f52\fs16\ql manufacture of clinical supply, including delays in the testing, validation, and delivery of the clinical supply of the\plain\cf1\f52\fs16\ql investigational drug to the clinical trial sites;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql delays in identification and auditing of central or other laboratories and the transfer and validation of assays or tests to be\plain\cf1\f52\fs16\ql used;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql delays in having subjects complete participation in a trial or return for post-treatment follow-up;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql difficulties obtaining IRB or ethics committee approval to conduct a trial at a prospective site, or complying with conditions\plain\cf1\f52\fs16\ql imposed by IRBs or ethics committees;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql challenges recruiting and enrolling subjects to participate in clinical trials for a variety of reasons, including competition\plain\cf1\f52\fs16\ql from other programs for the treatment of similar conditions;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql severe or unexpected drug-related adverse events experienced by subjects in a clinical trial;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql difficulty retaining subjects who have initiated a clinical trial but may be prone to withdraw due to side effects from the\plain\cf1\f52\fs16\ql therapy, lack of efficacy or personal issues, which are common among schizophrenia and MDD subjects who we require\plain\cf1\f52\fs16\ql for our clinical trials of our two lead product candidates, MIN-101 and MIN-117. For instance, 66\~out of 96\~subjects\plain\cf1\f52\fs16\ql ceased to participate in the Phase\~IIa clinical trial of MIN-101;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql delays in adding new investigators and clinical sites;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql withdrawal of clinical trial sites from clinical trials;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql lack of adequate funding; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql clinical holds or termination imposed by the EU national regulatory authorities or the FDA or IRBs or ethics committees.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, clinical trials may be suspended or\plain\cf1\f52\fs16\ql terminated by us, an IRB or ethics committee overseeing the clinical trial at a trial site (with respect to that site), the EU national regulatory\plain\cf1\f52\fs16\ql authorities or the FDA due to a number of factors, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql failure to conduct the clinical trial in accordance with regulatory requirements or the trial protocols;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql observations during inspection of the clinical trial operations or trial sites by the EMA, FDA or other comparable foreign\plain\cf1\f52\fs16\ql regulatory authorities that ultimately result in the imposition of a clinical hold;\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 15\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cq48001_1_16}{\*\bkmkend gmnh1page_cq48001_1_16}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql unforeseen safety issues; or
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql lack of adequate funding to continue the clinical trial.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Failure to conduct the clinical trial in accordance with regulatory requirements or the trial protocols may also result in the inability to use the\plain\cf1\f52\fs16\ql data to support product approval. Additionally, changes in regulatory requirements and guidance may occur, and we may need to amend\plain\cf1\f52\fs16\ql clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to the EMA, FDA, IRBs or\plain\cf1\f52\fs16\ql ethics committees for reexamination, which may impact the costs, timing and successful completion of a clinical trial. Many of the factors that\plain\cf1\f52\fs16\ql cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval\plain\cf1\f52\fs16\ql of our product candidates. If we experience delays in completion of, or if we terminate any of our clinical trials, our ability to obtain\plain\cf1\f52\fs16\ql regulatory approval for our product candidates may be materially harmed, and our commercial prospects and ability to generate product\plain\cf1\f52\fs16\ql revenues will be diminished.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We have no experience in advancing product candidates beyond Phase\~IIa, which makes it difficult to assess our ability to develop\plain\cf1\f52\fs16\b\i\ql and commercialize our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We commenced operations in 2007 under the name Cyrenaic Pharmaceuticals,\~Inc., or Cyrenaic, and our operations to date and those of\plain\cf1\f52\fs16\ql Sonkei and Mind-NRG have been limited to raising capital, identifying potential drug candidates, and undertaking pre-clinical and Phase\~I\plain\cf1\f52\fs16\ql and IIa clinical trials. Neither we nor Sonkei have conducted any clinical trials of our two lead product candidates, MIN-101 and MIN-117,\plain\cf1\f52\fs16\ql since 2009, resulting in our lead product candidates losing patent life without clinical advancement toward potential commercialization.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have no experience in progressing clinical trials past Phase\~IIa, obtaining regulatory approvals or commercializing product candidates.\plain\cf1\f52\fs16\ql We recently merged with Sonkei and acquired Mind-NRG and have limited operating history since the merger and acquisition. We may\plain\cf1\f52\fs16\ql encounter unforeseen expense, difficulties, complications, delays and other known or unknown factors in pursuing our business objectives.\plain\cf1\f52\fs16\ql We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a\plain\cf1\f52\fs16\ql variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods\plain\cf1\f52\fs16\ql as indications of future operating performance.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If we are unable to enroll subjects in clinical trials, we will be unable to complete these trials on a timely basis or at all.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The timely completion of clinical trials largely depends on subject enrollment. Many factors affect subject enrollment, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the size and nature of the subject population;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the number and location of clinical sites we enroll;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql competition with other companies for clinical sites or subjects;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the eligibility and exclusion criteria for the trial;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the design of the clinical trial;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql inability to obtain and maintain subject consents;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql risk that enrolled subjects will drop out before completion; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql competing clinical trials and clinicians' and subjects' perceptions as to the potential advantages or disadvantages of the\plain\cf1\f52\fs16\ql drug being studied in relation to other available therapies, including any new drugs that may be approved for the\plain\cf1\f52\fs16\ql indications we are investigating.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials in Europe and eventually in the United\plain\cf1\f52\fs16\ql States and, while we have agreements governing their committed activities, we have limited influence over their actual performance. We may\plain\cf1\f52\fs16\ql also experience difficulties enrolling subjects for our clinical trials relating to MIN-101 and MIN-117 due to the mental health of the\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 16\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cq48001_1_17}{\*\bkmkend gmnh1page_cq48001_1_17}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql subjects that we will need to enroll. For instance, according to Datamonitor, roughly one-third of purported schizophrenia patients may not\plain\cf1\f52\fs16\ql receive an accurate diagnosis, with negative symptoms more difficult to recognize. The patient discontinuation rate for current schizophrenia\plain\cf1\f52\fs16\ql drugs is also high. For instance, a significant number of subjects ceased to participate in our prior Phase\~IIa trial of MIN-101. As a result,\plain\cf1\f52\fs16\ql the process of finding, diagnosing and retaining subjects throughout a clinical trial targeting the negative symptoms of schizophrenia or MDD\plain\cf1\f52\fs16\ql may prove difficult and costly.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Our clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which could prevent or\plain\cf1\f52\fs16\b\i\ql delay regulatory approval and commercialization, and also increase costs.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and\plain\cf1\f52\fs16\ql expensive pre-clinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication, and\plain\cf1\f52\fs16\ql failures can occur at any stage of testing. Clinical trials often fail to demonstrate safety and efficacy of the product candidate studied for the\plain\cf1\f52\fs16\ql target indication. For instance, our clinical studies of MIN-101 and MIN-117 did not show statistically significant differences favorable to the\plain\cf1\f52\fs16\ql investigational products between the treatment and comparator groups on all the studies' primary, secondary and/or exploratory endpoints.\plain\cf1\f52\fs16\ql While these studies were not powered for statistical significance, regulatory authorities may find that the studies do not support, in\plain\cf1\f52\fs16\ql combination with other studies, approval of the target indication. In addition, our product candidates may be associated with undesirable side\plain\cf1\f52\fs16\ql effects or have characteristics that are unexpected, which may result in abandoning their development or regulatory authorities restricting or\plain\cf1\f52\fs16\ql denying marketing approval. For instance, prior clinical studies indicated that MIN-101 and MIN-117 may cause adverse events, including,\plain\cf1\f52\fs16\ql but not limited to, dizziness, vital sign changes, central nervous system events, cardiac events, including prolongation of the QT/QTc interval,\plain\cf1\f52\fs16\ql and gastrointestinal events. Most product candidates that commence clinical trials are never approved by the applicable regulatory\plain\cf1\f52\fs16\ql authorities.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In the case of our lead product candidates, MIN-101 and MIN-117, we are seeking to develop treatments for schizophrenia and MDD,\plain\cf1\f52\fs16\ql which adds a layer of complexity to our clinical trials and may delay regulatory approval. We do not fully understand the cause and\plain\cf1\f52\fs16\ql pathophysiology of schizophrenia and MDD, and our results will rely on subjective subject feedback, which is inherently difficult to evaluate.\plain\cf1\f52\fs16\ql It can also be influenced by factors outside of our control, and can vary widely from day to day for a particular subject, and from subject to\plain\cf1\f52\fs16\ql subject and site to site within a clinical study. The placebo effect may also have a more significant impact on our clinical trials.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If our product candidates are not shown to be both safe and effective in clinical trials, we will not be able to obtain regulatory approval or\plain\cf1\f52\fs16\ql commercialize our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product\plain\cf1\f52\fs16\b\i\ql candidates or indications that may be more profitable or for which there is a greater likelihood of success.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Because we have limited financial and management resources, we focus on a limited number of research programs and product candidates.\plain\cf1\f52\fs16\ql For instance, we are prioritizing the clinical trials and development of one of our two lead product candidates, MIN-101. As a result, we may\plain\cf1\f52\fs16\ql forego or delay pursuit of opportunities with other product candidates, including MIN-117, MIN-202 and MIN-301, or for other indications\plain\cf1\f52\fs16\ql that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable\plain\cf1\f52\fs16\ql commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and product\plain\cf1\f52\fs16\ql candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential\plain\cf1\f52\fs16\ql or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration,\plain\cf1\f52\fs16\ql licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and\plain\cf1\f52\fs16\ql commercialization rights.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 17\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cq48001_1_18}{\*\bkmkend gmnh1page_cq48001_1_18}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Even if we complete the necessary clinical trials, we cannot predict when or if we will obtain marketing approval to commercialize\plain\cf1\f52\fs16\b\i\ql a product candidate or the approval may be for a more narrow indication than we expect.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.\plain\cf1\f52\fs16\ql Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review\plain\cf1\f52\fs16\ql processes in a timely manner, or we may not be able to obtain marketing approval from the relevant regulatory agencies. Additional delays\plain\cf1\f52\fs16\ql may result if the EMA, FDA, an FDA Advisory Committee, or other regulatory authority recommends non-approval or restrictions on\plain\cf1\f52\fs16\ql approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or\plain\cf1\f52\fs16\ql administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties,\plain\cf1\f52\fs16\b\i\ql including ongoing regulatory obligations and continued regulatory review. Additionally, our product candidates, if approved, could\plain\cf1\f52\fs16\b\i\ql be subject to labeling and other restrictions and market withdrawal and we may be subject to administrative sanctions or penalties\plain\cf1\f52\fs16\b\i\ql if we fail to comply with regulatory requirements or experience unanticipated problems with our products.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Even if we obtain regulatory approval for a product candidate, product candidates may be subject to fewer or more limited indications,\plain\cf1\f52\fs16\ql including more limited subject populations, than we request, and regulatory authorities may require that contraindications, warnings, or\plain\cf1\f52\fs16\ql precautions be included in the product labeling, including a black box warning, may grant approval contingent on the performance of costly\plain\cf1\f52\fs16\ql post-marketing clinical trials or other post-market requirements, such as REMS, may require post-marketing surveillance, or may approve a\plain\cf1\f52\fs16\ql product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that\plain\cf1\f52\fs16\ql product candidate. For instance, in 2007, the FDA requested that makers of all antidepressant medications update existing black box\plain\cf1\f52\fs16\ql warnings about increased risk of suicidal thought and behavior in young adults, ages\~18 to\~24, during initial treatment. If approved for\plain\cf1\f52\fs16\ql marketing, our drugs may be required to carry warnings similar to this and other class-wide warnings.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Any approved products would further be subject to ongoing requirements imposed by the EMA, FDA, and other comparable foreign\plain\cf1\f52\fs16\ql regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety\plain\cf1\f52\fs16\ql surveillance, import, export, advertising, promotion, marketing, recordkeeping and reporting of safety and other post-market information. If\plain\cf1\f52\fs16\ql there are any modifications to the drug, including changes in indications, labeling, manufacturing processes or facilities, or new safety issues\plain\cf1\f52\fs16\ql arise, a new or supplemental NDA, a post-implementation notification or other reporting may be required or requested depending on the\plain\cf1\f52\fs16\ql change, which may require additional data or additional pre-clinical studies and clinical trials.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The EMA, FDA and other comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even\plain\cf1\f52\fs16\ql after approval. If the EMA, FDA or other comparable foreign regulatory authorities become aware of new safety information after approval of\plain\cf1\f52\fs16\ql any of our product candidates, a number of potentially significant negative consequences could result, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql we may suspend marketing of, or withdraw or recall, such product;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql regulatory authorities may withdraw approvals of such product;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql regulatory authorities may require additional warnings or otherwise restrict the product's indicated use, label, or marketing;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the EMA, FDA or other comparable foreign regulatory bodies may issue safety alerts, Dear Healthcare Provider letters,\plain\cf1\f52\fs16\ql press releases or other communications containing warnings about such product;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the FDA may require the establishment or modification of a REMS or the EMA or a comparable foreign regulatory\plain\cf1\f52\fs16\ql authority may require the establishment or modification of a similar strategy that may, for instance, require us to issue a\plain\cf1\f52\fs16\ql medication guide outlining the risks of such side effects for\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 18\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cq48001_1_19}{\*\bkmkend gmnh1page_cq48001_1_19}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql distribution to subjects or restrict distribution of our products and impose burdensome implementation requirements on us;\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql regulatory authorities may require that we conduct post-marketing studies or surveillance;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql we could be sued and held liable for harm caused to subjects or patients; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our reputation may suffer.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition, manufacturers of drug products and their facilities, including contracted facilities, are subject to continual review and periodic\plain\cf1\f52\fs16\ql inspections by national regulatory authorities in the European Union, the FDA and other regulatory authorities for compliance with current\plain\cf1\f52\fs16\ql Good Manufacturing Practices, or cGMP, regulations and standards. The EU\~cGMP guidelines are as set down in Commission\plain\cf1\f52\fs16\ql Directive\~2003/94/EC of October\~8, 2003 laying down the principles and guidelines of good manufacturing practice. If we or a regulatory\plain\cf1\f52\fs16\ql agency or authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, the\plain\cf1\f52\fs16\ql product's stability (changes in levels of impurities or dissolution profile) or problems with the facility where the product is manufactured, we\plain\cf1\f52\fs16\ql may be subject to reporting obligations, additional testing, additional sampling and a regulatory agency or authority may impose restrictions\plain\cf1\f52\fs16\ql on that product, the manufacturing facility, our suppliers, or us, including requiring recall or withdrawal of the product from the market or\plain\cf1\f52\fs16\ql suspension of manufacturing. If we, our product candidates, the manufacturing facilities for our product candidates, our CROs, or other\plain\cf1\f52\fs16\ql persons or entities working on our behalf fail to comply with applicable regulatory requirements either before or after marketing approval, a\plain\cf1\f52\fs16\ql regulatory agency may, depending on the stage of product development and approval:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql issue adverse inspectional findings;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql issue Warning Letters, Cyber Letters or Untitled Letters;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql amend and update labels or package inserts;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection\plain\cf1\f52\fs16\ql costs, required due dates for specific actions and penalties for noncompliance;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql seek an injunction or impose civil, criminal and/or administrative penalties, damages or monetary fines or imprisonment;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql suspend or withdraw regulatory approval;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql suspend or terminate any ongoing clinical studies;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql debar us;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql refuse to approve pending applications or supplements to applications filed by us;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql refuse to allow us to enter into government contracts;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql suspend or impose restrictions on operations, including restrictions on marketing or manufacturing of the product, or the\plain\cf1\f52\fs16\ql imposition of costly new manufacturing requirements or use of alternative suppliers; or
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and generate revenue.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our product candidates and the activities associated with their development and commercialization in the United States, including, but not\plain\cf1\f52\fs16\ql limited to, their advertising and promotion, will further be heavily scrutinized by the FDA, the U.S. Department of Justice, the U.S.\plain\cf1\f52\fs16\ql Department of Health and Human Services' Office of Inspector General, state attorneys general, members of Congress and the public.\plain\cf1\f52\fs16\ql Violations of applicable law, including advertising, marketing and promotion of our products for unapproved (or off-label) uses, are subject to\plain\cf1\f52\fs16\ql enforcement letters, inquiries and investigations, and civil, criminal and/or administrative sanctions by regulatory agencies. Additionally,\plain\cf1\f52\fs16\ql comparable foreign regulatory authorities will heavily scrutinize advertising\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 19\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cq48001_1_20}{\*\bkmkend gmnh1page_cq48001_1_20}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql and promotion of any product candidate that obtains approval outside of the United States. In this regard, advertising and promotion of\plain\cf1\f52\fs16\ql medicines in the European Union is governed by Directive\~2001/83 EC, as amended, and any such activities which we may undertake in the\plain\cf1\f52\fs16\ql European Union will have to be in strict compliance with the same. Any advertising of a prescription medicinal product to the public and any\plain\cf1\f52\fs16\ql promotion of a medicinal product which does not have marketing authorization or promotion not in accordance with that marketing\plain\cf1\f52\fs16\ql authorization (e.g.\~off-label) is prohibited. Advertisements and promotions of medicinal products are monitored nationally in the\~European\plain\cf1\f52\fs16\ql Union, and each country will have its own additional advertising laws and industry bodies, whose obligations may go further than those set\plain\cf1\f52\fs16\ql out in Directive 2001/83. For instance in the United Kingdom the code or practice of the Association of the British Pharmaceutical Industry\plain\cf1\f52\fs16\ql (the lead United Kingdom trade association) is considerably stricter than legislation. Any violations and sanctions will similarly be decided\plain\cf1\f52\fs16\ql and handled by the self regulatory body the relevant country's national authority.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In the United States, engaging in the impermissible promotion of our products for off-label uses can also subject us to false claims litigation\plain\cf1\f52\fs16\ql under federal and state statutes, which can lead to civil, criminal and/or administrative penalties, damages, monetary fines, disgorgement,\plain\cf1\f52\fs16\ql exclusion from participation in Medicare, Medicaid and other federal healthcare programs, curtailment or restructuring of our operations and\plain\cf1\f52\fs16\ql agreements that materially restrict the manner in which a company promotes or distributes drug products. These false claims statutes\plain\cf1\f52\fs16\ql include, but are not limited to, the federal civil False Claims Act, which allows any individual to bring a lawsuit against an individual or entity,\plain\cf1\f52\fs16\ql including a pharmaceutical company, on behalf of the federal government alleging the knowing submission of false or fraudulent claims, or\plain\cf1\f52\fs16\ql causing to present such false or fraudulent claims, for payment or approval by a federal program such as Medicare or Medicaid. If the\plain\cf1\f52\fs16\ql government decides to intervene and prevails in the lawsuit, the individual initiating the lawsuit will share in any fines or settlement funds. If\plain\cf1\f52\fs16\ql the government does not intervene, the individual may still proceed with the suit on his or her own. These False Claims Act lawsuits against\plain\cf1\f52\fs16\ql pharmaceutical companies have increased significantly in volume and breadth, leading to substantial civil and criminal settlements regarding\plain\cf1\f52\fs16\ql certain sales practices, including promoting off-label drug uses. This growth in litigation has increased the risk that a pharmaceutical\plain\cf1\f52\fs16\ql company will have to defend a false claims action, pay settlement fines or restitution, agree to comply with burdensome reporting and\plain\cf1\f52\fs16\ql compliance obligations, and/or be excluded from Medicare, Medicaid and other federal and state healthcare programs. If we do not lawfully\plain\cf1\f52\fs16\ql promote our products, we may become subject to such litigation which may have a material adverse effect on our business, financial\plain\cf1\f52\fs16\ql condition and results of operations. While no definition of "off-label use" exists at the European Union level, promotion of a medicinal\plain\cf1\f52\fs16\ql product for a purpose that has not been approved is strictly prohibited. Such promotion also gives rise to criminal prosecution in the\plain\cf1\f52\fs16\ql European Union, and national healthcare supervisory authorities may impose administrative fines. Engaging in such promotions in the\plain\cf1\f52\fs16\ql European Union could also lead to product liability claims, in accordance with EU product liability regime under Directive\~85/374.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The EMA's, FDA's, and other applicable government agencies' policies may change and additional government regulations may be enacted\plain\cf1\f52\fs16\ql that could prevent, limit or delay regulatory approval and marketing authorization, and the sale and promotion of our product candidates. If\plain\cf1\f52\fs16\ql we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to\plain\cf1\f52\fs16\ql maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and be subject to civil, criminal and\plain\cf1\f52\fs16\ql administrative enforcement, which would adversely affect our business, prospects and ability to achieve or sustain profitability.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql The regulatory pathway for our product candidate, MIN-301, has not yet been determined. Depending on the pathway, we may be\plain\cf1\f52\fs16\b\i\ql subject to different regulatory requirements.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql MIN-301 is a protein, and, as a protein, may be subject to the Public Health Service Act, or PHSA, and the Food, Drug, and Cosmetic Act,\plain\cf1\f52\fs16\ql or FDCA. We have yet to meet with the FDA regarding the approval pathway for this product candidate. Based on the definition of a biologic\plain\cf1\f52\fs16\ql in the PHSA, we believe that MIN-301 meets the definition of a biologic and, thus, we will need to submit a Biologics License Application, or\plain\cf1\f52\fs16\ql BLA,\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 20\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cq48001_1_21}{\*\bkmkend gmnh1page_cq48001_1_21}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql for product approval. Moreover, based on an FDA intercenter agreement, we believe that MIN-301 will be regulated by the FDA's Center for\plain\cf1\f52\fs16\ql Drug Evaluation and Research. However, we intend to discuss jurisdiction with the FDA to determine the appropriate regulatory pathway and\plain\cf1\f52\fs16\ql corresponding requirements. Depending on the pathway, we may be subject to different regulatory requirements, including different regulatory\plain\cf1\f52\fs16\ql and testing requirements, shorter or longer periods of market exclusivity, and different approval processes for generic drug and biosimilar\plain\cf1\f52\fs16\ql competitors.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If the market opportunities for any product that we or our collaborators develop are smaller than we believe they are, our revenue\plain\cf1\f52\fs16\b\i\ql may be adversely affected and our business may suffer.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our product candidates are intended for the treatment of schizophrenia, MDD, insomnia and Parkinson's disease. Our projections of both the\plain\cf1\f52\fs16\ql number of people who have these disorders or disease, as well as the subset of people who have the potential to benefit from treatment\plain\cf1\f52\fs16\ql with our product candidates and who will pursue such treatment, are based on our beliefs and estimates that may prove to be inaccurate.\plain\cf1\f52\fs16\ql For instance, with respect to schizophrenia and MDD, our estimates are based on patients that suffer from schizophrenia and MDD, but\plain\cf1\f52\fs16\ql these disorders are difficult to accurately diagnose and higher rates of patients may not seek or continue treatments. Our estimates and\plain\cf1\f52\fs16\ql beliefs are also based on the potential market of other drugs in development for schizophrenia and MDD, which may prove to be inaccurate\plain\cf1\f52\fs16\ql and our advantages over such drugs may not be or may not be perceived to be as significant as we believe they are. If our estimates prove\plain\cf1\f52\fs16\ql to be inaccurate, even if our products are approved, we may not be able to successfully commercialize them. In addition, the cause and\plain\cf1\f52\fs16\ql pathophysiology of schizophrenia and MDD are not fully understood, and additional scientific understanding and future drug or non-drug\plain\cf1\f52\fs16\ql therapies may make our product candidates obsolete.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As product candidates are developed through pre-clinical to late stage clinical trials towards approval and commercialization, it is common\plain\cf1\f52\fs16\ql that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to\plain\cf1\f52\fs16\ql optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes\plain\cf1\f52\fs16\ql could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials\plain\cf1\f52\fs16\ql conducted with the altered materials. Such changes may also require additional testing, EMA or FDA notification or EMA or FDA approval.\plain\cf1\f52\fs16\ql This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials,\plain\cf1\f52\fs16\ql increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate\plain\cf1\f52\fs16\ql revenue.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Our failure to obtain regulatory approval in additional international jurisdictions would prevent us from marketing our product\plain\cf1\f52\fs16\b\i\ql candidates outside the European Union and the United States.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We plan to seek regulatory approval to commercialize our product candidates in the European Union and, other than MIN-202, in the United\plain\cf1\f52\fs16\ql States. We also expect to seek regulatory approval in additional foreign countries. To market and sell our products in other jurisdictions, we\plain\cf1\f52\fs16\ql must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies\plain\cf1\f52\fs16\ql among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain\plain\cf1\f52\fs16\ql EMA or FDA approval. The regulatory approval process outside the European Union and United States generally includes risks substantially\plain\cf1\f52\fs16\ql similar to those associated with obtaining EMA or FDA approval. In addition, in many countries outside the United States, we must secure\plain\cf1\f52\fs16\ql product price and reimbursement approvals before regulatory authorities will approve the product for sale in that country or within a short\plain\cf1\f52\fs16\ql time after receiving such marketing approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements\plain\cf1\f52\fs16\ql could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries.\plain\cf1\f52\fs16\ql Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries and\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 21\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cq48001_1_22}{\*\bkmkend gmnh1page_cq48001_1_22}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in\plain\cf1\f52\fs16\ql one country may have a negative effect on the regulatory approval process in others. Also, regulatory approval for any of our product\plain\cf1\f52\fs16\ql candidates may be withdrawn. If we fail to comply with the regulatory requirements in international markets and do not receive applicable\plain\cf1\f52\fs16\ql marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be\plain\cf1\f52\fs16\ql harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. In some\plain\cf1\f52\fs16\ql foreign jurisdictions, approval by the domestic regulatory agency is required for approval in another jurisdiction. Our failure to obtain approval\plain\cf1\f52\fs16\ql of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that\plain\cf1\f52\fs16\ql product candidate and our business prospects could decline.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We face substantial competition, which may result in others discovering, developing or commercializing products before or more\plain\cf1\f52\fs16\b\i\ql successfully than us.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. We face competition with\plain\cf1\f52\fs16\ql respect to our current product candidates and will face competition with respect to any future product candidates from major pharmaceutical\plain\cf1\f52\fs16\ql companies, specialty pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater\plain\cf1\f52\fs16\ql financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly\plain\cf1\f52\fs16\ql through collaborative arrangements with large and established companies.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other\plain\cf1\f52\fs16\ql intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs\plain\cf1\f52\fs16\ql that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these\plain\cf1\f52\fs16\ql competitors may also be more successful than us in manufacturing and marketing their products.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing\plain\cf1\f52\fs16\ql clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our\plain\cf1\f52\fs16\ql programs.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql There are numerous currently approved therapies for treating the same diseases or indications for which our product candidates may be\plain\cf1\f52\fs16\ql useful and many of these currently approved therapies act through mechanisms similar to our product candidates. Many of these approved\plain\cf1\f52\fs16\ql drugs are well-established therapies or products and are widely accepted by physicians, patients and third-party payors. Some of these\plain\cf1\f52\fs16\ql drugs are branded and subject to patent protection and regulatory exclusivity, and others are available on a generic basis. Insurers and\plain\cf1\f52\fs16\ql other third-party payors may also encourage the use of generic products or specific branded products. Moreover, it is difficult to predict the\plain\cf1\f52\fs16\ql effect that introduction of biosimilars into the market will have on sales of the reference biologic product, as it will depend on the FDA's\plain\cf1\f52\fs16\ql standards for interchangeability, the structure of government and commercial managed care formularies, and state laws on substitution of\plain\cf1\f52\fs16\ql biosimilars. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic,\plain\cf1\f52\fs16\ql including branded generic, products, and biosimilars. This may make it difficult for us to differentiate our products from currently approved\plain\cf1\f52\fs16\ql therapies, which may adversely impact our business strategy. In addition, any new product that competes with an approved product must\plain\cf1\f52\fs16\ql demonstrate compelling advantages in efficacy, convenience, tolerability, and safety in order to overcome price competition and to be\plain\cf1\f52\fs16\ql commercially successful. If we are not able to compete effectively against our current and future competitors, our business will not grow and\plain\cf1\f52\fs16\ql our financial condition and operations will suffer. Moreover, many companies are developing new therapeutics, and we cannot predict what\plain\cf1\f52\fs16\ql the standard of care will be as our product candidates progress through clinical development. For additional information on the primary and\plain\cf1\f52\fs16\ql significant competition we expect each of our product candidates to face, if approved, please see the section of this prospectus titled\plain\cf1\f52\fs16\ql "Business\~\u8212? Competition."\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 22\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cs48001_1_23}{\*\bkmkend gmnh1page_cs48001_1_23}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Even if any of our drug candidates receives marketing approval, they may fail to achieve the degree of market acceptance by\plain\cf1\f52\fs16\b\i\ql physicians, patients, third-party payors and others in the medical community necessary for commercial success.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If any of our drug candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians,\plain\cf1\f52\fs16\ql patients, third-party payors and others in the medical community. If our drug candidates do not achieve an adequate level of acceptance,\plain\cf1\f52\fs16\ql we may not generate significant revenue from drug sales and we may not become profitable. Our commercial success also depends on\plain\cf1\f52\fs16\ql coverage and adequate reimbursement of our product candidates by third-party payors, including government payors, generally, which may\plain\cf1\f52\fs16\ql be difficult or time-consuming to obtain, may be limited in scope or may not be obtained in all jurisdictions in which we may seek to market\plain\cf1\f52\fs16\ql our products. The degree of market acceptance of our drug candidates, if approved for commercial sale, will depend on a number of factors,\plain\cf1\f52\fs16\ql including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the efficacy and perceived and potential advantages compared to alternative treatments, including any similar generics,\plain\cf1\f52\fs16\ql and biosimilars;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the timing of market introduction as well as alternative treatment;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to offer our drugs for sale at competitive prices;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the clinical indications for which the product candidate is approved;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the convenience and ease of administration compared to alternative treatments;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the cost of treatment in relation to alternative treatments;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the strength of marketing and distribution support;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the availability of third-party coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket\plain\cf1\f52\fs16\ql in the absence of coverage by third-party payors;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql unfavorable publicity relating to the product candidate;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the prevalence and severity of any side effects; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql any restrictions on the use of our drugs together with other medications.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our focus on neuropsychiatric disorders, in particular, places us at increased risk of serious side effects and disease events during use of\plain\cf1\f52\fs16\ql our product candidates, including suicide. Most approved neuropsychiatric medicines carry boxed warnings for clinically significant adverse\plain\cf1\f52\fs16\ql events, and we may categorically have to carry such warnings as well.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We currently have no marketing and sales organization. If we are unable to establish marketing and sales capabilities or enter into\plain\cf1\f52\fs16\b\i\ql agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell our\plain\cf1\f52\fs16\b\i\ql product candidates, if approved, or generate product revenues.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We currently do not have a marketing or sales organization for the marketing, sales and distribution of pharmaceutical products. In order to\plain\cf1\f52\fs16\ql commercialize any product candidates, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or\plain\cf1\f52\fs16\ql make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates\plain\cf1\f52\fs16\ql receive regulatory approval, we intend to establish our sales and marketing organization with technical expertise and supporting distribution\plain\cf1\f52\fs16\ql capabilities to commercialize our product candidates, which will be expensive and time consuming. Any failure or delay in the development\plain\cf1\f52\fs16\ql of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql To develop internal sales, distribution and marketing capabilities, we will have to invest significant amounts of financial and management\plain\cf1\f52\fs16\ql resources, some of which will be committed prior to any confirmation that our product candidates will be approved. For product candidates\plain\cf1\f52\fs16\ql for which we decide to perform sales, marketing and distribution functions ourselves, we could face a number of additional risks, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our inability to recruit and retain adequate numbers of effective sales and marketing personnel;\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 23\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cs48001_1_24}{\*\bkmkend gmnh1page_cs48001_1_24}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the clinical\plain\cf1\f52\fs16\ql benefits of our products to achieve market acceptance;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage\plain\cf1\f52\fs16\ql relative to companies with more extensive product lines;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the costs associated with training sales personnel on legal compliance matters and monitoring their actions;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql liability for sales personnel failing to comply with the applicable legal requirements; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql unforeseen costs and expenses associated with creating an independent sales and marketing organization.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our\plain\cf1\f52\fs16\ql own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we enter into arrangements with third\plain\cf1\f52\fs16\ql parties to perform sales, marketing and distribution services for our products, the resulting revenues or the profitability from these revenues\plain\cf1\f52\fs16\ql to us are likely to be lower than if we had sold, marketed and distributed our products ourselves. If we are unable to enter into such\plain\cf1\f52\fs16\ql arrangements on acceptable terms or at all, we may not be able to successfully commercialize any of our product candidates that receive\plain\cf1\f52\fs16\ql regulatory approval. Depending on the nature of the third party relationship, we may have little control over such third parties, and any of\plain\cf1\f52\fs16\ql these third parties may fail to devote the necessary resources and attention to sell, market and distribute our products effectively. If we are\plain\cf1\f52\fs16\ql not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our\plain\cf1\f52\fs16\ql future product revenue will suffer and we may incur significant additional losses.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Even if we commercialize any of our product candidates, these products may become subject to unfavorable pricing regulations,\plain\cf1\f52\fs16\b\i\ql third-party reimbursement practices or healthcare reform initiatives, which could harm our business.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The laws that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Current\plain\cf1\f52\fs16\ql and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in\plain\cf1\f52\fs16\ql obtaining approvals. In many countries, the pricing review period begins after marketing or product licensing approval is granted. Some\plain\cf1\f52\fs16\ql countries require approval of the sale price of a drug before it can be marketed or soon thereafter. Additionally, in some foreign markets,\plain\cf1\f52\fs16\ql prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we\plain\cf1\f52\fs16\ql might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial\plain\cf1\f52\fs16\ql launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we generate from the sale of the\plain\cf1\f52\fs16\ql product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product\plain\cf1\f52\fs16\ql candidates even if our product candidates obtain marketing approval.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In the European Union, the pricing and reimbursement of prescription drugs is controlled by each member state. In these countries, pricing\plain\cf1\f52\fs16\ql negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can\plain\cf1\f52\fs16\ql be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment\plain\cf1\f52\fs16\ql measures in the current economic climate in Europe. There is very limited harmonization on member state pricing and reimbursement\plain\cf1\f52\fs16\ql practices in the European Union.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced\plain\cf1\f52\fs16\ql member states, can further reduce prices. In particular, Germany, Portugal and Spain have all introduced a number of short-term measures\plain\cf1\f52\fs16\ql to lower healthcare spending, including mandatory discounts, clawbacks and price referencing rules, which could have a material adverse\plain\cf1\f52\fs16\ql effect on our business.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 24\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cs48001_1_25}{\*\bkmkend gmnh1page_cs48001_1_25}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement\plain\cf1\f52\fs16\ql for these products and related treatments will be available from government health administration authorities, private health insurers and\plain\cf1\f52\fs16\ql other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance\plain\cf1\f52\fs16\ql organizations, determine which medications they will cover and establish reimbursement levels. Assuming we obtain coverage for a given\plain\cf1\f52\fs16\ql product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients\plain\cf1\f52\fs16\ql find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians,\plain\cf1\f52\fs16\ql generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use\plain\cf1\f52\fs16\ql our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products.\plain\cf1\f52\fs16\ql Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and\plain\cf1\f52\fs16\ql economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or\plain\cf1\f52\fs16\ql subsequently become available.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such\plain\cf1\f52\fs16\ql as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug\plain\cf1\f52\fs16\ql companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and\plain\cf1\f52\fs16\ql preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. In\plain\cf1\f52\fs16\ql addition, in the United States, federal programs impose penalties on drug manufacturers in the form of mandatory additional rebates and/or\plain\cf1\f52\fs16\ql discounts if commercial prices increase at a rate greater than the Consumer Price Index-Urban, and these rebates and/or discounts, which\plain\cf1\f52\fs16\ql can be substantial, may impact our ability to raise commercial prices. Further, no uniform policy requirement for coverage and\plain\cf1\f52\fs16\ql reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug\plain\cf1\f52\fs16\ql products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly\plain\cf1\f52\fs16\ql process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance\plain\cf1\f52\fs16\ql that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is\plain\cf1\f52\fs16\ql available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product\plain\cf1\f52\fs16\ql candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to\plain\cf1\f52\fs16\ql limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited\plain\cf1\f52\fs16\ql than the purposes for which the drug is approved by the EMA, FDA or comparable foreign regulatory authorities. Moreover, eligibility for\plain\cf1\f52\fs16\ql coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research,\plain\cf1\f52\fs16\ql development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to\plain\cf1\f52\fs16\ql cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in\plain\cf1\f52\fs16\ql which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for\plain\cf1\f52\fs16\ql other services. Prices paid for a drug also vary depending on the class of trade. Prices charged to government customers and certain\plain\cf1\f52\fs16\ql customers that receive federal funds are subject to price controls, and private institutions may obtain discounts through group purchasing\plain\cf1\f52\fs16\ql organizations or use formularies to leverage discounts. Net prices for drugs may be reduced by mandatory discounts or rebates required by\plain\cf1\f52\fs16\ql government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries\plain\cf1\f52\fs16\ql where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement\plain\cf1\f52\fs16\ql rates from both government-funded and\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 25\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cs48001_1_26}{\*\bkmkend gmnh1page_cs48001_1_26}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise\plain\cf1\f52\fs16\ql capital needed to commercialize products and our overall financial condition.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Recently enacted and future legislation may increase the difficulty and cost for us to commercialize our product candidates and\plain\cf1\f52\fs16\b\i\ql affect the prices we may obtain.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In the United States and many foreign jurisdictions, the legislative landscape continues to evolve. There have been a number of enacted or\plain\cf1\f52\fs16\ql proposed legislative and regulatory changes affecting the healthcare system and pharmaceutical industry that could, among other things,\plain\cf1\f52\fs16\ql prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably\plain\cf1\f52\fs16\ql sell any product candidate for which we obtain marketing approval.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare\plain\cf1\f52\fs16\ql covers and pays for certain pharmaceutical products. The legislation expanded Medicare coverage for outpatient prescription drugs\plain\cf1\f52\fs16\ql dispensed to the elderly by establishing Medicare Part\~D and also introduced a new reimbursement methodology based on average sales\plain\cf1\f52\fs16\ql prices for physician-administered drugs under Medicare Part\~B. In addition, this legislation provided authority for limiting the number of\plain\cf1\f52\fs16\ql outpatient prescription drugs that Medicare will cover in any therapeutic class under the Medicare Part\~D program. Cost reduction initiatives\plain\cf1\f52\fs16\ql and other provisions of this legislation could decrease the coverage and reimbursement rate that we receive for any of our approved\plain\cf1\f52\fs16\ql products. While the MMA applies only to pharmacy benefits for Medicare beneficiaries, private payors often follow Medicare and Medicaid\plain\cf1\f52\fs16\ql coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results\plain\cf1\f52\fs16\ql from the MMA may result in a similar reduction in payments from private payors.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql More recently, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health\plain\cf1\f52\fs16\ql Care and Education Reconciliation Act of 2010, or, collectively, the PPACA, a law intended to, among other things, broaden access to health\plain\cf1\f52\fs16\ql insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new\plain\cf1\f52\fs16\ql transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device\plain\cf1\f52\fs16\ql manufacturers and impose additional health policy reforms. Among other things, the PPACA expanded manufacturers' rebate liability under\plain\cf1\f52\fs16\ql the Medicaid Drug Rebate Program by increasing the minimum rebate for single-source, multiple source innovator and non-innovator drugs,\plain\cf1\f52\fs16\ql effective the first quarter of 2010 and revising the definition of "average manufacturer price," or AMP, for calculating and reporting Medicaid\plain\cf1\f52\fs16\ql drug rebates on outpatient prescription drug prices. This could increase the amount of Medicaid drug rebates manufacturers are required to\plain\cf1\f52\fs16\ql pay to states. The PPACA further created a separate AMP for certain categories of drugs generally provided in non-retail outpatient settings.\plain\cf1\f52\fs16\ql The legislation also extended Medicaid drug rebates, previously due only on fee-for-service utilization, to Medicaid managed care utilization,\plain\cf1\f52\fs16\ql and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of\plain\cf1\f52\fs16\ql rebates due on those drugs. Also effective in 2010, the PPACA expanded the types of entities eligible to receive discounted 340B pricing,\plain\cf1\f52\fs16\ql although, with the exception of children's hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on\plain\cf1\f52\fs16\ql orphan drugs used in orphan indications. In addition, because 340B pricing is determined based on AMP and Medicaid drug rebate data, the\plain\cf1\f52\fs16\ql revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discounts to increase. The\plain\cf1\f52\fs16\ql PPACA also imposed a significant annual fee on companies that manufacture or import branded prescription drug products. Furthermore, as\plain\cf1\f52\fs16\ql of 2011, the new law changed the Medicare Part\~D coverage gap discount program by requiring manufacturers to provide a 50%\plain\cf1\f52\fs16\ql point-of-sale-discount off the negotiated price of applicable brand drugs to certain eligible beneficiaries during their coverage gap period as\plain\cf1\f52\fs16\ql a condition for the manufacturers' outpatient drugs to be covered under Medicare Part\~D. The PPACA further created a new approval\plain\cf1\f52\fs16\ql pathway for biosimilars intended to encourage competition and lower prices, and it amended Medicare Part\~B reimbursement rules for\plain\cf1\f52\fs16\ql physician-administered biologic products by making the purchase of lower cost\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 26\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cs48001_1_27}{\*\bkmkend gmnh1page_cs48001_1_27}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql biosimilars more attractive to providers reimbursed by Medicare Part\~B. As the FDA approves biosimilars, it is possible that similar rules will\plain\cf1\f52\fs16\ql be adopted by commercial managed care organizations. Substantial new provisions affecting compliance have also been enacted, which may\plain\cf1\f52\fs16\ql affect our business practices with healthcare practitioners. Notably, a significant number of provisions are not yet, or have only recently\plain\cf1\f52\fs16\ql become, effective.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. For example, in August 2011, the\plain\cf1\f52\fs16\ql President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit\plain\cf1\f52\fs16\ql Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a\plain\cf1\f52\fs16\ql targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation's automatic reduction to several\plain\cf1\f52\fs16\ql government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, that went into\plain\cf1\f52\fs16\ql effect beginning on April\~1, 2013.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Moreover, the recently enacted Drug Quality and Security Act imposes new obligations on manufacturers of pharmaceutical products, among\plain\cf1\f52\fs16\ql others, related to product tracking and tracing. Among the requirements of this new legislation, manufacturers will be required to provide\plain\cf1\f52\fs16\ql certain information regarding the drug products they produce to individuals and entities to which product ownership is transferred, label drug\plain\cf1\f52\fs16\ql products with a product identifier, and keep certain records regarding the drug products. The transfer of information to subsequent product\plain\cf1\f52\fs16\ql owners by manufacturers will eventually be required to be done electronically. Manufacturers will also be required to verify that purchasers of\plain\cf1\f52\fs16\ql the manufacturers' products are appropriately licensed. Further, under this new legislation, manufacturers will have drug product investigation,\plain\cf1\f52\fs16\ql quarantine, disposition, and FDA and trading partner notification responsibilities related to counterfeit, diverted, stolen, and intentionally\plain\cf1\f52\fs16\ql adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that\plain\cf1\f52\fs16\ql they would be reasonably likely to result in serious health consequences or death. In the European Union the Falsified Medicines Directive\plain\cf1\f52\fs16\ql imposes similar requirements which are expected to add materially to product costs.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We expect that the PPACA, as well as other federal and state healthcare reform measures that have and may be adopted in the future,\plain\cf1\f52\fs16\ql may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product,\plain\cf1\f52\fs16\ql and could seriously harm our future revenues. Any reduction in reimbursement from Medicare, Medicaid or other government programs may\plain\cf1\f52\fs16\ql result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms\plain\cf1\f52\fs16\ql may prevent us from being able to generate revenue, attain profitability or commercialize our products.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The full impact of these new laws, as well as laws and other reform measures that may be proposed and adopted in the future, remains\plain\cf1\f52\fs16\ql uncertain, but may continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also\plain\cf1\f52\fs16\ql increase our regulatory burdens and operating costs, which could have a material adverse effect on our business operations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted\plain\cf1\f52\fs16\ql price ceilings on specific products and therapies. In some countries, particularly in the European Union, the pricing of prescription\plain\cf1\f52\fs16\ql pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take\plain\cf1\f52\fs16\ql considerable time after the receipt of marketing approval for a drug. To obtain coverage and reimbursement or pricing approval in some\plain\cf1\f52\fs16\ql countries, we may be required to conduct a health technology assessment that compares the cost-effectiveness of our drug candidate to\plain\cf1\f52\fs16\ql other available therapies. There can be no assurance that our products will be considered cost-effective, that an adequate level of\plain\cf1\f52\fs16\ql reimbursement will be available or that a foreign country's reimbursement policies will not adversely affect our ability to sell our products\plain\cf1\f52\fs16\ql profitably.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 27\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cs48001_1_28}{\*\bkmkend gmnh1page_cs48001_1_28}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be\plain\cf1\f52\fs16\ql harmed, possibly materially.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Our international operations are subject to foreign currency and exchange rate risks.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Because we plan to conduct our clinical trials in Europe, we are exposed to currency fluctuations and exchange rate risks. The costs of our\plain\cf1\f52\fs16\ql CROs may be incurred in Euros and we may pay them in Euros, however, we expect to keep the substantial portion of our cash and cash\plain\cf1\f52\fs16\ql equivalents, including the net proceeds from this offering, in U.S. Dollars. Therefore, fluctuations in foreign currencies, especially the Euro,\plain\cf1\f52\fs16\ql could significantly impact our costs of conducting clinical trials. In addition, we may have to seek additional funding earlier than expected,\plain\cf1\f52\fs16\ql which may not be available on acceptable terms or at all. Changes in the applicable currency exchange rates might negatively affect the\plain\cf1\f52\fs16\ql profitability and business prospects of the third parties conducting our future clinical trials. This might cause such third parties to demand\plain\cf1\f52\fs16\ql higher fees or discontinue their operations. These situations could in turn increase our costs or delays our clinical development, which could\plain\cf1\f52\fs16\ql have a material adverse effect on our business, financial condition and results of operations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql A variety of risks associated with international operations could materially adversely affect our business.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We expect to engage in significant cross-border activities, and we will be subject to risks related to international operations, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql different regulatory requirements for maintaining approval of drugs in foreign countries;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql reduced protection for contractual and intellectual property rights in certain countries;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql unexpected changes in tariffs, trade barriers and regulatory requirements;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql economic weakness, including inflation, or political instability in particular foreign economies and markets;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other\plain\cf1\f52\fs16\ql obligations incident to doing business in another country;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql workforce uncertainty in countries where labor unrest is more common than in North America;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql tighter restrictions on privacy and the collection and use of patient data; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including\plain\cf1\f52\fs16\ql earthquakes, typhoons, floods and fires.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If any of these issues were to occur, our business could be materially harmed.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our\plain\cf1\f52\fs16\b\i\ql business strategy.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain\plain\cf1\f52\fs16\ql highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel,\plain\cf1\f52\fs16\ql especially Dr.\~Rogerio Vivaldi and Dr.\~Remy Luthringer, whose services are critical to the successful implementation of our product candidate\plain\cf1\f52\fs16\ql development and regulatory strategies. In order to induce valuable employees to continue their employment with us, we have provided stock\plain\cf1\f52\fs16\ql options that vest over time. The value to employees of stock options that vest over time is significantly affected by movements in our stock\plain\cf1\f52\fs16\ql price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their\plain\cf1\f52\fs16\ql employment with us on short notice. Pursuant to their employment arrangements, each of our executive officers may voluntarily terminate\plain\cf1\f52\fs16\ql their employment at any time by providing as little as thirty days advance notice. Our employment arrangements, other than those with our\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 28\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cs48001_1_29}{\*\bkmkend gmnh1page_cs48001_1_29}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql executive officers, provide for at-will employment, which means that any of our employees (other than our executive officers) could leave our\plain\cf1\f52\fs16\ql employment at any time, with or without notice. The loss of the services of any of our executive officers or other key employees and our\plain\cf1\f52\fs16\ql inability to find suitable replacements could potentially harm our business, financial condition and prospects. Our success also depends on\plain\cf1\f52\fs16\ql our ability to continue to attract, retain and motivate highly skilled junior, mid-level, and senior managers as well as junior, mid-level, and\plain\cf1\f52\fs16\ql senior scientific and medical personnel.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a\plain\cf1\f52\fs16\ql limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other businesses. Many of the other\plain\cf1\f52\fs16\ql pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles\plain\cf1\f52\fs16\ql and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career\plain\cf1\f52\fs16\ql advancement. Some of these characteristics may be more appealing to high quality candidates than what we have to offer. If we are unable\plain\cf1\f52\fs16\ql to continue to attract and retain high quality personnel, the rate and success at which we can develop and commercialize product candidates\plain\cf1\f52\fs16\ql will be limited.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We will need to grow the size of our organization, and we may experience difficulties in managing this growth.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As of June\~10, 2014, we had six full-time employees. As our development and commercialization plans and strategies develop, we expect to\plain\cf1\f52\fs16\ql need additional managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added\plain\cf1\f52\fs16\ql responsibilities on members of management, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql managing our clinical trials effectively;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql identifying, recruiting, maintaining, motivating and integrating additional employees;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql managing our internal development efforts effectively while complying with our contractual obligations to licensors,\plain\cf1\f52\fs16\ql licensees, contractors and other third parties;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql improving our managerial, development, operational and finance systems; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql developing our compliance infrastructure and processes to ensure compliance with complex regulations and industry\plain\cf1\f52\fs16\ql standards regarding us and our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other\plain\cf1\f52\fs16\ql third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend,\plain\cf1\f52\fs16\ql in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical\plain\cf1\f52\fs16\ql trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able\plain\cf1\f52\fs16\ql to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We are in the process of combining several corporate entities and assets into our company, which will increase our infrastructure\plain\cf1\f52\fs16\b\i\ql and reporting burden.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The integration of the businesses of Cyrenaic, Sonkei and Mind-NRG, our predecessor and acquired companies, is of critical importance to\plain\cf1\f52\fs16\ql our future success. The success of the integration will depend, in a large part, on our ability to realize the anticipated benefits, including\plain\cf1\f52\fs16\ql synergies, cost savings, innovation and operational efficiencies, from combining these businesses. To realize these anticipated benefits,\plain\cf1\f52\fs16\ql these three businesses must be successfully integrated. The failure to integrate successfully and to manage successfully the challenges\plain\cf1\f52\fs16\ql presented by the integration process may prevent us from achieving the anticipated benefits of these mergers. Any difficulties in successfully\plain\cf1\f52\fs16\ql integrating these businesses, or any delays in the integration process, could adversely affect our business, financial results and financial\plain\cf1\f52\fs16\ql condition.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 29\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cu48001_1_30}{\*\bkmkend gmnh1page_cu48001_1_30}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Future acquisitions, mergers or joint ventures could disrupt our business and otherwise harm our business.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We actively evaluate various strategic transactions on an ongoing basis and may acquire other businesses, products or technologies as well\plain\cf1\f52\fs16\ql as pursue strategic alliances, joint ventures or investments in complementary businesses. We merged with Sonkei in November 2013 and\plain\cf1\f52\fs16\ql acquired Mind-NRG in February 2014. These transactions, as well as any future strategic transactions, expose us to many risks, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql disruption in our relationships with collaborators or suppliers as a result of such a transaction;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql unanticipated liabilities related to acquired companies;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql difficulties integrating acquired personnel, technologies and operations into our existing business;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql retention of key employees;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql diversion of management time and focus from operating our business to management of strategic alliances or joint\plain\cf1\f52\fs16\ql ventures or acquisition integration challenges;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql increases in our expenses and reductions in our cash available for operations and other uses; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql possible write-offs or impairment charges relating to acquired businesses.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Foreign acquisitions, including the acquisition of Mind-NRG, a Swiss company, involve unique risks in addition to those mentioned above,\plain\cf1\f52\fs16\ql including those related to integration of operations across different cultures and languages, currency risks and the particular economic,\plain\cf1\f52\fs16\ql political and regulatory risks associated with specific countries.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize. Future acquisitions or dispositions\plain\cf1\f52\fs16\ql could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or\plain\cf1\f52\fs16\ql write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures\plain\cf1\f52\fs16\ql or acquisitions, or the effect that any such transactions might have on our operating results.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit\plain\cf1\f52\fs16\b\i\ql commercialization of our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if\plain\cf1\f52\fs16\ql we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise\plain\cf1\f52\fs16\ql unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in\plain\cf1\f52\fs16\ql manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties\plain\cf1\f52\fs16\ql brought by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. Claims\plain\cf1\f52\fs16\ql could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we\plain\cf1\f52\fs16\ql may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense\plain\cf1\f52\fs16\ql would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql decreased demand for our product candidates or products that we may develop;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql termination of clinical trial sites or entire trial programs;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql injury to our reputation and significant negative media attention;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql withdrawal of clinical trial participants;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql initiation of investigations by regulators;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql costs to defend the related litigation;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql a diversion of management's time and our resources;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql substantial monetary awards to trial participants or patients;\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 30\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cu48001_1_31}{\*\bkmkend gmnh1page_cu48001_1_31}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql product recalls, withdrawals or labeling revisions, marketing or promotional restrictions;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql loss of revenues from product sales; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the inability to commercialize our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims\plain\cf1\f52\fs16\ql could prevent or inhibit the commercialization of products we develop. We do not currently carry any product liability insurance. Although we\plain\cf1\f52\fs16\ql anticipate obtaining and maintaining such insurance in line with our needs for our upcoming trials, such insurance may be more costly than\plain\cf1\f52\fs16\ql we anticipate and any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered,\plain\cf1\f52\fs16\ql in whole or in part, by such insurance or that is in excess of the limits of such insurance coverage. We also expect our insurance policies\plain\cf1\f52\fs16\ql will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We will have to pay\plain\cf1\f52\fs16\ql any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our\plain\cf1\f52\fs16\ql insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Our business and operations would suffer in the event of system failures.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and\plain\cf1\f52\fs16\ql consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication\plain\cf1\f52\fs16\ql and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to\plain\cf1\f52\fs16\ql occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the\plain\cf1\f52\fs16\ql loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and\plain\cf1\f52\fs16\ql significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss\plain\cf1\f52\fs16\ql of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the\plain\cf1\f52\fs16\ql further development of our product candidates could be delayed.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We have identified material weaknesses and significant deficiencies in our internal control over financial reporting. If we do not\plain\cf1\f52\fs16\b\i\ql remediate the material weaknesses in our internal control over financial reporting, we may not be able to accurately report our\plain\cf1\f52\fs16\b\i\ql financial results or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported\plain\cf1\f52\fs16\b\i\ql financial information and may lead to a decline in the market price of our stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. In connection\plain\cf1\f52\fs16\ql with the preparation of our financial statements for the years ended December\~31, 2012 and 2013, we concluded that there were material\plain\cf1\f52\fs16\ql weaknesses and significant deficiencies in our internal control over financial reporting. A material weakness is a significant deficiency, or a\plain\cf1\f52\fs16\ql combination of significant deficiencies, in internal control over financial reporting such that it is reasonably possible that a material\plain\cf1\f52\fs16\ql misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses that\plain\cf1\f52\fs16\ql we identified related to (1)\~lack of segregation of duties, (2)\~lack of personnel competent to perform complex accounting, including\plain\cf1\f52\fs16\ql stock-based compensation, the convertible promissory notes beneficial conversion features and income tax disclosures, (3)\~lack of financial\plain\cf1\f52\fs16\ql statement disclosure controls, and (4)\~not performing a risk assessment. As of March\~31, 2014, certain material weaknesses and significant\plain\cf1\f52\fs16\ql deficiencies continued to exist, including (1)\~lack of segregation of duties, (2)\~lack of financial statement disclosure controls and (3)\~not\plain\cf1\f52\fs16\ql performing a risk assessment.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql While we have established certain procedures and control over our financial reporting processes, we cannot assure you that these efforts will\plain\cf1\f52\fs16\ql remediate our material weaknesses and significant deficiencies in a timely manner, or at all, or prevent restatements of our financial\plain\cf1\f52\fs16\ql statements in the future. If we are unable to\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 31\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cu48001_1_32}{\*\bkmkend gmnh1page_cu48001_1_32}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql successfully remediate our material weaknesses, or identify any future significant deficiencies or material weaknesses, the accuracy and\plain\cf1\f52\fs16\ql timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements\plain\cf1\f52\fs16\ql regarding timely filing of periodic reports, and the market price of our stock may decline as a result.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We are not currently required to comply with the SEC's rules that implement Section\~404 of the Sarbanes-Oxley Act, and are therefore not\plain\cf1\f52\fs16\ql yet required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. However, upon\plain\cf1\f52\fs16\ql becoming a public company, we will be required to comply with certain of these rules, which will require management to certify financial and\plain\cf1\f52\fs16\ql other information in our quarterly and annual reports and provide an annual management report on the effectiveness of our internal control\plain\cf1\f52\fs16\ql over financial reporting commencing with our second annual report. This assessment will need to include the disclosure of any material\plain\cf1\f52\fs16\ql weaknesses or significant deficiencies in our internal control over financial reporting identified by our management or our independent\plain\cf1\f52\fs16\ql registered public accounting firm.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Upon completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our\plain\cf1\f52\fs16\ql disclosure controls and procedures to reasonably assure us that the information we disclose in reports we file in accordance with the\plain\cf1\f52\fs16\ql Exchange Act is accurate, complete, reviewed by management and reported within the required time period. We believe that any disclosure\plain\cf1\f52\fs16\ql controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the\plain\cf1\f52\fs16\ql objectives of the control system are met.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of\plain\cf1\f52\fs16\ql simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more\plain\cf1\f52\fs16\ql people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements\plain\cf1\f52\fs16\ql due to error or fraud may occur and not be detected.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have historically operated without full time employees, relying on the services of consultants to provide certain accounting and finance\plain\cf1\f52\fs16\ql functions, including representatives of our affiliate, Care Capital\~LLC, as we have not previously had the need or resources to internally hire\plain\cf1\f52\fs16\ql sufficient qualified personnel, and our disclosure controls are not effective. We will need to hire qualified personnel and continue to develop\plain\cf1\f52\fs16\ql our disclosure control procedures. If we are unsuccessful in building an appropriate infrastructure, or unable to develop procedures and\plain\cf1\f52\fs16\ql controls to ensure timely and accurate reporting, we may be unable to meet our disclosure requirements under the Exchange Act, which\plain\cf1\f52\fs16\ql could adversely affect the market price of our common stock and impair our access to the capital markets.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Our employees, independent contractors, principal investigators, CROs, consultants, commercial partners and vendors may engage\plain\cf1\f52\fs16\b\i\ql in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal\plain\cf1\f52\fs16\ql investigators, CROs, manufacturers, consultants, commercial partners and vendors, could include failures to comply with EMA or FDA\plain\cf1\f52\fs16\ql regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with\plain\cf1\f52\fs16\ql European, federal and state healthcare fraud and abuse laws, to report financial information or data accurately or to disclose unauthorized\plain\cf1\f52\fs16\ql activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws\plain\cf1\f52\fs16\ql intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of business\plain\cf1\f52\fs16\ql activities, including, but not limited to certain activities related to research, manufacturing, distribution, pricing, discounting, marketing and\plain\cf1\f52\fs16\ql promotion, sales commission, customer incentive programs and other\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 32\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cu48001_1_33}{\*\bkmkend gmnh1page_cu48001_1_33}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql business arrangements. Employee and independent contractor misconduct could also involve the improper use of individually identifiable\plain\cf1\f52\fs16\ql information, including, without limitation, information obtained in the course of clinical trials, which could result in sanctions, monetary\plain\cf1\f52\fs16\ql penalties, and serious harm to our reputation. In addition, federal procurement laws impose substantial penalties for misconduct in\plain\cf1\f52\fs16\ql connection with government contracts and require certain contractors to maintain a code of business ethics and conduct.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Prior to the consummation of this offering, we will adopt a code of business ethics and conduct, but it is not always possible to identify and\plain\cf1\f52\fs16\ql deter employee and independent contractor misconduct, and the precautions we take to detect and prevent improper activities may not be\plain\cf1\f52\fs16\ql effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or\plain\cf1\f52\fs16\ql lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, those\plain\cf1\f52\fs16\ql actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages,\plain\cf1\f52\fs16\ql monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual\plain\cf1\f52\fs16\ql damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could\plain\cf1\f52\fs16\ql adversely affect our ability to operate.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and\plain\cf1\f52\fs16\b\i\ql third-party payors in connection with our current and future business activities are and will continue to be subject, directly or\plain\cf1\f52\fs16\b\i\ql indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, marketing expenditure tracking and disclosure\plain\cf1\f52\fs16\b\i\ql (or "sunshine") laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or\plain\cf1\f52\fs16\b\i\ql have not fully complied, with such laws, we could face penalties, contractual damages, reputational harm, diminished profits and\plain\cf1\f52\fs16\b\i\ql future earnings and curtailment or restructuring of our operations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our business operations and activities may be directly, or indirectly, subject to various federal, state and local fraud and abuse laws,\plain\cf1\f52\fs16\ql including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things,\plain\cf1\f52\fs16\ql our current activities with principal investigators and research subjects, as well as proposed and future sales, marketing and education\plain\cf1\f52\fs16\ql programs. In addition, we may be subject to patient privacy regulation by the federal government, state governments and foreign jurisdictions\plain\cf1\f52\fs16\ql in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering\plain\cf1\f52\fs16\ql or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in\plain\cf1\f52\fs16\ql kind, to induce, or in return for, the referral of an individual for the furnishing or arranging for the furnishing of any item or\plain\cf1\f52\fs16\ql service, or the purchase, lease, order, arrangement for, or recommendation of the purchase, lease, or order of any good,\plain\cf1\f52\fs16\ql facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as\plain\cf1\f52\fs16\ql the Medicare and Medicaid programs;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the civil federal False Claims Act, which imposes civil penalties, including through civil whistleblower or\plain\cf1\f52\fs16\i\ql qui tam\plain\cf1\f52\fs16\ql actions,\plain\cf1\f52\fs16\ql against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal\plain\cf1\f52\fs16\ql government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a\plain\cf1\f52\fs16\ql false record or statement to get a false or fraudulent claim paid or approved by the government; conspiring to defraud the\plain\cf1\f52\fs16\ql government by getting a false or fraudulent claim paid or approved by the government; or knowingly making, using or\plain\cf1\f52\fs16\ql causing to be made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the\plain\cf1\f52\fs16\ql federal government;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the criminal federal False Claims Act, which imposes criminal fines or imprisonment against individuals or entities who\plain\cf1\f52\fs16\ql make or present a claim to the government knowing such claim to be false, fictitious or fraudulent;\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 33\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cu48001_1_34}{\*\bkmkend gmnh1page_cu48001_1_34}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is\plain\cf1\f52\fs16\ql determined to have presented or caused to be presented a claim to a federal health program that the person knows or\plain\cf1\f52\fs16\ql should know is for an item or service that was not provided as claimed or is false or fraudulent;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the Veterans Health Care Act of 1992 that requires manufacturers of "covered drugs" to offer them for sale to certain\plain\cf1\f52\fs16\ql federal agencies, including but not limited to, the Department of Veterans Affairs, on the Federal Supply Schedule, which\plain\cf1\f52\fs16\ql requires compliance with applicable federal procurement laws and regulations and subjects manufacturers to contractual\plain\cf1\f52\fs16\ql remedies as well as administrative, civil and criminal sanctions;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal\plain\cf1\f52\fs16\ql statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare\plain\cf1\f52\fs16\ql benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or\plain\cf1\f52\fs16\ql property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor\plain\cf1\f52\fs16\ql (e.g.,\~public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully\plain\cf1\f52\fs16\ql obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering\plain\cf1\f52\fs16\ql up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or\plain\cf1\f52\fs16\ql payment for, healthcare benefits, items or services relating to healthcare matters;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and\plain\cf1\f52\fs16\ql their respective implementing regulations, which impose requirements on certain covered healthcare providers, health\plain\cf1\f52\fs16\ql plans and healthcare clearinghouses as well as their respective business associates that perform services for them that\plain\cf1\f52\fs16\ql involve individually identifiable health information, relating to the privacy, security and transmission of individually\plain\cf1\f52\fs16\ql identifiable health information without appropriate authorization, including mandatory contractual terms as well as directly\plain\cf1\f52\fs16\ql applicable privacy and security standards and requirements;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the federal Physician Payment Sunshine Act, created under the PPACA, and its implementing regulations requires\plain\cf1\f52\fs16\ql manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare,\plain\cf1\f52\fs16\ql Medicaid or the Children's Health Insurance Program (with certain exceptions) to report annually to the United States\plain\cf1\f52\fs16\ql Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to\plain\cf1\f52\fs16\ql physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well\plain\cf1\f52\fs16\ql as ownership and investment interests held by physicians and their immediate family members, with data collection\plain\cf1\f52\fs16\ql required beginning August\~1, 2013 and reporting to CMS required by March\~31, 2014 and by the 90th\~day of each\plain\cf1\f52\fs16\ql subsequent calendar year;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that\plain\cf1\f52\fs16\ql potentially harm consumers;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql federal government price reporting laws, changed by the PPACA to, among other things, increase the minimum Medicaid\plain\cf1\f52\fs16\ql rebates owed by most manufacturers under the Medicaid Drug Rebate Program and offer such rebates to additional\plain\cf1\f52\fs16\ql populations, that require us to calculate and report complex pricing metrics to government programs, where such reported\plain\cf1\f52\fs16\ql prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs. Participation in these\plain\cf1\f52\fs16\ql programs and compliance with the applicable requirements may subject us to potentially significant discounts on our\plain\cf1\f52\fs16\ql products, increased infrastructure costs and potentially limit our ability to offer certain marketplace discounts and failure to\plain\cf1\f52\fs16\ql report accurate pricing information exposes us to federal False Claims Act liability;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign\plain\cf1\f52\fs16\ql government officials (which could include, for example, certain medical professionals); and\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 34\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cu48001_1_35}{\*\bkmkend gmnh1page_cu48001_1_35}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql state law equivalents of each of the above federal laws, such as anti-kickback, false claims, consumer protection and\plain\cf1\f52\fs16\ql unfair competition laws which may apply to our business practices, including but not limited to, research, distribution,\plain\cf1\f52\fs16\ql sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any\plain\cf1\f52\fs16\ql third-party payors, including commercial insurers; state laws that require pharmaceutical companies to comply with the\plain\cf1\f52\fs16\ql pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the\plain\cf1\f52\fs16\ql federal government that otherwise restricts payments that may be made to healthcare providers; state laws that require\plain\cf1\f52\fs16\ql drug manufacturers to file reports with states regarding marketing information, such as the tracking and reporting of gifts,\plain\cf1\f52\fs16\ql compensations and other remuneration and items of value provided to healthcare professionals and entities (compliance\plain\cf1\f52\fs16\ql with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some\plain\cf1\f52\fs16\ql of these laws result in the public disclosure of various types of payments and relationships, which could potentially have a\plain\cf1\f52\fs16\ql negative effect on our business and/or increase enforcement scrutiny of our activities); and state laws governing the\plain\cf1\f52\fs16\ql privacy and security of health information in certain circumstances, many of which differ from each other in significant\plain\cf1\f52\fs16\ql ways, with differing effects.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Recent health care reform legislation has strengthened these laws. For example, the PPACA, among other things, amends the intent\plain\cf1\f52\fs16\ql requirement of the federal anti-kickback and HIPAA criminal healthcare fraud statutes. A person or entity no longer needs to have actual\plain\cf1\f52\fs16\ql knowledge of the statute or specific intent to violate it. Moreover, the PPACA provides that the government may assert that a claim including\plain\cf1\f52\fs16\ql items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the\plain\cf1\f52\fs16\ql federal Civil False Claims Act.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition, any sales of our products or product candidates once commercialized outside the United States will also likely subject us to\plain\cf1\f52\fs16\ql foreign equivalents of the healthcare laws mentioned above, among other foreign laws such as, for instance, the UK Bribery Act 2010 other\plain\cf1\f52\fs16\ql national anti-corruption legislation made as a consequence of a member states' adherence to the OECD Convention on Combating Bribery\plain\cf1\f52\fs16\ql of Foreign Public Officials in International Business Transactions, the European Union data protection regime set out in Directive 95/46/EC\plain\cf1\f52\fs16\ql as implemented nationally by the member states, and European Union consumer laws protecting against defective products including\plain\cf1\f52\fs16\ql Directive 85/374/EEC. In addition there are national laws and codes which are comparable to the United States "sunshine laws" including\plain\cf1\f52\fs16\ql certain provisions under the UK ABPI Code of Practice and French disclosure requirements on manufacturers to publicly disclose interactions\plain\cf1\f52\fs16\ql with French health care professionals.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that\plain\cf1\f52\fs16\ql governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes,\plain\cf1\f52\fs16\ql regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any\plain\cf1\f52\fs16\ql of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal\plain\cf1\f52\fs16\ql and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other\plain\cf1\f52\fs16\ql federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring\plain\cf1\f52\fs16\ql of our operations, any of which could adversely affect our ability to operate.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 35\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cu48001_1_36}{\*\bkmkend gmnh1page_cu48001_1_36}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Risks Related to Our Dependence on Third Parties\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We expect to rely on third parties to conduct our future clinical trials. The failure of these third parties to successfully carry out\plain\cf1\f52\fs16\b\i\ql their contractual duties or meet expected deadlines could substantially harm our business because we may not obtain regulatory\plain\cf1\f52\fs16\b\i\ql approval for or commercialize our product candidates in a timely manner or at all.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We plan to rely upon third-party CROs to monitor and manage data for our future clinical programs. We will rely on these parties for\plain\cf1\f52\fs16\ql execution of our clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of\plain\cf1\f52\fs16\ql our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the\plain\cf1\f52\fs16\ql CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with current GCP, which are\plain\cf1\f52\fs16\ql regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and\plain\cf1\f52\fs16\ql comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCP through\plain\cf1\f52\fs16\ql periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, the\plain\cf1\f52\fs16\ql clinical data generated in our clinical trials may be deemed unreliable and the EMA, FDA or comparable regulatory authorities may require\plain\cf1\f52\fs16\ql us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given\plain\cf1\f52\fs16\ql regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, we\plain\cf1\f52\fs16\ql must conduct our clinical trials with product produced under cGMP requirements. Failure to comply with these regulations may require us to\plain\cf1\f52\fs16\ql repeat pre-clinical and clinical trials, which would delay the regulatory approval process.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control\plain\cf1\f52\fs16\ql whether or not they devote sufficient time and resources to our ongoing clinical, nonclinical and pre-clinical programs. These CROs may\plain\cf1\f52\fs16\ql also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or\plain\cf1\f52\fs16\ql other drug development activities that could harm our competitive position. If necessary, switching or adding CROs involves substantial cost\plain\cf1\f52\fs16\ql and requires extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As\plain\cf1\f52\fs16\ql a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully\plain\cf1\f52\fs16\ql manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or\plain\cf1\f52\fs16\ql that these delays or challenges will not have a material adverse impact on our business, prospects, financial condition and results of\plain\cf1\f52\fs16\ql operations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the\plain\cf1\f52\fs16\ql clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons,\plain\cf1\f52\fs16\ql our clinical trials may be extended, delayed or terminated, we may need to conduct additional trials, and we may not be able to obtain\plain\cf1\f52\fs16\ql regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial\plain\cf1\f52\fs16\ql prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To\plain\cf1\f52\fs16\ql the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business\plain\cf1\f52\fs16\ql may be adversely affected.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We contract with third parties for the manufacturing of our product candidates for pre-clinical and clinical testing and expect to\plain\cf1\f52\fs16\b\i\ql continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities\plain\cf1\f52\fs16\b\i\ql of our product candidates or products, or such quantities at an acceptable cost, which could delay, prevent or impair our\plain\cf1\f52\fs16\b\i\ql development or commercialization efforts.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We do not have any manufacturing facilities. For our product candidates, we rely, and expect to continue to rely, on third parties for the\plain\cf1\f52\fs16\ql manufacturing of our drug candidates for pre-clinical and clinical testing, as well as for commercial manufacture if any of our drug\plain\cf1\f52\fs16\ql candidates receive marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug\plain\cf1\f52\fs16\ql candidates or drugs, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our ability to timely conduct our\plain\cf1\f52\fs16\ql clinical trials or our other development or commercialization efforts.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 36\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cw48001_1_37}{\*\bkmkend gmnh1page_cw48001_1_37}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We also expect to rely on third-party manufacturers or third-party collaborators for the manufacturing of commercial supply of any other\plain\cf1\f52\fs16\ql drug candidates for which we or our collaborators obtain marketing approval. We may be unable to establish any agreements with\plain\cf1\f52\fs16\ql third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers,\plain\cf1\f52\fs16\ql reliance on third-party manufacturers entails additional risks, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql reliance on the third party for regulatory compliance and quality assurance;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the possible breach of the manufacturing agreement by the third party;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the possible misappropriation of our proprietary information, including our trade secrets and know-how;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql disruption and costs associated with changing suppliers, including additional regulatory filings; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Moreover, the facilities used by our contract manufacturers to manufacture our products must be approved by the FDA pursuant to\plain\cf1\f52\fs16\ql inspections that will be conducted after we submit our marketing application to the FDA. Other national regulatory authorities have\plain\cf1\f52\fs16\ql comparable powers. While we are ultimately responsible for the manufacture of our product candidates, other than through our contractual\plain\cf1\f52\fs16\ql arrangements, we do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for\plain\cf1\f52\fs16\ql compliance with cGMP requirements, for manufacture of both active drug substances and finished drug products. If our contract\plain\cf1\f52\fs16\ql manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA\plain\cf1\f52\fs16\ql or other regulatory authorities, we will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition,\plain\cf1\f52\fs16\ql other than through our contractual agreements, we have no control over the ability of our contract manufacturers to maintain adequate\plain\cf1\f52\fs16\ql quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these\plain\cf1\f52\fs16\ql facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative\plain\cf1\f52\fs16\ql manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product\plain\cf1\f52\fs16\ql candidates, if approved.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Further, our suppliers are subject to regulatory requirements, covering manufacturing, testing, quality control, and record keeping relating to\plain\cf1\f52\fs16\ql our product candidates, and subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with\plain\cf1\f52\fs16\ql applicable regulations may result in long delays and interruptions to our manufacturing capacity while we seek to secure another supplier\plain\cf1\f52\fs16\ql that meets all regulatory requirements, as well as market disruption related to any necessary recalls or other corrective actions.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Third-party manufacturers may not be able to comply with cGMP, regulations or similar regulatory requirements outside the United States.\plain\cf1\f52\fs16\ql Additionally, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being\plain\cf1\f52\fs16\ql imposed on us, including clinical hold or termination, fines, imprisonment, injunctions, civil penalties, delays, suspension or withdrawal of\plain\cf1\f52\fs16\ql approvals, license revocation, seizures, refusal to allow product import or export, Warning Letters, Untitled Letters, or recalls of drug\plain\cf1\f52\fs16\ql candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our\plain\cf1\f52\fs16\ql drugs.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our drug candidates and any drugs that we may develop may compete with other drug candidates and drugs for access to manufacturing\plain\cf1\f52\fs16\ql facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for\plain\cf1\f52\fs16\ql us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We\plain\cf1\f52\fs16\ql do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current contract\plain\cf1\f52\fs16\ql manufacturers cannot perform as agreed, we may be required to replace such\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 37\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cw48001_1_38}{\*\bkmkend gmnh1page_cw48001_1_38}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql manufacturers and we may incur added costs and delays in identifying and qualifying any such replacement.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our current and anticipated future dependence upon others for the manufacturing of our drug candidates or drugs may adversely affect our\plain\cf1\f52\fs16\ql future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law,\plain\cf1\f52\fs16\b\i\ql we may be liable for damages.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological\plain\cf1\f52\fs16\ql materials, by our third-party manufacturers. Our manufacturers are or will be subject to federal, state and local laws in the United States\plain\cf1\f52\fs16\ql and in Europe governing the use, manufacture, storage, handling and disposal of medical, radioactive and hazardous materials. Although we\plain\cf1\f52\fs16\ql believe that our manufacturers' procedures for using, handling, storing and disposing of these materials comply with legally prescribed\plain\cf1\f52\fs16\ql standards, we cannot completely eliminate the risk of contamination or injury resulting from medical, radioactive or hazardous materials. As a\plain\cf1\f52\fs16\ql result of any such contamination or injury, we may incur liability or local, city, state, federal authorities or other equivalent national authorities\plain\cf1\f52\fs16\ql may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for\plain\cf1\f52\fs16\ql damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from\plain\cf1\f52\fs16\ql medical radioactive or hazardous materials. Compliance with applicable environmental laws is expensive, and current or future environmental\plain\cf1\f52\fs16\ql regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or\plain\cf1\f52\fs16\ql results of operations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We may engage third party collaborators to market and commercialize our product candidates, who may fail to effectively\plain\cf1\f52\fs16\b\i\ql commercialize our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We may utilize strategic partners or contract sales forces, where appropriate, to assist in the commercialization of our product candidates, if\plain\cf1\f52\fs16\ql approved. We currently possess limited resources and may not be successful in establishing collaborations or co-promotion arrangements\plain\cf1\f52\fs16\ql on acceptable terms, if at all. We also face competition in our search for collaborators and co-promoters. By entering into strategic\plain\cf1\f52\fs16\ql collaborations or similar arrangements, we will rely on third parties for financial resources and for development, commercialization, sales and\plain\cf1\f52\fs16\ql marketing and regulatory expertise. Any collaborators may fail to develop or effectively commercialize our product candidates because they\plain\cf1\f52\fs16\ql cannot obtain the necessary regulatory approvals, they lack adequate financial or other resources or they decide to focus on other initiatives.\plain\cf1\f52\fs16\ql Any failure to enter into collaboration or co-promotion arrangements or the failure of our third party collaborators to successfully market and\plain\cf1\f52\fs16\ql commercialize our product candidates would diminish our revenues and harm our results of operations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We depend on our collaborations with Mitsubishi Tanabe Pharma Corporation, or MTPC, and Janssen and could be seriously\plain\cf1\f52\fs16\b\i\ql harmed if our license agreements with MTPC and Janssen were terminated.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We exclusively license MIN-101 and MIN-117 from MTPC, with the rights to develop, sell and import MIN-101 and MIN-117 globally,\plain\cf1\f52\fs16\ql excluding most of Asia. Under the MIN-101 license agreement, we have to achieve the commencement of a clinical pharmacology study\plain\cf1\f52\fs16\ql containing MIN-101 by the end of April 2015. If we fail to reach this milestone, we may elect to extend the timeline to achieve the milestone\plain\cf1\f52\fs16\ql by making extension payments. If we fail to achieve this milestone by April 2015, as it may be extended, MTPC may elect to terminate the\plain\cf1\f52\fs16\ql MIN-101 license agreement. In addition, under the MIN-117 license agreement, we have to have the first subject enrolled in either a\plain\cf1\f52\fs16\ql Phase\~IIa trial or a Phase\~IIb trial in MDD with a product containing MIN-117 by the end of April 2015. We do not intend to use any of the\plain\cf1\f52\fs16\ql proceeds of this offering to pursue the development of MIN-117; therefore, we will need to raise additional financing to achieve this\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 38\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cw48001_1_39}{\*\bkmkend gmnh1page_cw48001_1_39}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql milestone. If we fail to achieve this milestone, we may elect to extend the timeline to achieve the milestone by making extension payments.\plain\cf1\f52\fs16\ql If we fail to achieve this development milestone by April 2015, as may be extended, MTPC may elect to terminate the MIN-117 license\plain\cf1\f52\fs16\ql agreement. MTPC may also terminate the licenses following a material breach or certain insolvency events. If our license agreements with\plain\cf1\f52\fs16\ql MTPC are terminated, our business would be seriously harmed.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our co-development and license agreement with Janssen provides us with European commercialization rights for MIN-202 and the right to\plain\cf1\f52\fs16\ql royalties on any sales of MIN-202 outside of the European Union. We are obligated to pay 40% of the development costs for MIN-202 and\plain\cf1\f52\fs16\ql will only realize revenues from MIN-202, if approved, and provided the license agreement with Janssen is not terminated by Janssen for\plain\cf1\f52\fs16\ql material breach or insolvency events, including if we are unable to fund our portion of the development costs. As a result, we may never\plain\cf1\f52\fs16\ql realize any revenues from the commercialization of this product candidate, even if approved. In addition, at certain development milestones,\plain\cf1\f52\fs16\ql including the completion of a single dose Phase\~I clinical trial in patients with MDD, Janssen has the right to opt out. Upon such opt out,\plain\cf1\f52\fs16\ql Janssen will not have to fund further development of MIN-202 and we may be unable to fund such development without Janssen's financial\plain\cf1\f52\fs16\ql support.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Even if we receive revenues on European Union sales or royalties on sales outside of the European Union under the Janssen license\plain\cf1\f52\fs16\ql agreement, we may not receive revenues that equal or exceed to the amount we are obligated to invest in MIN-202's clinical development\plain\cf1\f52\fs16\ql under the agreement. As a result, the license agreement for MIN-202 may never result in any profits to us and may have a material\plain\cf1\f52\fs16\ql adverse effect on us or our business prospects.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We may not be successful in establishing new collaborations which could adversely affect our ability to develop future product\plain\cf1\f52\fs16\b\i\ql candidates and commercialize future products.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have a collaboration with Janssen for the development of MIN-202. We may also seek to enter into additional product collaborations in\plain\cf1\f52\fs16\ql the future, including alliances with other biotechnology or pharmaceutical companies, to enhance and accelerate the development of our\plain\cf1\f52\fs16\ql future product candidates and the commercialization of any resulting products. In particular, we plan to explore the potential for partnerships\plain\cf1\f52\fs16\ql for the clinical development of MIN-117. We face significant competition in seeking appropriate collaborators and the negotiation process is\plain\cf1\f52\fs16\ql time-consuming and complex. Moreover, we may not be successful in our efforts to establish collaborations or other alternative\plain\cf1\f52\fs16\ql arrangements for any future product candidates because our research and development pipeline may be insufficient, our product candidates\plain\cf1\f52\fs16\ql may be deemed to be at too early of a stage of development for collaboration effort and/or third parties may view our product candidates as\plain\cf1\f52\fs16\ql lacking the requisite potential to demonstrate safety and efficacy. As a result, we may have to delay the development of a product candidate\plain\cf1\f52\fs16\ql and attempt to raise significant additional capital to fund development. Even if we are successful in our efforts to establish collaborations, the\plain\cf1\f52\fs16\ql terms that we agree upon may not be favorable to us and we may not be able to maintain such collaborations if, for example, development\plain\cf1\f52\fs16\ql or approval of a product candidate is delayed or sales of an approved product are disappointing.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Risks Related to Intellectual Property\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our success depends in significant part on our and our licensors', licensees' or collaborators' ability to establish, maintain and protect patents\plain\cf1\f52\fs16\ql and other intellectual property rights and operate without infringing the intellectual property rights of others. We have filed numerous patent\plain\cf1\f52\fs16\ql applications both in the United States and in foreign jurisdictions to obtain patent rights to inventions we have discovered. We have also\plain\cf1\f52\fs16\ql licensed from third parties rights to patent portfolios. None of these licenses give us the right to prepare, file and prosecute patent\plain\cf1\f52\fs16\ql applications and maintain patents we have licensed, although we may provide\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 39\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cw48001_1_40}{\*\bkmkend gmnh1page_cw48001_1_40}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql comments on prosecution matters which our licensors may or may not choose to follow. If our licensors elect to discontinue prosecution or\plain\cf1\f52\fs16\ql maintenance of our licensed patents, we have the right, at our expense, to pursue and maintain those patents and applications.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators\plain\cf1\f52\fs16\ql may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is\plain\cf1\f52\fs16\ql also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of\plain\cf1\f52\fs16\ql development and commercialization activities before it is too late to obtain patent protection on them. Moreover, in some circumstances, we\plain\cf1\f52\fs16\ql may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering\plain\cf1\f52\fs16\ql technology that we license from or license to third parties and are reliant on our licensors, licensees or collaborators. Therefore, these\plain\cf1\f52\fs16\ql patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current\plain\cf1\f52\fs16\ql or future licensors, licensees or collaborators fail to establish, maintain or protect such patents and other intellectual property rights, such\plain\cf1\f52\fs16\ql rights may be reduced or eliminated. If our licensors, licensees or collaborators are not fully cooperative or disagree with us as to the\plain\cf1\f52\fs16\ql prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. Because the issuance of a patent\plain\cf1\f52\fs16\ql is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may\plain\cf1\f52\fs16\ql be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in the loss of patent protection, the\plain\cf1\f52\fs16\ql narrowing of claims in such patents or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using\plain\cf1\f52\fs16\ql or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and products.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual\plain\cf1\f52\fs16\ql questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and\plain\cf1\f52\fs16\ql commercial value of our and our current or future licensors', licensees' or collaborators' patent rights are highly uncertain. Our and our\plain\cf1\f52\fs16\ql licensors', licensees' or collaborators' pending and future patent applications may not result in patents being issued which protect our\plain\cf1\f52\fs16\ql technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products.\plain\cf1\f52\fs16\ql The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our\plain\cf1\f52\fs16\ql licensors', licensees' or collaborators' pending and future patent applications, which may limit the scope of patent protection that may be\plain\cf1\f52\fs16\ql obtained. Our and our licensors', licensees' or collaborators' patent applications cannot be enforced against third parties practicing the\plain\cf1\f52\fs16\ql technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued\plain\cf1\f52\fs16\ql claims cover the technology.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents\plain\cf1\f52\fs16\ql protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed\plain\cf1\f52\fs16\ql patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We\plain\cf1\f52\fs16\ql expect to seek extensions of patent terms where these are available in any countries where we are pursuing patents. This includes in the\plain\cf1\f52\fs16\ql United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to\plain\cf1\f52\fs16\ql five years beyond the expiration of the patent. However the applicable authorities, including the FDA in the United States, and any\plain\cf1\f52\fs16\ql equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may\plain\cf1\f52\fs16\ql refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may take\plain\cf1\f52\fs16\ql advantage of our investment in development and clinical trials by referencing our clinical and pre-clinical data and launch their product\plain\cf1\f52\fs16\ql earlier than might otherwise be the case.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 40\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cw48001_1_41}{\*\bkmkend gmnh1page_cw48001_1_41}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The expiration of composition of matter patent protection with respect to one or more of our product candidates may diminish our ability to\plain\cf1\f52\fs16\ql maintain a proprietary position for our intended uses of a particular product candidate. Moreover, we cannot be certain that we will be the\plain\cf1\f52\fs16\ql first applicant to obtain an FDA approval for any indication of one or more of our product candidates and we cannot be certain that it will be\plain\cf1\f52\fs16\ql entitled to NCE exclusivity. Such diminution of its proprietary position could have a material adverse effect on our business, results of\plain\cf1\f52\fs16\ql operation and financial condition.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql One or more of our owned or licensed patents directed to our proprietary products or technologies may expire or have limited\plain\cf1\f52\fs16\b\i\ql commercial life before the proprietary product or technology is approved for marketing in a relevant jurisdiction.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our\plain\cf1\f52\fs16\ql product candidates might expire before or shortly after our product candidates obtain regulatory approval, which may subject us to increased\plain\cf1\f52\fs16\ql competition and reduce or eliminate our ability to recover our development costs. As a result, our owned and licensed patent portfolio may\plain\cf1\f52\fs16\ql not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. For example, our in-licensed\plain\cf1\f52\fs16\ql U.S. and European patents covering composition of matter and pharmaceutical compositions of MIN-101, respectively, are expected to\plain\cf1\f52\fs16\ql expire as soon as\~2021. In addition, our in-licensed U.S. and European patents relating to pharmaceutical compositions and uses of\plain\cf1\f52\fs16\ql MIN-117 to treat depression are expected to expire as soon as\~2020. Finally, certain of our U.S. patents relating to methods of diagnostic\plain\cf1\f52\fs16\ql indication and methods of screening for agents for MIN-301 are expected to expire as early as\~2021 and\~2022, respectively. Although we\plain\cf1\f52\fs16\ql expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents, we cannot be\plain\cf1\f52\fs16\ql certain that an extension will be granted, or if granted, what the applicable time period or the scope of patent protection afforded during any\plain\cf1\f52\fs16\ql extended period will be. Furthermore, the applicable authorities, including the EMA, FDA, and any equivalent regulatory authority in other\plain\cf1\f52\fs16\ql countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents,\plain\cf1\f52\fs16\ql or may grant more limited extensions than we request. If this occurs, our competitors may take advantage of our investment in development\plain\cf1\f52\fs16\ql and trials by referencing our clinical and pre-clinical data and launch their product earlier than might otherwise be the case. See the section\plain\cf1\f52\fs16\ql of this prospectus titled "Business\~\u8212?\~Intellectual Property" for further discussion of the limited life of one or more of our patents.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We have in-licensed or acquired a portion of our intellectual property necessary to develop our product candidates, and if we fail\plain\cf1\f52\fs16\b\i\ql to comply with our obligations under any of these arrangements, we could lose such intellectual property rights.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We are a party to and rely on several arrangements with third parties, which give us rights to intellectual property that is necessary for the\plain\cf1\f52\fs16\ql development of our product candidates. In addition, we may enter into similar arrangements in the future. Our current arrangements impose\plain\cf1\f52\fs16\ql various development, royalty and other obligations on us. If we materially breach these obligations or if our counterparts fail to adequately\plain\cf1\f52\fs16\ql perform their respective obligations, these exclusive arrangements could be terminated, which would result in our inability to develop,\plain\cf1\f52\fs16\ql manufacture and sell products that are covered by such intellectual property.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive,\plain\cf1\f52\fs16\b\i\ql time consuming and unsuccessful.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Competitors may infringe our issued patents or other intellectual property. In some cases, it may be difficult or impossible to detect\plain\cf1\f52\fs16\ql third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such\plain\cf1\f52\fs16\ql infringement may be even more difficult. Accordingly, for such undetectable infringement or misappropriation our ability to recover damages\plain\cf1\f52\fs16\ql will be negligible and we could be at a market disadvantage. To counter infringement or unauthorized use, we may be required to file\plain\cf1\f52\fs16\ql infringement claims, which can be expensive and time consuming. Any claims we assert\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 41\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cw48001_1_42}{\*\bkmkend gmnh1page_cw48001_1_42}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition,\plain\cf1\f52\fs16\ql in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the\plain\cf1\f52\fs16\ql patent's claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover\plain\cf1\f52\fs16\ql the technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted\plain\cf1\f52\fs16\ql narrowly.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which\plain\cf1\f52\fs16\b\i\ql would be uncertain and could harm our business.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our commercial success depends upon our ability to develop, manufacture, market and sell our products, and to use our related proprietary\plain\cf1\f52\fs16\ql technologies. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights\plain\cf1\f52\fs16\ql with respect to our products, including interference or derivation proceedings before the U.S. Patent and Trademark Office, or the USPTO.\plain\cf1\f52\fs16\ql Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are\plain\cf1\f52\fs16\ql found to infringe a third party's intellectual property rights, we could be required to obtain a license from such third party to continue\plain\cf1\f52\fs16\ql commercializing our products. However, we may not be able to obtain any required license on commercially reasonable terms or at all.\plain\cf1\f52\fs16\ql Under certain circumstances, we could be forced, including by court order, to cease commercializing our products. In addition, in any such\plain\cf1\f52\fs16\ql proceeding or litigation, we could be found liable for monetary damages.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Restrictions on our patent rights relating to our product candidates may limit our ability to prevent third parties from competing\plain\cf1\f52\fs16\b\i\ql against us.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our success will depend, in part, on our ability to obtain and maintain patent protection for our product candidates, preserve our trade\plain\cf1\f52\fs16\ql secrets, prevent third parties from infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others.\plain\cf1\f52\fs16\ql Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest\plain\cf1\f52\fs16\ql form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use.\plain\cf1\f52\fs16\ql We have filed composition-of-matter patent applications for all of our product candidates. However, we cannot be certain that the claims in\plain\cf1\f52\fs16\ql our patent applications to inventions covering our product candidates will be considered patentable by the USPTO and courts in the United\plain\cf1\f52\fs16\ql States or by the patent offices and courts in foreign countries.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition to composition-of-matter patents and patent applications, we also have filed method-of-use patent applications. This type of\plain\cf1\f52\fs16\ql patent protects the use of the product only for the specified method. However, this type of patent does not prevent a competitor from making\plain\cf1\f52\fs16\ql and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if\plain\cf1\f52\fs16\ql these competitors do not actively promote their product for our targeted indication, physicians may prescribe these products "off-label."\plain\cf1\f52\fs16\ql Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such\plain\cf1\f52\fs16\ql infringement is difficult to prevent or prosecute.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Patent applications in the United States and most other countries are confidential for a period of time until they are published, and\plain\cf1\f52\fs16\ql publication of discoveries in scientific or patent literature typically lags actual discoveries by several months or more. As a result, we cannot\plain\cf1\f52\fs16\ql be certain that we and the inventors of the issued patents and applications that we may in-license were the first to conceive of the\plain\cf1\f52\fs16\ql inventions covered by such patents and pending patent applications or that we and those inventors were the first to file patent applications\plain\cf1\f52\fs16\ql covering such inventions. Also, we have a number of issued patents and numerous patent applications pending before the USPTO and\plain\cf1\f52\fs16\ql foreign patent offices and the patent protection may lapse before we manage to obtain commercial value from them, which might result in\plain\cf1\f52\fs16\ql increased competition and materially affect our position in the market.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 42\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cw48001_1_43}{\*\bkmkend gmnh1page_cw48001_1_43}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product\plain\cf1\f52\fs16\b\i\ql candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly\plain\cf1\f52\fs16\ql patents. Obtaining and enforcing patents in the biopharmaceutical industry involve technological and legal complexity, and obtaining and\plain\cf1\f52\fs16\ql enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain. The Supreme Court has ruled on several patent\plain\cf1\f52\fs16\ql cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent\plain\cf1\f52\fs16\ql owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors' or collaborators' ability to obtain\plain\cf1\f52\fs16\ql patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on\plain\cf1\f52\fs16\ql decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways\plain\cf1\f52\fs16\ql that would weaken our and our licensors' or collaborators' ability to obtain new patents or to enforce existing patents and patents we and our\plain\cf1\f52\fs16\ql licensors or collaborators may obtain in the future.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors' or\plain\cf1\f52\fs16\ql collaborators' patent applications and the enforcement or defense of our or our licensors' or collaborators' issued patents. On September\~16,\plain\cf1\f52\fs16\ql 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of\plain\cf1\f52\fs16\ql significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect\plain\cf1\f52\fs16\ql patent litigation. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many\plain\cf1\f52\fs16\ql of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became\plain\cf1\f52\fs16\ql effective on March\~16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.\plain\cf1\f52\fs16\ql However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our\plain\cf1\f52\fs16\ql licensors' or collaborators' patent applications and the enforcement or defense of our or our licensors' or collaborators' issued patents, all of\plain\cf1\f52\fs16\ql which could have a material adverse effect on our business and financial condition.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We may not be able to protect our intellectual property rights throughout the world.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. Competitors\plain\cf1\f52\fs16\ql may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may\plain\cf1\f52\fs16\ql export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United\plain\cf1\f52\fs16\ql States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or\plain\cf1\f52\fs16\ql other intellectual property rights may not be effective or sufficient to prevent them from so competing.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The\plain\cf1\f52\fs16\ql legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual\plain\cf1\f52\fs16\ql property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our\plain\cf1\f52\fs16\ql patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign\plain\cf1\f52\fs16\ql jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee\plain\cf1\f52\fs16\b\i\ql payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or\plain\cf1\f52\fs16\b\i\ql eliminated for non-compliance with these requirements.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment\plain\cf1\f52\fs16\ql and other provisions during the patent process. There are situations\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 43\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cw48001_1_44}{\*\bkmkend gmnh1page_cw48001_1_44}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent\plain\cf1\f52\fs16\ql rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the\plain\cf1\f52\fs16\ql case.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Intellectual property rights do not necessarily address all potential threats to our competitive advantage.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,\plain\cf1\f52\fs16\ql and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql Others may be able to make compounds that are similar to our product candidates but that are not covered by the claims\plain\cf1\f52\fs16\ql of the patents that we own or have exclusively licensed.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql We or our licensors or strategic partners might not have been the first to make the inventions covered by the issued\plain\cf1\f52\fs16\ql patent or pending patent application that we own or have exclusively licensed.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql We or our licensors or strategic partners might not have been the first to file patent applications covering certain of our\plain\cf1\f52\fs16\ql inventions.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql Others may independently develop similar or alternative technologies or duplicate any of our technologies without\plain\cf1\f52\fs16\ql infringing our intellectual property rights.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql It is possible that our pending patent applications will not lead to issued patents.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql Issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be\plain\cf1\f52\fs16\ql held invalid or unenforceable, as a result of legal challenges by our competitors.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql Our competitors might conduct research and development activities in countries where we do not have patent rights and\plain\cf1\f52\fs16\ql then use the information learned from such activities to develop competitive products for sale in our major commercial\plain\cf1\f52\fs16\ql markets.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql We may not develop additional proprietary technologies that are patentable.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql The patents of others may have an adverse effect on our business.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Should any of these events occur, they could significantly harm our business, results of operations and prospects.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of\plain\cf1\f52\fs16\b\i\ql our employees' or consultants' former employers or their clients. These claims may be costly to defend and if we do not\plain\cf1\f52\fs16\b\i\ql successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Many of our employees were previously employed at universities or biotechnology or pharmaceutical companies, including our competitors or\plain\cf1\f52\fs16\ql potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have\plain\cf1\f52\fs16\ql inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be\plain\cf1\f52\fs16\ql necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose\plain\cf1\f52\fs16\ql valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to\plain\cf1\f52\fs16\ql commercialize, or prevent us from commercializing our product candidates, which could severely harm our business. Even if we are\plain\cf1\f52\fs16\ql successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 44\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cy48001_1_45}{\*\bkmkend gmnh1page_cy48001_1_45}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented\plain\cf1\f52\fs16\ql know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in\plain\cf1\f52\fs16\ql part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees,\plain\cf1\f52\fs16\ql corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter\plain\cf1\f52\fs16\ql into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to assign their\plain\cf1\f52\fs16\ql inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including\plain\cf1\f52\fs16\ql our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed\plain\cf1\f52\fs16\ql or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts\plain\cf1\f52\fs16\ql inside and outside the United States, including in foreign jurisdictions, are less willing or unwilling to protect trade secrets. If any of our trade\plain\cf1\f52\fs16\ql secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that\plain\cf1\f52\fs16\ql technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a\plain\cf1\f52\fs16\ql competitor, our competitive position would be harmed.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Risks Related to Our Common Stock and This Offering\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price\plain\cf1\f52\fs16\b\i\ql of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Prior to this offering there has been no market for shares of our common stock. Although our common stock has been approved for listing\plain\cf1\f52\fs16\ql on The NASDAQ Global Market, an active trading market for our shares may never develop or be sustained following this offering. The\plain\cf1\f52\fs16\ql initial public offering price for our common stock was determined through negotiations with the underwriters, and the negotiated price may\plain\cf1\f52\fs16\ql not be indicative of the market price of our common stock after this offering. This initial public offering price may vary from the market price\plain\cf1\f52\fs16\ql of our common stock after the offering. As a result of these and other factors, you may be unable to resell your shares of our common\plain\cf1\f52\fs16\ql stock at or above the initial public offering price. Further, an inactive market may also impair our ability to raise capital by selling shares of\plain\cf1\f52\fs16\ql our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of\plain\cf1\f52\fs16\ql common stock as consideration.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql The market price of our stock may be volatile, and you could lose all or part of your investment.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The trading price of our common stock following this offering is likely to be highly volatile and subject to wide fluctuations in response to\plain\cf1\f52\fs16\ql various factors, some of which we cannot control. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this\plain\cf1\f52\fs16\ql prospectus, these factors include:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the success of competitive products or technologies;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql regulatory actions with respect to our products or our competitors' products;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql actual or anticipated changes in our growth rate relative to our competitors;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations\plain\cf1\f52\fs16\ql or capital commitments;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql results of clinical trials of our product candidates or those of our competitors;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql developments or disputes concerning patent applications, issued patents or other proprietary rights;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the recruitment or departure of key personnel;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the results of our efforts to in-license or acquire additional product candidates or products;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities\plain\cf1\f52\fs16\ql analysts;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql variations in our financial results or those of companies that are perceived to be similar to us;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 45\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cy48001_1_46}{\*\bkmkend gmnh1page_cy48001_1_46}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql announcement or expectation of additional financing efforts;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql sales of our common stock by us, our insiders or our other stockholders;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql changes in the structure of healthcare payment systems, including coverage and reimbursement;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql market conditions in the pharmaceutical and biotechnology sectors; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql general economic, industry and market conditions.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition, companies listed on The NASDAQ Global Market, and biotechnology companies in particular, have experienced extreme price\plain\cf1\f52\fs16\ql and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market\plain\cf1\f52\fs16\ql and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The\plain\cf1\f52\fs16\ql realization of any of the above risks or any of a broad range of other risks, including those described in this "Risk Factors" section, could\plain\cf1\f52\fs16\ql have a dramatic and material adverse impact on the market price of our common stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control\plain\cf1\f52\fs16\b\i\ql over matters subject to stockholder approval.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially\plain\cf1\f52\fs16\ql owned approximately 94.1% of our voting stock on an as-converted basis and, upon completion of this offering, that same group will hold\plain\cf1\f52\fs16\ql approximately 66% of our outstanding voting stock (assuming no exercise of the underwriters' option to purchase additional shares, no\plain\cf1\f52\fs16\ql exercise of outstanding options and without giving effect to any purchases of shares in this offering by any of this group), in each case\plain\cf1\f52\fs16\ql assuming the conversion of all of our convertible notes into shares of our common stock upon the completion of this offering, the purchase\plain\cf1\f52\fs16\ql of common stock by certain former stockholders of Mind-NRG for an aggregate of $4.0\~million and the Janssen Transactions. Assuming an\plain\cf1\f52\fs16\ql initial public offering price of $6.00, if our 5% stockholders purchase all of the shares that they have indicated an interest in purchase in this\plain\cf1\f52\fs16\ql offering, the ownership of this group will increase to 85%. After this offering, this group of stockholders will have the ability to control us\plain\cf1\f52\fs16\ql through this ownership position even if they do not purchase any additional shares in this offering. These stockholders may be able to\plain\cf1\f52\fs16\ql determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors,\plain\cf1\f52\fs16\ql amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may\plain\cf1\f52\fs16\ql prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of\plain\cf1\f52\fs16\ql our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other\plain\cf1\f52\fs16\ql stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including\plain\cf1\f52\fs16\ql seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your\plain\cf1\f52\fs16\b\i\ql shares.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The initial public offering price is substantially higher than the net tangible book value per share of our common stock. Investors purchasing\plain\cf1\f52\fs16\ql common stock in this offering will pay a price per share that substantially exceeds the book value of our tangible assets after subtracting our\plain\cf1\f52\fs16\ql liabilities. As a result, investors purchasing common stock in this offering will incur immediate dilution of $4.74\~per share, based on an initial\plain\cf1\f52\fs16\ql public offering price of $6.00\~per share. Further, investors purchasing common stock in this offering will contribute approximately 28.9% of\plain\cf1\f52\fs16\ql the total amount invested by stockholders since our inception, and will own approximately 29.8% of the shares of common stock outstanding\plain\cf1\f52\fs16\ql after giving effect to this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql This dilution is due to our investors who purchased shares prior to this offering having paid substantially less than the price offered to the\plain\cf1\f52\fs16\ql public in this offering when they purchased their shares. As a result of the dilution to investors purchasing shares in this offering, investors\plain\cf1\f52\fs16\ql may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. Further, because we\plain\cf1\f52\fs16\ql will\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 46\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cy48001_1_47}{\*\bkmkend gmnh1page_cy48001_1_47}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql need to raise additional capital to fund our clinical development programs, we may in the future sell substantial amounts of common stock or\plain\cf1\f52\fs16\ql securities convertible into or exchangeable for common stock. These future issuances of common stock or common stock-related securities,\plain\cf1\f52\fs16\ql together with the exercise of outstanding options and any additional shares issued in connection with any acquisitions or other strategic\plain\cf1\f52\fs16\ql transactions, may result in further dilution to investors. For a further description of the dilution that you will experience immediately after this\plain\cf1\f52\fs16\ql offering, see the section of this prospectus titled "Dilution."\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our\plain\cf1\f52\fs16\b\i\ql stock price to fall.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or if the\plain\cf1\f52\fs16\ql market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market following this offering,\plain\cf1\f52\fs16\ql the market price of our common stock could decline significantly.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Upon the completion of this offering, we will have outstanding 18,278,084\~shares of common stock. The 5,454,545\~shares sold in this\plain\cf1\f52\fs16\ql offering will be freely tradable. The remaining 12,823,539\~additional shares of common stock will be available for sale in the public market\plain\cf1\f52\fs16\ql beginning 180\~days after the date of this prospectus following the expiration of lock-up agreements between some of our stockholders and\plain\cf1\f52\fs16\ql the representative of the underwriters, of which 1,099,919\~shares are held by our directors, executive officers and other affiliates and will be\plain\cf1\f52\fs16\ql subject to volume limitations under Rule\~144 under the Securities Act of 1933, or the Securities Act. The representative of the underwriters\plain\cf1\f52\fs16\ql may release these stockholders from their lock-up agreements with the underwriters at any time, which would allow for earlier sales of\plain\cf1\f52\fs16\ql shares in the public market.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition, following the completion of this offering, we intend to file one or more registration statements on Form\~S-8 registering the\plain\cf1\f52\fs16\ql issuance of approximately 3,543,754 shares of common stock subject to options or other equity awards issued or reserved for future\plain\cf1\f52\fs16\ql issuance under our Amended and Restated 2013 Equity Incentive Plan. Shares registered under these registration statements on Form\~S-8\plain\cf1\f52\fs16\ql will be available for sale in the public market subject to vesting arrangements and exercise of options, the lock-up agreements described\plain\cf1\f52\fs16\ql above and the restrictions of Rule\~144 in the case of our affiliates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Certain of our existing stockholders have indicated an interest in purchasing up to an aggregate of approximately $16\~million of shares of our\plain\cf1\f52\fs16\ql common stock in this offering at the initial public offering price. Any such shares purchased by these stockholders could not be resold in the\plain\cf1\f52\fs16\ql public market immediately following this offering as a result of restrictions under securities laws and lock-up agreements, but would be able\plain\cf1\f52\fs16\ql to be sold following the expiration of these restrictions as described in "Shares Eligible for Future Sale." However, because indications of\plain\cf1\f52\fs16\ql interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this\plain\cf1\f52\fs16\ql offering to any of these stockholders. In addition, any of these stockholders may determine to purchase more, less or no shares in this\plain\cf1\f52\fs16\ql offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Future sales and issuances of equity and debt securities could result in additional dilution to our stockholders and could place\plain\cf1\f52\fs16\b\i\ql restrictions on our operations and assets, and such securities could have rights, preferences and privileges senior to those of our\plain\cf1\f52\fs16\b\i\ql common stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We expect that significant additional capital will be needed in the future to fund our planned operations, including to complete potential\plain\cf1\f52\fs16\ql clinical trials for our two lead product candidates, MIN-101 and MIN-117. To raise capital, we may sell common stock, convertible securities\plain\cf1\f52\fs16\ql or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock,\plain\cf1\f52\fs16\ql convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in\plain\cf1\f52\fs16\ql material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our\plain\cf1\f52\fs16\ql common stock, including shares of common stock sold in this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 47\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cy48001_1_48}{\*\bkmkend gmnh1page_cy48001_1_48}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Pursuant to our Amended and Restated 2013 Equity Incentive Plan, our management is authorized to grant up to 3,543,754 stock options to\plain\cf1\f52\fs16\ql our employees, directors and consultants, and the number of shares of our common stock reserved for future issuance under the plan will\plain\cf1\f52\fs16\ql be subject to automatic annual increases in accordance with the terms of the plan. To the extent that new options are granted and\plain\cf1\f52\fs16\ql exercised or we issue additional shares of common stock in the future, our stockholders may experience additional dilution, which could\plain\cf1\f52\fs16\ql cause our stock price to fall.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our management will have broad discretion in the application of the net proceeds from this offering, and you will be relying on the judgment\plain\cf1\f52\fs16\ql of our management regarding the application of these proceeds. You will not have the opportunity, as part of your investment decision, to\plain\cf1\f52\fs16\ql assess whether we are using the proceeds appropriately. Our management might not apply our net proceeds in ways that ultimately\plain\cf1\f52\fs16\ql increase the value of your investment. Because of the number and variability of factors that will determine our use of the net proceeds from\plain\cf1\f52\fs16\ql this offering, their ultimate use may vary substantially from their currently intended use. If we do not invest or apply the net proceeds from\plain\cf1\f52\fs16\ql this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to\plain\cf1\f52\fs16\ql decline.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We are an "emerging growth company" and we cannot be certain if the reduced disclosure requirements applicable to emerging\plain\cf1\f52\fs16\b\i\ql growth companies will make our common stock less attractive to investors.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We are an "emerging growth company," as defined in the JOBS Act, and may take advantage of certain exemptions from various reporting\plain\cf1\f52\fs16\ql requirements that are applicable to other public companies that are not "emerging growth companies" including not being required to comply\plain\cf1\f52\fs16\ql with the auditor attestation requirements of section\~404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive\plain\cf1\f52\fs16\ql compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on\plain\cf1\f52\fs16\ql executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an emerging\plain\cf1\f52\fs16\ql growth company for up to five years following the year in which we complete this offering, although circumstances could cause us to lose\plain\cf1\f52\fs16\ql that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0\~million as of any June\~30 before\plain\cf1\f52\fs16\ql that time or if we have total annual gross revenue of $1.0\~billion or more during any fiscal year before that time, in which cases we would\plain\cf1\f52\fs16\ql no longer be an emerging growth company as of the following December\~31 or, if we issue more than $1.0\~billion in non-convertible debt\plain\cf1\f52\fs16\ql during any three year period before that time, we would cease to be an emerging growth company immediately. Even after we no longer\plain\cf1\f52\fs16\ql qualify as an emerging growth company, we may still qualify as a "smaller reporting company" which would allow us to take advantage of\plain\cf1\f52\fs16\ql many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements\plain\cf1\f52\fs16\ql of Section\~404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and our\plain\cf1\f52\fs16\ql periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on\plain\cf1\f52\fs16\ql these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our\plain\cf1\f52\fs16\ql common stock and our stock price may be more volatile.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition, Section\~102 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition\plain\cf1\f52\fs16\ql period provided in Section\~7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. An "emerging growth\plain\cf1\f52\fs16\ql company" can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private\plain\cf1\f52\fs16\ql companies.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We will incur increased costs and demands upon management as a result of being a public company.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As a public company listed in the United States, we will incur significant additional legal, accounting and other costs. We will be subject to\plain\cf1\f52\fs16\ql the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act which will require, among other things, that we file\plain\cf1\f52\fs16\ql with the Securities and Exchange\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 48\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cy48001_1_49}{\*\bkmkend gmnh1page_cy48001_1_49}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, changing\plain\cf1\f52\fs16\ql laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and\plain\cf1\f52\fs16\ql The NASDAQ Stock Market, may increase legal and financial compliance costs and make some activities more time consuming. These laws,\plain\cf1\f52\fs16\ql regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new\plain\cf1\f52\fs16\ql guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and\plain\cf1\f52\fs16\ql standards, and this investment will result in increased general and administrative expenses and a diversion of management's time and\plain\cf1\f52\fs16\ql attention. If we do not comply with new laws, regulations and standards, regulatory authorities may initiate legal proceedings against us and\plain\cf1\f52\fs16\ql our business may be harmed.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer\plain\cf1\f52\fs16\ql liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the\plain\cf1\f52\fs16\ql same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve\plain\cf1\f52\fs16\ql on our board of directors, on committees of our board of directors or as members of senior management.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We may be subject to securities litigation, which is expensive and could divert management attention.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The market price of our common stock may be volatile, and in the past, companies that have experienced volatility in the market price of\plain\cf1\f52\fs16\ql their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities\plain\cf1\f52\fs16\ql litigation against us could result in substantial costs and divert our management's attention from other business concerns, which could\plain\cf1\f52\fs16\ql seriously harm our business.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to\plain\cf1\f52\fs16\b\i\ql change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may\plain\cf1\f52\fs16\b\i\ql be lower as a result.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql There are provisions in our certificate of incorporation and bylaws that may make it difficult for a third party to acquire, or attempt to acquire,\plain\cf1\f52\fs16\ql control of our company, even if a change in control was considered favorable by you and other stockholders. For example, our board of\plain\cf1\f52\fs16\ql directors has the authority to issue up to 100,000,000 shares of preferred stock. The board of directors can fix the price, rights, preferences,\plain\cf1\f52\fs16\ql privileges and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred\plain\cf1\f52\fs16\ql stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other\plain\cf1\f52\fs16\ql rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to\plain\cf1\f52\fs16\ql other stockholders.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our charter documents also contain other provisions that could have an anti-takeover effect, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql establishing a classified board of directors such that not all members of the board are elected at one time;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql allowing the authorized number of directors to be changed only by resolution of our board of directors;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql limiting the removal of directors by the stockholders;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql authorizing the issuance of "blank check" preferred stock, the terms of which may be established and shares of which\plain\cf1\f52\fs16\ql may be issued without stockholder approval;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our\plain\cf1\f52\fs16\ql stockholders;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql eliminating the ability of stockholders to call a special meeting of stockholders;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql establishing advance notice requirements for nominations for election to the board of directors or for proposing matters\plain\cf1\f52\fs16\ql than can be acted upon at stockholder meetings; and\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 49\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_cy48001_1_50}{\*\bkmkend gmnh1page_cy48001_1_50}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql requiring the approval of the holders of at least 66\plain\cf1\f52\fs11\ql\super 2\plain\cf1\f52\fs16\ql /\plain\cf1\f52\fs11\ql 3\plain\cf1\f52\fs16\ql % of the votes that all of our stockholders would be entitled to cast\plain\cf1\f52\fs16\ql to amend or repeal our bylaws.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In addition, we are subject to the anti-takeover provisions of Section\~203 of the Delaware General Corporation Law, which regulates\plain\cf1\f52\fs16\ql corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with particular stockholders of\plain\cf1\f52\fs16\ql those companies. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control\plain\cf1\f52\fs16\ql transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions\plain\cf1\f52\fs16\ql that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are\plain\cf1\f52\fs16\ql willing to pay for our stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our\plain\cf1\f52\fs16\b\i\ql stock price and trading volume could decline.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about\plain\cf1\f52\fs16\ql us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or\plain\cf1\f52\fs16\ql industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event\plain\cf1\f52\fs16\ql securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or\plain\cf1\f52\fs16\ql unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our\plain\cf1\f52\fs16\ql company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading\plain\cf1\f52\fs16\ql volume to decline.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql We have never paid dividends on our capital stock, and because we do not anticipate paying any cash dividends in the\plain\cf1\f52\fs16\b\i\ql foreseeable future, capital appreciation, if any, of our common stock will be your sole source of gain on an investment in our\plain\cf1\f52\fs16\b\i\ql common stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have paid no cash dividends on any of our classes of capital stock to date, and we currently intend to retain our future earnings, if any,\plain\cf1\f52\fs16\ql to fund the development and growth of our business. We do not anticipate paying any cash dividends on our common stock in the\plain\cf1\f52\fs16\ql foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.\plain\cf1\f52\fs16\ql There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which you purchase shares of\plain\cf1\f52\fs16\ql our common stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 50\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_da48001_1_51}{\*\bkmkend gmnh1page_da48001_1_51}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart da48001_special_note_regarding_f}{\*\bkmkend da48001_special_note_regarding_f}{\*\bkmkstart toc_da48001_1}{\*\bkmkend toc_da48001_1}
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\ql This prospectus, including the sections titled "Prospectus Summary," "Risk Factors," "Use of Proceeds," "Management's Discussion and\plain\cf1\f52\fs16\ql Analysis of Financial Condition and Results of Operations," and "Business," contains forward-looking statements. All statements other than\plain\cf1\f52\fs16\ql statements of historical facts contained in this prospectus, including statements regarding our future operating results and financial position,\plain\cf1\f52\fs16\ql business strategy, and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can\plain\cf1\f52\fs16\ql identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects,"\plain\cf1\f52\fs16\ql "contemplates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of these terms or other similar expressions.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Forward-looking statements in this prospectus include, but are not limited to, statements about:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the initiation, timing, cost, progress and success of our research and development, pre-clinical studies and clinical trials;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql developments relating to our competitors and our industry, including the success of competing therapies that are or may\plain\cf1\f52\fs16\ql become available;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to advance product candidates into, and successfully complete, clinical trials;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the therapeutic benefits, effectiveness and safety of our product candidates;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to recruit sufficient numbers of subjects for our future clinical trials;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to obtain funding for our operations, including funding clinical trials for our lead product candidates, MIN-101\plain\cf1\f52\fs16\ql and MIN-117;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to achieve profitability;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our expectation of receiving royalties under our collaboration agreement with Janssen, and the timing of such payments;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the implementation of our business model and strategic plans;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to develop and commercialize product candidates and obtain coverage and adequate reimbursement from\plain\cf1\f52\fs16\ql third-party payors;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our commercialization, marketing and manufacturing capabilities and strategy;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to protect our intellectual property and operate our business without infringing upon the intellectual property\plain\cf1\f52\fs16\ql rights of others;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our expectations regarding federal, state and foreign regulatory requirements;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the rate and degree of market acceptance and clinical utility of our product candidates, if any;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to maintain and establish collaborations;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our use of proceeds from this offering;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our expectations regarding market risk, including interest rate changes and foreign currency fluctuations;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our belief in the sufficiency of our cash position to meet our needs until the end of 2015;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our product\plain\cf1\f52\fs16\ql candidates;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to remediate our material weaknesses in our internal control over financial reporting;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our expectations regarding the timing during which we will be an emerging growth company under the JOBS Act;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our ability to engage and retain the employees required to grow our business;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql our future financial performance and projected expenditures;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql estimates of our expenses, future revenue, capital requirements and our needs for additional financing; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the potential purchases by certain of our existing stockholders in this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 51\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_da48001_1_52}{\*\bkmkend gmnh1page_da48001_1_52}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The forward-looking statements contained in this prospectus reflect our views as of the date of this prospectus about future events and are\plain\cf1\f52\fs16\ql subject to risks, uncertainties, assumptions, and changes in circumstances that may cause our actual results, performance, or achievements\plain\cf1\f52\fs16\ql to differ significantly from those expressed or implied in any forward-looking statement. Although we believe that the expectations reflected\plain\cf1\f52\fs16\ql in the forward-looking statements are reasonable, we cannot guarantee future events, results, performance, or achievements. A number of\plain\cf1\f52\fs16\ql important factors could cause actual results to differ materially from those indicated by the forward-looking statements, including, without\plain\cf1\f52\fs16\ql limitation, those factors described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of\plain\cf1\f52\fs16\ql Operations." Except as required by law, after the date of this prospectus, we are under no duty to update or revise any of the\plain\cf1\f52\fs16\ql forward-looking statements, whether as a result of new information, future events or otherwise.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration\plain\cf1\f52\fs16\ql statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different\plain\cf1\f52\fs16\ql from what we expect. We qualify all of our forward-looking statements by these cautionary statements.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate or expect\plain\cf1\f52\fs16\ql to operate is based on information from independent industry and research organizations, such as Datamonitor, Decision Resources and\plain\cf1\f52\fs16\ql other industry publications, surveys and forecasts, and management estimates and are subject to all applicable copyrights. Management\plain\cf1\f52\fs16\ql estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data\plain\cf1\f52\fs16\ql from our internal research, and are based on assumptions made by us upon reviewing such data and our knowledge of our industry and\plain\cf1\f52\fs16\ql markets, which we believe to be reasonable. In addition, projections, assumptions and estimates of the future performance of our industry\plain\cf1\f52\fs16\ql and our future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those\plain\cf1\f52\fs16\ql described in the section of this prospectus titled "Risk Factors." These and other factors could cause results to differ materially from those\plain\cf1\f52\fs16\ql expressed in the estimates made by the independent parties and by us.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 52\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_da48001_1_53}{\*\bkmkend gmnh1page_da48001_1_53}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart da48001_use_of_proceeds}{\*\bkmkend da48001_use_of_proceeds}{\*\bkmkstart toc_da48001_2}{\*\bkmkend toc_da48001_2}
\par\pard\plain\fs16{\*\bkmkstart item_1_3_3}{\*\bkmkend item_1_3_3}\pard\plain\cf1\f52\fs16\b\qc USE OF PROCEEDS
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\ql We estimate that the net proceeds from our issuance and sale of 5,454,545 shares of our common stock in this offering will be\plain\cf1\f52\fs16\ql approximately $26.9\~million, or approximately $31.5\~million if the underwriters exercise their option to purchase additional shares in full, based\plain\cf1\f52\fs16\ql upon an assumed initial public offering price of $6.00 per share, after deducting estimated underwriting discounts and commissions and\plain\cf1\f52\fs16\ql estimated offering expenses payable by us.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Each $1.00 increase or decrease in the assumed initial public offering price of $6.00 per share, would increase or decrease the net\plain\cf1\f52\fs16\ql proceeds to us from this offering by approximately $5.1\~million, assuming that the number of shares offered by us, as set forth on the cover\plain\cf1\f52\fs16\ql page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions. Each increase or decrease of\plain\cf1\f52\fs16\ql 1,000,000 in the number of shares we are offering would increase or decrease the net proceeds to us from this offering, after deducting\plain\cf1\f52\fs16\ql estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $5.6\~million, assuming\plain\cf1\f52\fs16\ql the assumed initial public offering price stays the same.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Further, at the time of closing of this offering, we will also concurrently (i)\~sell $19.7\~million of common stock to JJDC in a private placement\plain\cf1\f52\fs16\ql and pay $22.0\~million to Janssen in connection with our co-development and license agreement for certain rights to MIN-202 and (ii)\~sell\plain\cf1\f52\fs16\ql $4.0\~million of our common stock to certain former shareholders of Mind-NRG in a private placement. As a result of these transactions, or\plain\cf1\f52\fs16\ql the Private Placement Transactions, we expect to receive an additional $1.7\~million of net cash at the time of the closing of this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As of March\~31, 2014, we had cash and cash equivalents of $2.1\~million. We currently estimate that we will use the net proceeds from this\plain\cf1\f52\fs16\ql offering and the Private Placement Transactions, together with our existing cash and cash equivalents, as follows:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql $15.3\~million to fund MIN-101 through Phase\~II clinical development;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql $5.0\~million to fund MIN-202 through Phase\~I clinical development;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql $0.8\~million to fund pre-clinical development of MIN-301;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql $0.6\~million to repay the April Bridge Loan;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql $1.0\~million to repay the May Bridge Loan;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql \u8364?0.5\~million (or $0.7\~million, as converted) to pay the ProteoSys License Fee with respect to MIN-301; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the remainder for working capital and general corporate purposes.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The April Bridge Loan was provided subsequent to March\~31, 2014 for working capital purposes by Index Ventures\~V (Jersey), L.P., an\plain\cf1\f52\fs16\ql affiliate of Index Ventures, Limburgse Reconversiemaatschappij NV, and KMOFIN\~2 NV, who became our stockholders in connection with the\plain\cf1\f52\fs16\ql Mind-NRG Acquisition, and all principal and accrued interest must be paid in connection with the closing of this offering. The April Bridge\plain\cf1\f52\fs16\ql Loan was incurred in April 2014 and has an interest rate of 8% per annum that is added to the original principal amount of $0.6\~million.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The May Bridge Loan was provided subsequent to March\~31, 2014 for working capital purposes by certain of our stockholders and their\plain\cf1\f52\fs16\ql affiliates. All principal and accrued interest must be paid in connection with the closing of this offering. The May Bridge Loan was incurred in\plain\cf1\f52\fs16\ql May 2014 and has an interest rate of 8% per annum. We have drawn down $0.5\~million under the May Bridge Loan as of June\~10, 2014.\plain\cf1\f52\fs16\ql We expect to draw down the remaining $0.5\~million prior to the closing of this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Although it is difficult to predict future liquidity requirements, we believe that the net proceeds from this offering, the Private Placement\plain\cf1\f52\fs16\ql Transactions and our existing cash and cash equivalents, will be sufficient to\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 53\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_da48001_1_54}{\*\bkmkend gmnh1page_da48001_1_54}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql fund our operations through at least the end of 2015. However, these funds will not be sufficient to complete advanced clinical development\plain\cf1\f52\fs16\ql of any of our product candidates, or if applicable, to prepare for commercializing any product candidate which achieves approval.\plain\cf1\f52\fs16\ql Accordingly, we will continue to require substantial additional capital beyond the expected proceeds of this offering to continue our clinical\plain\cf1\f52\fs16\ql development and potential commercialization activities. Because successful development of our product candidates is uncertain, we are\plain\cf1\f52\fs16\ql unable to estimate the actual funds we will require to complete research and development and commercialize our products under\plain\cf1\f52\fs16\ql development.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our intentions described above are based upon our current plans and business conditions, and could change in the future as our plans and\plain\cf1\f52\fs16\ql business conditions evolve. In addition, the development of MIN-202 is dependent on the contributions and willingness of our\plain\cf1\f52\fs16\ql co-development partner, Janssen. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors,\plain\cf1\f52\fs16\ql including the progress of our development, the status of and results from clinical trials, as well as any collaborations that we may enter into\plain\cf1\f52\fs16\ql with third parties for our product candidates, and any unforeseen cash needs. As a result, our management will have broad discretion in the\plain\cf1\f52\fs16\ql application of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application\plain\cf1\f52\fs16\ql of the net proceeds of this offering.{\*\bkmkstart da48001_dividend_policy}{\*\bkmkend da48001_dividend_policy}{\*\bkmkstart toc_da48001_3}{\*\bkmkend toc_da48001_3}
\par\pard\plain\fs16{\*\bkmkstart item_1_3_4}{\*\bkmkend item_1_3_4}\pard\plain\cf1\f52\fs16\b\qc DIVIDEND POLICY
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\ql We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. Any future determination as to\plain\cf1\f52\fs16\ql the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then existing\plain\cf1\f52\fs16\ql conditions, including our operating results, financial condition, contractual restrictions, capital requirements, business prospects, and other\plain\cf1\f52\fs16\ql factors our board of directors may deem relevant.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 54\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dc48001_1_55}{\*\bkmkend gmnh1page_dc48001_1_55}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart dc48001_capitalization}{\*\bkmkend dc48001_capitalization}{\*\bkmkstart toc_dc48001_1}{\*\bkmkend toc_dc48001_1}
\par\pard\plain\fs16{\*\bkmkstart item_1_3_5}{\*\bkmkend item_1_3_5}\pard\plain\cf1\f52\fs16\b\qc CAPITALIZATION
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\ql The following table sets forth our cash and cash equivalents and capitalization as of March\~31, 2014:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql on an actual basis;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql on a supplemental pro forma basis to reflect (i)\~the filing of our amended and restated certificate of incorporation on\plain\cf1\f52\fs16\ql June\~9, 2014; (ii)\~the repayment of $0.5\~million of debt to certain of our stockholders in April 2014; (iii)\~the incurrence of\plain\cf1\f52\fs16\ql the $0.6\~million April Bridge Loan; and (iv)\~the incurrence of the $1.0\~million May Bridge Loan, of which we have drawn\plain\cf1\f52\fs16\ql down $0.5\~million as of June\~10, 2014 and expect to draw down the remaining $0.5\~million prior to the closing of this\plain\cf1\f52\fs16\ql offering; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql on a pro forma as adjusted basis to further reflect (i)\~the conversion of the 2013 Notes, including accrued interest thereon,\plain\cf1\f52\fs16\ql into an aggregate of 351,595 shares of common stock upon the closing of this offering assuming an initial public offering\plain\cf1\f52\fs16\ql price of $6.00 per share and a closing date of June\~30, 2014; (ii)\~the repayment of the April Bridge Loan that is due and\plain\cf1\f52\fs16\ql payable upon the closing of this offering; (iii)\~the repayment of $1.0\~million relating to the May Bridge Loan that is due and\plain\cf1\f52\fs16\ql payable upon the closing of this offering; (iv)\~the payment of \u8364?0.5\~million (or $0.7\~million, as converted) to\plain\cf1\f52\fs16\ql ProteoSys for the ProteoSys License Fee; (v)\~the purchase of 3,284,353 shares of our common stock by JJDC in a\plain\cf1\f52\fs16\ql private placement concurrent with the closing of this offering at an assumed price of $6.00 per share, the assumed initial\plain\cf1\f52\fs16\ql public offering price set forth on the cover page of this prospectus for an aggregate of $19.7\~million, and our subsequent\plain\cf1\f52\fs16\ql payment of $22.0\~million to Janssen, pursuant to the co-development and license agreement with Janssen which will be\plain\cf1\f52\fs16\ql expensed upon payment; (vi)\~the purchase of 666,666 shares of our common stock by certain former stockholders of\plain\cf1\f52\fs16\ql Mind-NRG in a private placement concurrent with the closing of this offering at an assumed price of $6.00 per share, the\plain\cf1\f52\fs16\ql assumed initial public offering price set forth on the cover page of this prospectus, for an aggregate of $4.0\~million;\plain\cf1\f52\fs16\ql (vii)\~926,604 shares of common stock held by one of our stockholders that have been considered non-vested stock for\plain\cf1\f52\fs16\ql accounting purposes vesting due to the closing of this offering, resulting in a charge for stock-based compensation of\plain\cf1\f52\fs16\ql approximately $10.5\~million; and (viii)\~the sale of 5,454,545 shares of common stock in this offering at an assumed initial\plain\cf1\f52\fs16\ql public offering price of $6.00 per share, and after deducting estimated underwriting discounts and commissions and\plain\cf1\f52\fs16\ql estimated offering expenses.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql You should read this table together with "Selected Historical Financial Data," "Unaudited Pro Forma Condensed Combined Financial\plain\cf1\f52\fs16\ql Statements" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the financial statements and\plain\cf1\f52\fs16\ql related notes included elsewhere in this prospectus.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 55\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dc48001_1_56}{\*\bkmkend gmnh1page_dc48001_1_56}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1485\clvertalc\cellx2108\clvertalc\cellx2794\clvertalc\cellx3417\clvertalc\cellx4040\clvertalc\cellx4726\clvertalc\cellx5349\clvertalc\cellx5972\clvertalc\cellx6658\clvertalc\cellx7281\clvertalc\cellx7904\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1485\clvertalc\cellx2108\clvertalc\cellx2794\clvertalc\cellx3417\clvertalc\cellx4040\clvertalc\cellx4726\clvertalc\cellx5349\clvertalc\cellx5972\clvertalc\cellx6658\clvertalc\cellx7281\clvertalc\cellx7904\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1485\clvertalb\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7286\clvertalb\cellx7909\trrh197
\pard\plain\intbl\cf1\f52\fs13\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs12\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs12\b\qc AS OF MARCH\~31, 2014\cell\pard\plain\intbl\cf1\f52\fs12\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1485\clvertalb\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7286\clvertalb\cellx7909\trrh197\row}}}
{\trowd\trqc\clvertalb\cellx1485\clvertalb\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3418\clvertalb\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5351\clvertalb\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7284\clvertalb\cellx7907\trrh316
\pard\plain\intbl\cf1\f52\fs12\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs12\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs12\b\qc ACTUAL\cell\pard\plain\intbl\cf1\f52\fs12\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs12\b\qc SUPPLEMENTAL
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs12\b\qc PRO FORMA\cell\pard\plain\intbl\cf1\f52\fs12\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs12\b\qc PRO FORMA AS
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs12\b\qc ADJUSTED\cell\pard\plain\intbl\cf1\f52\fs12\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1485\clvertalb\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3418\clvertalb\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5351\clvertalb\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7284\clvertalb\cellx7907\trrh316\row}}}
{\trowd\trqc\clvertalb\cellx1485\clvertalb\cellx2108\clvertalb\cellx7286\clvertalb\cellx7909\trrh197
\pard\plain\intbl\cf1\f52\fs12\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs12\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs12\b\qc (in thousands)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs12\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1485\clvertalb\cellx2108\clvertalb\cellx7286\clvertalb\cellx7909\trrh197\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh329
\pard\plain\intbl\li198\fi-154\cf1\f52\fs13\ql Cash and cash\plain\intbl\li198\cf1\f52\fs13\ql equivalents\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 2,141\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 3,234\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 29,508\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh329\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197
\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197
\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh493
\pard\plain\intbl\li198\fi-154\cf1\f52\fs13\ql Convertible promissory\plain\intbl\li198\cf1\f52\fs13\ql notes, net of debt\plain\intbl\li198\cf1\f52\fs13\ql discount\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 333\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 333\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh493\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh164
\pard\plain\intbl\li198\fi-154\cf1\f52\fs13\ql Loans payable\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 500\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 1,600\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh164\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh164
\pard\plain\intbl\li198\fi-154\cf1\f52\fs13\ql Stockholders' equity:\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh164\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh3454
\pard\plain\intbl\li396\fi-154\cf1\f52\fs13\ql Common stock,\plain\intbl\li396\cf1\f52\fs13\ql $0.0001 par value;\plain\intbl\li396\cf1\f52\fs13\ql 45,000,000 shares\plain\intbl\li396\cf1\f52\fs13\ql authorized, actual;\plain\intbl\li396\cf1\f52\fs13\ql 125,000,000 shares\plain\intbl\li396\cf1\f52\fs13\ql authorized\plain\intbl\li396\cf1\f52\fs13\ql supplemental pro\plain\intbl\li396\cf1\f52\fs13\ql forma and pro\plain\intbl\li396\cf1\f52\fs13\ql forma as adjusted;\plain\intbl\li396\cf1\f52\fs13\ql 7,594,321\~shares\plain\intbl\li396\cf1\f52\fs13\ql issued and\plain\intbl\li396\cf1\f52\fs13\ql outstanding actual;\plain\intbl\li396\cf1\f52\fs13\ql 7,594,321 shares\plain\intbl\li396\cf1\f52\fs13\ql issued and\plain\intbl\li396\cf1\f52\fs13\ql outstanding\plain\intbl\li396\cf1\f52\fs13\ql supplemental pro\plain\intbl\li396\cf1\f52\fs13\ql forma; and\plain\intbl\li396\cf1\f52\fs13\ql 18,278,084 shares\plain\intbl\li396\cf1\f52\fs13\ql issued and\plain\intbl\li396\cf1\f52\fs13\ql outstanding pro\plain\intbl\li396\cf1\f52\fs13\ql forma as adjusted\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 1\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 1\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 2\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh3454\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh1809
\pard\plain\intbl\li396\fi-154\cf1\f52\fs13\ql Preferred stock,\plain\intbl\li396\cf1\f52\fs13\ql $0.0001 par value\plain\intbl\li396\cf1\f52\fs13\ql per share, no\plain\intbl\li396\cf1\f52\fs13\ql shares authorized\plain\intbl\li396\cf1\f52\fs13\ql actual; 100,000,000\plain\intbl\li396\cf1\f52\fs13\ql shares authorized\plain\intbl\li396\cf1\f52\fs13\ql supplemental pro\plain\intbl\li396\cf1\f52\fs13\ql forma and pro\plain\intbl\li396\cf1\f52\fs13\ql forma as adjusted,\plain\intbl\li396\cf1\f52\fs13\ql no shares issued\plain\intbl\li396\cf1\f52\fs13\ql and outstanding\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh1809\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh329
\pard\plain\intbl\li198\fi-154\cf1\f52\fs13\ql Additional paid-in\plain\intbl\li198\cf1\f52\fs13\ql capital\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 54,852\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 54,852\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 118,069\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh329\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh164
\pard\plain\intbl\li198\fi-154\cf1\f52\fs13\ql Accumulated deficit\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr (20,768\cell\pard\plain\intbl\cf1\f52\fs13\ql )\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr (20,775\cell\pard\plain\intbl\cf1\f52\fs13\ql )\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr (55,031\cell\pard\plain\intbl\cf1\f52\fs13\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh164\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197
\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh329
\pard\plain\intbl\li594\fi-154\cf1\f52\fs13\ql Total stockholders'\plain\intbl\li594\cf1\f52\fs13\ql equity\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 34,085\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 34,078\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 63,040\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1485\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2108\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3417\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4040\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4726\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5349\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5972\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7904\trrh329\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197
\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh329
\pard\plain\intbl\li792\fi-154\cf1\f52\fs13\ql Total\plain\intbl\li792\cf1\f52\fs13\ql capitalization\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 34,918\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 36,011\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 63,040\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh329\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197
\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197
\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs15\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2794\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3417\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4040\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4726\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5349\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5972\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7281\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7904\trrh197\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1485\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3418\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4041\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5351\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5974\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7284\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7907\trrh30\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\sa220\cf1\f52\fs16\ql A $1.00 increase (decrease) in the assumed initial public offering price of $6.00 per share would increase (decrease) each of cash and cash\plain\cf1\f52\fs16\ql equivalents, additional paid-in capital, and total capitalization by $5.1\~million, and decrease (increase) total stockholders' equity by\plain\cf1\f52\fs16\ql $5.1\~million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after\plain\cf1\f52\fs16\ql deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a 1,000,000\plain\cf1\f52\fs16\ql share increase (decrease) in the number of shares offered by us, as set forth on the cover of this prospectus, would increase (decrease)\plain\cf1\f52\fs16\ql each of cash and cash equivalents, additional paid-in capital, and total capitalization by $5.6\~million, and decrease (increase) total\plain\cf1\f52\fs16\ql stockholders' equity by $5.6\~million, assuming the assumed initial public offering price of $6.00 per share, remains the same and after\plain\cf1\f52\fs16\ql deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The table above excludes the following, unless otherwise indicated:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql 646,759 shares of common stock issuable upon the exercise of stock options outstanding as of March\~31, 2014 with an\plain\cf1\f52\fs16\ql exercise price of $9.49 per share;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql 2,896,995 shares of common stock reserved for future issuance under our Amended and Restated 2013 Equity Incentive\plain\cf1\f52\fs16\ql Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance\plain\cf1\f52\fs16\ql under the Plan; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql 926,604 shares of common stock issued and held by one of our stockholders that is not considered outstanding for\plain\cf1\f52\fs16\ql accounting purposes.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 56\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dc48001_1_57}{\*\bkmkend gmnh1page_dc48001_1_57}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart dc48001_dilution}{\*\bkmkend dc48001_dilution}{\*\bkmkstart toc_dc48001_2}{\*\bkmkend toc_dc48001_2}
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc DILUTION
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\ql If you invest in our common stock, your interest will be immediately diluted to the extent of the difference between the initial public offering\plain\cf1\f52\fs16\ql price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately\plain\cf1\f52\fs16\ql after this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The historical net tangible book deficit of our common stock as of March\~31, 2014 was $(3.2)\~million, or $(0.42) per share. Historical net\plain\cf1\f52\fs16\ql tangible book deficit is the amount of our total tangible assets less our total liabilities. Historical net tangible book deficit per share is our\plain\cf1\f52\fs16\ql historical net tangible book deficit, divided by the number of outstanding shares of common stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The pro forma net tangible book deficit of our common stock as of March\~31, 2014 was approximately $(3.2)\~million, or approximately $(0.42)\plain\cf1\f52\fs16\ql per share. Pro forma net tangible book deficit and pro forma net tangible book deficit per share give effect to (i)\~the repayment of\plain\cf1\f52\fs16\ql $0.5\~million of debt to certain of our stockholders in April 2014; (ii)\~the incurrence of the $0.6\~million April Bridge Loan; and (iii)\~the incurrence\plain\cf1\f52\fs16\ql of the $1.0\~million May Bridge Loan.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Pro forma as adjusted net tangible book value is our pro forma net tangible book deficit, after giving effect to (i)\~the conversion of the 2013\plain\cf1\f52\fs16\ql Notes, including accrued interest thereon, into an aggregate of 351,595 shares of common stock upon the closing of this offering at the\plain\cf1\f52\fs16\ql assumed initial public offering price of $6.00 per share and assuming a closing date of June\~30, 2014; (ii)\~the repayment of the April Bridge\plain\cf1\f52\fs16\ql Loan that is due and payable upon the closing of this offering; (iii) the repayment of the May Bridge Loan that is due and payable upon the\plain\cf1\f52\fs16\ql closing of this offering; (iv)\~the payment of \u8364?0.5\~million (or $0.7\~million, as converted) to ProteoSys for the ProteoSys License Fee;\plain\cf1\f52\fs16\ql (v)\~the purchase of 3,284,353 shares of our common stock by JJDC in a private placement concurrent with the closing of this offering at an\plain\cf1\f52\fs16\ql assumed price of $6.00 per share, the assumed initial public offering price set forth on the cover page of this prospectus, for an aggregate\plain\cf1\f52\fs16\ql of $19.7\~million, and our subsequent payment to Janssen of $22.0\~million, pursuant to the co-development and license agreement with\plain\cf1\f52\fs16\ql Janssen; (vi)\~the purchase of 666,666 shares of our common stock by certain former shareholders of Mind-NRG in a private placement\plain\cf1\f52\fs16\ql concurrent with the closing of this offering at an assumed price of $6.00 per share, the assumed initial public offering price set forth on the\plain\cf1\f52\fs16\ql cover page of this prospectus, for an aggregate of $4.0\~million; (vii)\~926,604 shares of common stock held by one of our stockholders that\plain\cf1\f52\fs16\ql have been considered non-vested stock for accounting purposes vesting due to the closing of this offering, resulting in a charge for\plain\cf1\f52\fs16\ql stock-based compensation of approximately $10.5\~million; and (viii)\~the sale of 5,454,545 shares of common stock in this offering at an\plain\cf1\f52\fs16\ql assumed initial public offering price of $6.00 per share, and after deducting estimated underwriting discounts and commissions and estimated\plain\cf1\f52\fs16\ql offering expenses payable by us. As of March\~31, 2014, our pro forma as adjusted net tangible book value would have been approximately\plain\cf1\f52\fs16\ql $23.1\~million, or approximately $1.26 per share. This represents an immediate increase in pro forma net tangible book value of $1.68 per\plain\cf1\f52\fs16\ql share to our existing stockholders and an immediate dilution of $4.74 per share to investors purchasing common stock in this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 57\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dc48001_1_58}{\*\bkmkend gmnh1page_dc48001_1_58}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The following table illustrates this dilution on a per share basis to new investors:\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1484\clvertalc\cellx2366\clvertalc\cellx3324\clvertalc\cellx4244\clvertalc\cellx5126\clvertalc\cellx6084\clvertalc\cellx7064\clvertalc\cellx7946\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1484\clvertalc\cellx2366\clvertalc\cellx3324\clvertalc\cellx4244\clvertalc\cellx5126\clvertalc\cellx6084\clvertalc\cellx7064\clvertalc\cellx7946\trrh-66\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1484\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2366\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3324\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4244\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5126\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6084\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7064\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7946\trrh619
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Assumed initial\plain\intbl\li198\cf1\f52\fs16\ql public offering\plain\intbl\li198\cf1\f52\fs16\ql price per share\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 6.00\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1484\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2366\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3324\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4244\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5126\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6084\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7064\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7946\trrh619\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh1237
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Historical net\plain\intbl\li396\cf1\f52\fs16\ql tangible book\plain\intbl\li396\cf1\f52\fs16\ql deficit per\plain\intbl\li396\cf1\f52\fs16\ql share as of\plain\intbl\li396\cf1\f52\fs16\ql March\~31,\plain\intbl\li396\cf1\f52\fs16\ql 2014\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr (0.42\cell\pard\plain\intbl\cf1\f52\fs16\ql )\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh1237\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1484\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2366\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3324\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4244\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5126\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6084\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7064\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7946\trrh2062
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Pro forma\plain\intbl\li396\cf1\f52\fs16\ql increase in\plain\intbl\li396\cf1\f52\fs16\ql net tangible\plain\intbl\li396\cf1\f52\fs16\ql book deficit\plain\intbl\li396\cf1\f52\fs16\ql per share\plain\intbl\li396\cf1\f52\fs16\ql attributable to\plain\intbl\li396\cf1\f52\fs16\ql the pro forma\plain\intbl\li396\cf1\f52\fs16\ql transactions\plain\intbl\li396\cf1\f52\fs16\ql described\plain\intbl\li396\cf1\f52\fs16\ql above\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1484\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2366\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3324\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4244\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5126\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6084\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7064\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7946\trrh2062\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh1238
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Pro forma net\plain\intbl\li396\cf1\f52\fs16\ql tangible book\plain\intbl\li396\cf1\f52\fs16\ql deficit per\plain\intbl\li396\cf1\f52\fs16\ql share as of\plain\intbl\li396\cf1\f52\fs16\ql March\~31,\plain\intbl\li396\cf1\f52\fs16\ql 2014\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr (0.42\cell\pard\plain\intbl\cf1\f52\fs16\ql )\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh1238\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1484\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2366\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3324\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4244\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5126\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6084\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7064\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7946\trrh2063
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Increase in pro\plain\intbl\li396\cf1\f52\fs16\ql forma net\plain\intbl\li396\cf1\f52\fs16\ql tangible book\plain\intbl\li396\cf1\f52\fs16\ql value per\plain\intbl\li396\cf1\f52\fs16\ql share\plain\intbl\li396\cf1\f52\fs16\ql attributable to\plain\intbl\li396\cf1\f52\fs16\ql new investors\plain\intbl\li396\cf1\f52\fs16\ql purchasing\plain\intbl\li396\cf1\f52\fs16\ql shares in this\plain\intbl\li396\cf1\f52\fs16\ql offering\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 1.68\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1484\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2366\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3324\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4244\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5126\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6084\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7064\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7946\trrh2063\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh1031
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Pro forma as\plain\intbl\li198\cf1\f52\fs16\ql adjusted net\plain\intbl\li198\cf1\f52\fs16\ql tangible book\plain\intbl\li198\cf1\f52\fs16\ql value per share\plain\intbl\li198\cf1\f52\fs16\ql after this offering\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 1.26\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh1031\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1484\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2366\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3324\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4244\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5126\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6084\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7064\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7946\trrh1031
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Dilution per share\plain\intbl\li198\cf1\f52\fs16\ql to new investors\plain\intbl\li198\cf1\f52\fs16\ql purchasing\plain\intbl\li198\cf1\f52\fs16\ql shares in this\plain\intbl\li198\cf1\f52\fs16\ql offering\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 4.74\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1484\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2366\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3324\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4244\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5126\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6084\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7064\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7946\trrh1031\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6084\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1484\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2366\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3324\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4244\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5126\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7064\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7946\trrh37\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\sa220\cf1\f52\fs16\ql A $1.00 increase (decrease) in the assumed initial public offering price of $6.00 per share would increase (decrease) the pro forma as\plain\cf1\f52\fs16\ql adjusted net tangible book value after this offering by $0.28 per share and the dilution to new investors by $0.72 per share, assuming the\plain\cf1\f52\fs16\ql number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated\plain\cf1\f52\fs16\ql underwriting discounts and commissions and estimated offering expenses payable by us.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Similarly, a 1,000,000 increase (decrease) in the number of shares offered by us, as set forth on the cover of this prospectus, would\plain\cf1\f52\fs16\ql increase (decrease) the pro forma as adjusted net tangible book value (deficit) after this offering by approximately $0.22 per share and\plain\cf1\f52\fs16\ql decrease (increase) the dilution to investors participating in this offering by approximately $0.22 per share, assuming the initial public offering\plain\cf1\f52\fs16\ql price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by\plain\cf1\f52\fs16\ql us.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If the underwriters' option to purchase additional shares in this offering is exercised in full, the pro forma as adjusted net tangible book value\plain\cf1\f52\fs16\ql after this offering would be $1.45 per share and the dilution to new investors would be $4.55 per share.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The table below summarizes as of March\~31, 2014, on a pro forma as adjusted basis described above, the number of shares of our\plain\cf1\f52\fs16\ql common stock, the total consideration, and the average price per share (i)\~paid to us by our existing stockholders and convertible\plain\cf1\f52\fs16\ql noteholders, including the investors purchasing shares in the Private Placement Transactions concurrent with the closing of this offering, and\plain\cf1\f52\fs16\ql (ii)\~to be paid by new investors purchasing our common stock in this offering at an assumed initial public offering price of $6.00 per share,\plain\cf1\f52\fs16\ql before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx540\clvertalc\cellx873\clvertalc\cellx1206\clvertalc\cellx1589\clvertalc\cellx1922\clvertalc\cellx2255\clvertalc\cellx2588\clvertalc\cellx2921\clvertalc\cellx3254\clvertalc\cellx3679\clvertalc\cellx4012\clvertalc\cellx4345\clvertalc\cellx4678\clvertalc\cellx5011\clvertalc\cellx5344\clvertalc\cellx5677\clvertalc\cellx6010\cellx6014\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx540\clvertalc\cellx873\clvertalc\cellx1206\clvertalc\cellx1589\clvertalc\cellx1922\clvertalc\cellx2255\clvertalc\cellx2588\clvertalc\cellx2921\clvertalc\cellx3254\clvertalc\cellx3679\clvertalc\cellx4012\clvertalc\cellx4345\clvertalc\cellx4678\clvertalc\cellx5011\clvertalc\cellx5344\clvertalc\cellx5677\clvertalc\cellx6010\cellx6014\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx540\clvertalb\clvmgf\cellx873\clvertalb\clvmgf\cellx2591\clvertalb\clvmgf\cellx2924\clvertalb\clvmgf\cellx4684\clvertalb\cellx5017\clvertalb\cellx5684\clvertalb\cellx6017\cellx6021\trrh106
\pard\plain\intbl\cf1\f52\fs7\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc SHARES PURCHASED\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc TOTAL\~CONSIDERATION\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs6\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx540\clvertalb\clvmgf\cellx873\clvertalb\clvmgf\cellx2591\clvertalb\clvmgf\cellx2924\clvertalb\clvmgf\cellx4684\clvertalb\cellx5017\clvertalb\cellx5684\clvertalb\cellx6017\cellx6021\trrh106\row}}}
{\trowd\trqc\clvertalb\cellx540\clvertalb\clvmrg\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx2591\clvertalb\clvmrg\cellx2924\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx4684\clvertalb\clvmgf\cellx5017\clvertalb\clvmgf\cellx5684\clvertalb\cellx6017\clvertalc\cellx6017\clvertalc\cellx6017\clvertalc\cellx6017\clvertalc\cellx6017\cellx6017\trrh106
\pard\plain\intbl\cf1\f52\fs6\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc AVERAGE
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs6\b\qc PRICE
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs6\b\qc PER SHARE\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx540\clvertalb\clvmrg\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx2591\clvertalb\clvmrg\cellx2924\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx4684\clvertalb\clvmgf\cellx5017\clvertalb\clvmgf\cellx5684\clvertalb\cellx6017\clvertalc\cellx6017\clvertalc\cellx6017\clvertalc\cellx6017\clvertalc\cellx6017\cellx6017\trrh106\row}}}
{\trowd\trqc\clvertalb\cellx540\clvertalb\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1590\clvertalb\cellx1923\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2590\clvertalb\cellx2923\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3682\clvertalb\cellx4015\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4682\clvertalb\clvmrg\cellx5015\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx5682\clvertalb\cellx6015\clvertalc\cellx6015\clvertalc\cellx6015\clvertalc\cellx6015\clvertalc\cellx6015\clvertalc\cellx6015\trrh106
\pard\plain\intbl\cf1\f52\fs6\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc NUMBER\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc PERCENT\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc AMOUNT\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc PERCENT\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs6\b\qc \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx540\clvertalb\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1590\clvertalb\cellx1923\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2590\clvertalb\cellx2923\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3682\clvertalb\cellx4015\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4682\clvertalb\clvmrg\cellx5015\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx5682\clvertalb\cellx6015\clvertalc\cellx6015\clvertalc\cellx6015\clvertalc\cellx6015\clvertalc\cellx6015\clvertalc\cellx6015\trrh106\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx540\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx873\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1206\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1589\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1922\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2255\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2588\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2921\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3254\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4345\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4678\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5011\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5344\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5677\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\trrh176
\pard\plain\intbl\li198\fi-66\cf1\f52\fs7\ql Existing\plain\intbl\li198\cf1\f52\fs7\ql stockholders\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 12,823,539\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 70.2\cell\pard\plain\intbl\cf1\f52\fs7\ql %\cell\pard\plain\intbl\cf1\f52\fs7\qr $\cell\pard\plain\intbl\cf1\f52\fs7\qr 80,669,034\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 71.1\cell\pard\plain\intbl\cf1\f52\fs7\ql %\cell\pard\plain\intbl\cf1\f52\fs7\qr $\cell\pard\plain\intbl\cf1\f52\fs7\qr 6.29\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx540\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx873\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1206\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1589\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1922\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2255\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2588\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2921\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3254\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4345\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4678\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5011\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5344\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5677\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\trrh176\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1206\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1589\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2255\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2588\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2921\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3254\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4012\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4345\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4678\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5011\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5344\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5677\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\trrh88
\pard\plain\intbl\li198\fi-66\cf1\f52\fs7\ql New investors\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 5,454,545\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 29.8\cell\pard\plain\intbl\cf1\f52\fs7\ql %\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 32,727,270\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 28.9\cell\pard\plain\intbl\cf1\f52\fs7\ql %\cell\pard\plain\intbl\cf1\f52\fs7\qr $\cell\pard\plain\intbl\cf1\f52\fs7\qr 6.00\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1206\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1589\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2255\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2588\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2921\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3254\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4012\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4345\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4678\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5011\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5344\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5677\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\trrh88\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4686\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5019\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5352\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\trrh16
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4686\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5019\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5352\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\trrh16\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1206\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1589\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2255\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2588\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2921\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3254\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4012\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4345\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4678\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5011\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5344\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5677\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\trrh106
\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1206\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1589\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2255\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2588\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2921\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3254\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4012\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4345\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4678\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5011\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5344\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5677\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\trrh106\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx540\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx873\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1206\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1589\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1922\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2255\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2588\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2921\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3254\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4345\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4678\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5011\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5344\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5677\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\trrh88
\pard\plain\intbl\li396\fi-66\cf1\f52\fs7\ql Total\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 18,278,084\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 100.0\cell\pard\plain\intbl\cf1\f52\fs7\ql %\cell\pard\plain\intbl\cf1\f52\fs7\qr $\cell\pard\plain\intbl\cf1\f52\fs7\qr 113,396,304\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr 100.0\cell\pard\plain\intbl\cf1\f52\fs7\ql %\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\cf1\f52\fs7\qr \~\cell\pard\plain\intbl\cf1\f52\fs7\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx540\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx873\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1206\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1589\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1922\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2255\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2588\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2921\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3254\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4345\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4678\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5011\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5344\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5677\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6010\trrh88\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4686\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5019\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5352\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\trrh16
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4686\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5019\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5352\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\trrh16\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1206\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1589\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2255\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2588\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2921\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3254\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4012\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4345\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4678\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5011\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5344\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5677\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\trrh106
\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1206\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1589\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2255\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2588\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2921\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3254\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4012\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4345\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4678\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5011\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5344\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5677\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\trrh106\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1206\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1589\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2255\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2588\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2921\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3254\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4012\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4345\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4678\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5011\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5344\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5677\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\trrh106
\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs8\ql \u8203?\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1206\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1589\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2255\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2588\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2921\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3254\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4012\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4345\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4678\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5011\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5344\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5677\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6010\trrh106\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4686\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5019\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5352\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\trrh16
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx540\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx873\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4686\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5019\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5352\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6018\trrh16\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\sa220\cf1\f52\fs16\ql A $1.00 increase (decrease) in the assumed initial public offering price of $6.00 per share would increase (decrease) total consideration paid\plain\cf1\f52\fs16\ql by new investors by $5.5\~million and increase (decrease) the percent of\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 58\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dc48001_1_59}{\*\bkmkend gmnh1page_dc48001_1_59}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql total consideration paid by new investors by 3.3%, assuming the number of shares offered by us, as set forth on the cover page of this\plain\cf1\f52\fs16\ql prospectus, remains the same.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Similarly, a 1,000,000 share increase (decrease) in the number of shares offered by us, as set forth on the cover of this prospectus, would\plain\cf1\f52\fs16\ql increase (decrease) total consideration paid by new investors by $6.0\~million and increase (decrease) the percent of total consideration paid\plain\cf1\f52\fs16\ql by new investors by 3.6%, assuming the initial public offering price remains the same.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql If the underwriters' option to purchase additional shares in this offering is exercised in full, the percentage of shares of our common stock\plain\cf1\f52\fs16\ql held by existing stockholders will be reduced to 67.2% of the total number of shares of our common stock outstanding after this offering, and\plain\cf1\f52\fs16\ql the number of shares held by new investors will increase to 6,272,727 shares, or 32.8% of the total number of shares of our common stock\plain\cf1\f52\fs16\ql outstanding after this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The discussion and tables above are based on 7,594,321 shares of our common stock outstanding as of March\~31, 2014, and exclude the\plain\cf1\f52\fs16\ql following, unless otherwise indicated:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql 646,759\~shares of common stock issuable upon the exercise of stock options outstanding as of March\~31, 2014 with an\plain\cf1\f52\fs16\ql exercise price of $9.49 per share;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql 2,896,995 shares of common stock reserved for future issuance under our Amended and Restated 2013 Equity Incentive\plain\cf1\f52\fs16\ql Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance\plain\cf1\f52\fs16\ql under the Plan; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql 926,604 shares of common stock issued and held by one of our stockholders that is not considered outstanding for\plain\cf1\f52\fs16\ql accounting purposes.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql To the extent that options are exercised, new options are issued under our Amended and Restated 2013 Equity Incentive Plan or we issue\plain\cf1\f52\fs16\ql additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may\plain\cf1\f52\fs16\ql choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds\plain\cf1\f52\fs16\ql for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance\plain\cf1\f52\fs16\ql of these securities could result in further dilution to our stockholders.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Certain of our existing stockholders have indicated an interest in purchasing up to an aggregate of approximately $16\~million of shares of our\plain\cf1\f52\fs16\ql common stock in this offering at the initial public offering price. Assuming an initial public offering price of $6.00 per share, these existing\plain\cf1\f52\fs16\ql stockholders would purchase an aggregate of up to approximately 2.7\~million of the 5,454,545 shares in this offering based on these\plain\cf1\f52\fs16\ql indications of interest. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters\plain\cf1\f52\fs16\ql may determine to sell more, less or no shares in this offering to any of these stockholders. In addition, any of these stockholders may\plain\cf1\f52\fs16\ql determine to purchase more, less or no shares in this offering. The foregoing discussion and tables do not reflect potential purchases of\plain\cf1\f52\fs16\ql shares of our common stock by such stockholders or our directors or officers in this offering as described in "Underwriting."\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 59\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_de48001_1_60}{\*\bkmkend gmnh1page_de48001_1_60}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart de48001_selected_historical_fina}{\*\bkmkend de48001_selected_historical_fina}{\*\bkmkstart toc_de48001_1}{\*\bkmkend toc_de48001_1}
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc SELECTED HISTORICAL FINANCIAL DATA
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\ql The following selected historical financial data should be read together with "Management's Discussion and Analysis of Financial Condition\plain\cf1\f52\fs16\ql and Results of Operations" and our historical financial statements and related notes, each of which are included elsewhere in this\plain\cf1\f52\fs16\ql prospectus.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have derived our statements of operations data for the two years ended December\~31, 2012 and 2013 and our selected balance sheet\plain\cf1\f52\fs16\ql data as of December\~31, 2012 and 2013 from our audited financial statements included elsewhere in this prospectus. We have derived our\plain\cf1\f52\fs16\ql statements of operations data for the three months ended March\~31, 2013 and 2014 and the selected balance sheet data as of March\~31,\plain\cf1\f52\fs16\ql 2014 from our unaudited interim financial statements included elsewhere in this prospectus. The selected historical results set forth below\plain\cf1\f52\fs16\ql are not necessarily indicative of results to be expected for any future period.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql This financial data does not include the results of Sonkei prior to our merger with it on November\~12, 2013, the results of Mind-NRG prior to\plain\cf1\f52\fs16\ql our acquisition of it on February\~11, 2014, the incurrence of the April Bridge Loan or the May Bridge Loan or any of the transactions\plain\cf1\f52\fs16\ql occurring at the closing of this offering. Please see "Summary Historical Financial Data," "Capitalization," "Unaudited Pro Forma Condensed\plain\cf1\f52\fs16\ql Combined Financial Statements," the Sonkei consolidated financial statements and the Mind-NRG financial statements included elsewhere in\plain\cf1\f52\fs16\ql this prospectus.\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1646\clvertalc\cellx2151\clvertalc\cellx2656\clvertalc\cellx3174\clvertalc\cellx3679\clvertalc\cellx4184\clvertalc\cellx4702\clvertalc\cellx5207\clvertalc\cellx5712\clvertalc\cellx6230\clvertalc\cellx6735\clvertalc\cellx7240\clvertalc\cellx7758\clvertalc\cellx8263\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1646\clvertalc\cellx2151\clvertalc\cellx2656\clvertalc\cellx3174\clvertalc\cellx3679\clvertalc\cellx4184\clvertalc\cellx4702\clvertalc\cellx5207\clvertalc\cellx5712\clvertalc\cellx6230\clvertalc\cellx6735\clvertalc\cellx7240\clvertalc\cellx7758\clvertalc\cellx8263\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1646\clvertalb\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4704\clvertalb\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7762\clvertalb\cellx8267\trrh256
\pard\plain\intbl\cf1\f52\fs10\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs10\b\qc YEAR ENDED DECEMBER\~31,\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs10\b\qc THREE MONTHS ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs10\b\qc MARCH\~31,\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1646\clvertalb\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4704\clvertalb\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7762\clvertalb\cellx8267\trrh256\row}}}
{\trowd\trqc\clvertalb\cellx1646\clvertalb\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3175\clvertalb\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4704\clvertalb\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6233\clvertalb\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7762\clvertalb\cellx8267\trrh160
\pard\plain\intbl\cf1\f52\fs10\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs10\b\qc 2012\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs10\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs10\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs10\b\qc 2014\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1646\clvertalb\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3175\clvertalb\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4704\clvertalb\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6233\clvertalb\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7762\clvertalb\cellx8267\trrh160\row}}}
{\trowd\trqc\clvertalb\cellx1646\clvertalb\cellx2151\clvertalb\cellx7764\clvertalb\cellx8269\trrh288
\pard\plain\intbl\cf1\f52\fs10\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs10\b\qc (in thousands, except share
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs10\b\qc and per share data)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs10\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1646\clvertalb\cellx2151\clvertalb\cellx7764\clvertalb\cellx8269\trrh288\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\b\ql Statement of Operations Data:\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh133
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Expenses\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh133\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133
\pard\plain\intbl\li396\fi-110\cf1\f52\fs10\ql Research\~and\~development\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr 550\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr 708\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr 104\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr 586\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh133
\pard\plain\intbl\li396\fi-110\cf1\f52\fs10\ql General and administrative\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 1,031\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 2,467\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 167\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 2,037\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh133\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3175\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6233\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7762\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8267\trrh24
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3175\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6233\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7762\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8267\trrh24\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh160
\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh160\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Total expenses\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 1,581\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 3,175\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 271\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 2,623\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh267
\pard\plain\intbl\li396\fi-110\cf1\f52\fs10\ql Foreign exchange\plain\intbl\li396\cf1\f52\fs10\ql (gains)/losses and other, net\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 1\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 29\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 7\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh267\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133
\pard\plain\intbl\li396\fi-110\cf1\f52\fs10\ql Interest expense, net\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 58\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 308\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3175\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6233\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7762\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8267\trrh24
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3175\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6233\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7762\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8267\trrh24\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh160
\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh160\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh133
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Net loss\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (1,582\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (3,262\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (271\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (2,938\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh133\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3175\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6233\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7762\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8267\trrh24
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3175\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6233\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7762\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8267\trrh24\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh160
\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh160\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh160
\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh160\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3175\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6233\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7762\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8267\trrh24
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3175\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3680\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5209\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6233\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6738\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7762\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8267\trrh24\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\b\ql Per Share Data:\plain\intbl\li198\cf1\f52\fs7\b\ql\super (1)\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh133\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh267
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Net loss per share\~\u8212? basic\plain\intbl\li198\cf1\f52\fs10\ql and diluted\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (0.47\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (0.78\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (0.08\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (0.43\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1646\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2151\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2656\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3174\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3679\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4184\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5207\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6230\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6735\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7240\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7758\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8263\trrh267\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh400
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Weighted average shares\plain\intbl\li198\cf1\f52\fs10\ql outstanding\~\u8212? basic and\plain\intbl\li198\cf1\f52\fs10\ql diluted\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 3,386,914\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 4,186,104\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 3,562,454\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 6,902,910\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1646\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2151\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2656\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3174\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3679\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4184\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5207\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6230\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6735\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7240\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8263\trrh400\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\li440\ri220\sb220\sa220\cf1\f52\fs16\i\ql (1)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql Per share data excludes 926,604 shares of common stock held by one of our stockholders that is not considered outstanding for\plain\li440\ri220\cf1\f52\fs16\ql accounting purposes for the periods presented. See "Management Discussion and Analysis\~\u8212? Results of Operations."\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 60\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_de48001_1_61}{\*\bkmkend gmnh1page_de48001_1_61}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1343\clvertalc\cellx1583\clvertalc\cellx1823\clvertalc\cellx2445\clvertalc\cellx2685\clvertalc\cellx2925\clvertalc\cellx3905\clvertalc\cellx4145\clvertalc\cellx4586\clvertalc\cellx6306\clvertalc\cellx6546\cellx7031\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1343\clvertalc\cellx1583\clvertalc\cellx1823\clvertalc\cellx2445\clvertalc\cellx2685\clvertalc\cellx2925\clvertalc\cellx3905\clvertalc\cellx4145\clvertalc\cellx4586\clvertalc\cellx6306\clvertalc\cellx6546\cellx7031\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1343\clvertalb\clvmgf\cellx1583\clvertalb\clvmgf\cellx3906\clvertalb\cellx4146\clvertalb\cellx6307\clvertalb\cellx6547\cellx7032\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc DECEMBER\~31,\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx1343\clvertalb\clvmgf\cellx1583\clvertalb\clvmgf\cellx3906\clvertalb\cellx4146\clvertalb\cellx6307\clvertalb\cellx6547\cellx7032\trrh248\row}}}
{\trowd\trqc\clvertalb\cellx1343\clvertalb\clvmrg\cellx1583\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx3906\clvertalb\clvmgf\cellx4146\clvertalb\clvmgf\cellx6307\clvertalb\cellx6547\clvertalc\cellx6644\clvertalc\cellx6741\clvertalc\cellx6838\clvertalc\cellx6935\cellx7032\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc MARCH\~31, 2014\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx1343\clvertalb\clvmrg\cellx1583\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx3906\clvertalb\clvmgf\cellx4146\clvertalb\clvmgf\cellx6307\clvertalb\cellx6547\clvertalc\cellx6644\clvertalc\cellx6741\clvertalc\cellx6838\clvertalc\cellx6935\cellx7032\trrh248\row}}}
{\trowd\trqc\clvertalb\cellx1343\clvertalb\cellx1583\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2445\clvertalb\cellx2685\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3905\clvertalb\clvmrg\cellx4145\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx6306\clvertalb\cellx6546\clvertalc\cellx6643\clvertalc\cellx6740\clvertalc\cellx6837\clvertalc\cellx6934\clvertalc\cellx7031\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2012\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2013\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx1343\clvertalb\cellx1583\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2445\clvertalb\cellx2685\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3905\clvertalb\clvmrg\cellx4145\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx6306\clvertalb\cellx6546\clvertalc\cellx6643\clvertalc\cellx6740\clvertalc\cellx6837\clvertalc\cellx6934\clvertalc\cellx7031\trrh248\row}}}
{\trowd\trqc\clvertalb\cellx1343\clvertalb\cellx1583\clvertalb\cellx6307\clvertalb\cellx6547\clvertalc\cellx6644\clvertalc\cellx6741\clvertalc\cellx6838\clvertalc\cellx6935\clvertalc\cellx7032\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc (in thousands)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\cellx1343\clvertalb\cellx1583\clvertalb\cellx6307\clvertalb\cellx6547\clvertalc\cellx6644\clvertalc\cellx6741\clvertalc\cellx6838\clvertalc\cellx6935\clvertalc\cellx7032\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh619
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\b\ql Selected\plain\intbl\li198\cf1\f52\fs16\b\ql Balance\plain\intbl\li198\cf1\f52\fs16\b\ql Sheet Data:\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh619\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh412
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Cash and cash\plain\intbl\li198\cf1\f52\fs16\ql equivalents\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 200\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 1,818\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 2,141\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh412\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh619
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql In-process\plain\intbl\li198\cf1\f52\fs16\ql research and\plain\intbl\li198\cf1\f52\fs16\ql development\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 19,000\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 34,200\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh619\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Goodwill\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 7,918\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 15,104\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh825
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Other current\plain\intbl\li198\cf1\f52\fs16\ql and\plain\intbl\li198\cf1\f52\fs16\ql non-current\plain\intbl\li198\cf1\f52\fs16\ql assets\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 9\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 439\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 1,693\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh825\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\b\ql Total assets\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 209\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 29,175\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 53,138\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh1031
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Accounts\plain\intbl\li198\cf1\f52\fs16\ql payable,\plain\intbl\li198\cf1\f52\fs16\ql accrued\plain\intbl\li198\cf1\f52\fs16\ql expenses and\plain\intbl\li198\cf1\f52\fs16\ql other liabilities\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 190\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 1,348\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 5,051\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh1031\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh825
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Convertible\plain\intbl\li198\cf1\f52\fs16\ql promissory\plain\intbl\li198\cf1\f52\fs16\ql notes, net of\plain\intbl\li198\cf1\f52\fs16\ql discount\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 58\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 333\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh825\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh413
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Deferred tax\plain\intbl\li198\cf1\f52\fs16\ql liability\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 7,589\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 13,669\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh413\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Total liabilities\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 190\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 8,995\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 19,053\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh619
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\b\ql Total\plain\intbl\li198\cf1\f52\fs16\b\ql stockholders'\plain\intbl\li198\cf1\f52\fs16\b\ql equity\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 19\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 20,180\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 34,085\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1343\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1583\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2445\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2685\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2925\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3905\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4145\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4586\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6306\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6546\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6643\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6740\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6837\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx6934\clvertalc\clshdng100\clcfpat11\clcbpat11\cellx7031\trrh619\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh825
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\b\ql Total liabilities\plain\intbl\li198\cf1\f52\fs16\b\ql and\plain\intbl\li198\cf1\f52\fs16\b\ql stockholders'\plain\intbl\li198\cf1\f52\fs16\b\ql equity\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 209\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 29,175\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 53,138\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1343\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1583\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2445\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2685\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2925\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3905\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4145\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4586\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6306\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6546\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6643\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6740\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6837\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx6934\clvertalc\clshdng100\clcfpat7\clcbpat7\cellx7031\trrh825\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\cf1\f52\fs16\qc 61\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dg48001_1_62}{\*\bkmkend gmnh1page_dg48001_1_62}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart dg48001_unaudited_pro_forma_co__}{\*\bkmkend dg48001_unaudited_pro_forma_co__}{\*\bkmkstart toc_dg48001_1}{\*\bkmkend toc_dg48001_1}
\par\pard\plain\fs16\pard\plain\cf1\f52\fs16\b\qc UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\ql The following unaudited pro forma condensed combined financial information presents the unaudited pro forma condensed combined\plain\cf1\f52\fs16\ql statements of operations for the year ended December\~31, 2013 and the three months ended March\~31, 2014 after giving effect to the\plain\cf1\f52\fs16\ql transactions and adjustments as described in the accompanying notes. The unaudited pro forma condensed combined financial information\plain\cf1\f52\fs16\ql includes our historical results of operations, after giving pro forma effect to\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the November 2013 Sonkei Merger, presented as "Total Minerva and Sonkei" in the unaudited pro forma condensed\plain\cf1\f52\fs16\ql combined statements of operations for the year ended December\~31, 2013; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql the February\~2014 Mind-NRG Acquisition, presented as "Pro Forma Combined for Mind-NRG Acquisition" in the\plain\cf1\f52\fs16\ql unaudited pro forma statement of operations for the year ended December\~31, 2013 and the three months ended\plain\cf1\f52\fs16\ql March\~31, 2014.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The unaudited pro forma condensed combined statements of operations for the year ended December\~31, 2013 reflect the above\plain\cf1\f52\fs16\ql transactions as if they occurred on January\~1, 2013. The unaudited pro forma condensed combined statements of operations for the three\plain\cf1\f52\fs16\ql months ended March\~31, 2014 reflect the Mind-NRG Acquisition as if it occurred on January\~1, 2013.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The historical financial information has been adjusted to give pro forma effect to events that are directly attributable to the transactions\plain\cf1\f52\fs16\ql described above, have an ongoing effect on our statements of operations and are factually supportable. The unaudited pro forma condensed\plain\cf1\f52\fs16\ql combined statements of operations show the impact on the combined statement of operations of the acquisition method of accounting under\plain\cf1\f52\fs16\ql Financial Accounting Standards Board ASC 805,\plain\cf1\f52\fs16\i\ql Business Combinations\plain\cf1\f52\fs16\ql .\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The unaudited pro forma condensed combined financial information was prepared in accordance with Article\~11 of Regulation\~S-X, using the\plain\cf1\f52\fs16\ql assumptions set forth in the notes to the unaudited pro forma condensed combined financial information. The following unaudited pro forma\plain\cf1\f52\fs16\ql condensed combined financial information is presented for illustrative purposes only and does not purport to reflect the results we may\plain\cf1\f52\fs16\ql achieve in future periods or the historical results that would have been obtained had the above transactions been completed as of January\~1,\plain\cf1\f52\fs16\ql 2013.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The unaudited pro forma condensed combined financial information also does not give effect to the potential impact of current financial\plain\cf1\f52\fs16\ql conditions, any anticipated synergies, operating efficiencies or cost savings that may result from the above transaction. Further, the\plain\cf1\f52\fs16\ql unaudited pro forma condensed combined financial information does not include any other transactions since March\~31, 2014 or transactions\plain\cf1\f52\fs16\ql that will occur in connection with the closing of this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The unaudited pro forma condensed combined financial information is derived from and should be read in conjunction with our historical\plain\cf1\f52\fs16\ql financial statements and related notes included elsewhere in this prospectus.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 62\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_di48001_1_63}{\*\bkmkend gmnh1page_di48001_1_63}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx513\clvertalc\cellx755\clvertalc\cellx1063\clvertalc\cellx1371\clvertalc\cellx1613\clvertalc\cellx1855\clvertalc\cellx2097\clvertalc\cellx2339\clvertalc\cellx2581\clvertalc\cellx2823\clvertalc\cellx3065\clvertalc\cellx3307\clvertalc\cellx3549\clvertalc\cellx3791\clvertalc\cellx4033\clvertalc\cellx4275\clvertalc\cellx4517\clvertalc\cellx4759\clvertalc\cellx5001\clvertalc\cellx5243\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx513\clvertalc\cellx755\clvertalc\cellx1063\clvertalc\cellx1371\clvertalc\cellx1613\clvertalc\cellx1855\clvertalc\cellx2097\clvertalc\cellx2339\clvertalc\cellx2581\clvertalc\cellx2823\clvertalc\cellx3065\clvertalc\cellx3307\clvertalc\cellx3549\clvertalc\cellx3791\clvertalc\cellx4033\clvertalc\cellx4275\clvertalc\cellx4517\clvertalc\cellx4759\clvertalc\cellx5001\clvertalc\cellx5243\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx513\clvertalb\cellx755\clvertalb\cellx5005\clvertalb\cellx5247\trrh77
\pard\plain\intbl\cf1\f52\fs4\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc YEAR ENDED DECEMBER\~31, 2013
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx513\clvertalb\cellx755\clvertalb\cellx5005\clvertalb\cellx5247\trrh77\row}}}
{\trowd\trqc\clvertalb\cellx513\clvertalb\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1371\clvertalb\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2097\clvertalb\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2823\clvertalb\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3549\clvertalb\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4275\clvertalb\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5001\clvertalb\cellx5243\trrh307
\pard\plain\intbl\cf1\f52\fs4\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc HISTORICAL MINERVA
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc NEUROSCIENCES,\~INC.\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc HISTORICAL
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc SONKEI
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc JANUARY\~1, 2013-
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc NOVEMBER\~12,\plain\intbl\cf1\f52\fs4\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc ADJUSTMENT\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc TOTAL
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc MINERVA
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc AND SONKEI\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc HISTORICAL
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc MIND-NRG\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc PRO FORMA FOR
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc SONKEI
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc MERGER AND
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc MIND-NRG
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs4\b\qc ACQUISITION\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx513\clvertalb\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\cellx1371\clvertalb\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2097\clvertalb\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2823\clvertalb\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3549\clvertalb\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4275\clvertalb\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5001\clvertalb\cellx5243\trrh307\row}}}
{\trowd\trqc\clvertalb\cellx513\clvertalb\cellx755\clvertalb\cellx5005\clvertalb\cellx5247\trrh77
\pard\plain\intbl\cf1\f52\fs4\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc (in thousands, except share and per share amounts)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx513\clvertalb\cellx755\clvertalb\cellx5005\clvertalb\cellx5247\trrh77\row}}}
{\trowd\trqc\clvertalb\cellx513\clvertalb\cellx755\clvertalb\cellx5005\clvertalb\cellx5247\trrh77
\pard\plain\intbl\cf1\f52\fs4\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs4\b\qc (unaudited)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs4\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx513\clvertalb\cellx755\clvertalb\cellx5005\clvertalb\cellx5247\trrh77\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh123
\pard\plain\intbl\li44\cf1\f52\fs4\b\ql Statement of\plain\intbl\li44\cf1\f52\fs4\b\ql Operations Data:\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh123\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh61
\pard\plain\intbl\li44\cf1\f52\fs4\ql Expenses\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh61\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh123
\pard\plain\intbl\li44\cf1\f52\fs4\ql Research and\plain\intbl\li44\cf1\f52\fs4\ql development\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 708\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 1,497\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (1,126\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 1,079\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 1,218\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 2,297\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh123\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh123
\pard\plain\intbl\li44\cf1\f52\fs4\ql General and\plain\intbl\li44\cf1\f52\fs4\ql administrative\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 2,467\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 233\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 2,700\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 479\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 3,179\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh123\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh12
\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh12\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh77
\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh77\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh61
\pard\plain\intbl\li44\cf1\f52\fs4\ql Total expenses\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 3,175\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 1,730\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr (1,126\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 3,779\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 1,697\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 5,476\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh61\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh184
\pard\plain\intbl\li308\fi-44\cf1\f52\fs4\ql Foreign exchange\plain\intbl\li308\cf1\f52\fs4\ql (gains)/losses and\plain\intbl\li308\cf1\f52\fs4\ql other, net\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 29\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr (4\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 25\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr (32\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr (7\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh184\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh123
\pard\plain\intbl\li308\fi-44\cf1\f52\fs4\ql Interest expense\plain\intbl\li308\cf1\f52\fs4\ql (income), net\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 58\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 15\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 73\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr (1\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 72\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh123\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh12
\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh12\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh77
\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh77\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh61
\pard\plain\intbl\li44\cf1\f52\fs4\ql Net loss\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (3,262\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (1,741\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr 1,126\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (3,877\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (1,664\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (5,541\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh61\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh12
\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh12\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh77
\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh77\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh77
\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs6\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh77\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh12
\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell\pard\plain\intbl\cf1\f52\fs0\qr \~\cell\pard\plain\intbl\cf1\f52\fs0\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh12\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh61
\pard\plain\intbl\li44\cf1\f52\fs4\b\ql Per Share Data:\plain\intbl\li44\cf1\f52\fs3\b\ql (1)\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh61\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh184
\pard\plain\intbl\li44\cf1\f52\fs4\ql Net loss per\plain\intbl\li44\cf1\f52\fs4\ql share\~\u8212? basic\plain\intbl\li44\cf1\f52\fs4\ql and diluted\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (0.78\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr $\cell\pard\plain\intbl\cf1\f52\fs4\qr (0.75\cell\pard\plain\intbl\cf1\f52\fs4\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx513\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx755\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1063\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1371\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1613\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1855\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2097\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2339\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2581\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2823\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3065\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3307\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3549\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3791\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4033\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4275\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4517\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4759\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5001\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5243\trrh184\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh245
\pard\plain\intbl\li44\cf1\f52\fs4\ql Weighted average\plain\intbl\li44\cf1\f52\fs4\ql shares\plain\intbl\li44\cf1\f52\fs4\ql outstanding\~\u8212?\plain\intbl\li44\cf1\f52\fs4\ql basic and diluted\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 4,186,104\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell\pard\plain\intbl\cf1\f52\fs4\qr 7,396,760\cell\pard\plain\intbl\cf1\f52\fs4\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx513\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1063\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1371\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1613\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1855\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2097\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2339\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2581\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2823\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3065\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3307\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3791\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4033\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4275\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4517\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4759\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5001\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5243\trrh245\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\li440\ri220\sb220\sa220\cf1\f52\fs16\i\ql (1)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql Per share data excludes 926,604 shares of non-vested common stock held by one of our stockholders that are not considered\plain\li440\ri220\cf1\f52\fs16\ql outstanding for accounting purposes for the periods presented. See "Management's Discussion and Analysis\~\u8212? Share Repurchase\plain\li440\ri220\cf1\f52\fs16\ql in Settlement of Nonrecourse Notes."\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1533\clvertalc\cellx2213\clvertalc\cellx2911\clvertalc\cellx3609\clvertalc\cellx4289\clvertalc\cellx4969\clvertalc\cellx5649\clvertalc\cellx6329\clvertalc\cellx7009\clvertalc\cellx7689\clvertalc\cellx8369\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1533\clvertalc\cellx2213\clvertalc\cellx2911\clvertalc\cellx3609\clvertalc\cellx4289\clvertalc\cellx4969\clvertalc\cellx5649\clvertalc\cellx6329\clvertalc\cellx7009\clvertalc\cellx7689\clvertalc\cellx8369\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1533\clvertalb\cellx2213\clvertalb\cellx7691\clvertalb\cellx8371\trrh215
\pard\plain\intbl\cf1\f52\fs13\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs13\b\qc THREE MONTHS ENDED MARCH\~31, 2014
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1533\clvertalb\cellx2213\clvertalb\cellx7691\clvertalb\cellx8371\trrh215\row}}}
{\trowd\trqc\clvertalb\cellx1533\clvertalb\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3609\clvertalb\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5649\clvertalb\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7689\clvertalb\cellx8369\trrh1034
\pard\plain\intbl\cf1\f52\fs13\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs13\b\qc HISTORICAL\plain\intbl\cf1\f52\fs13\b\qc MINERVA
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc NEUROSCIENCES,\plain\intbl\cf1\f52\fs13\b\qc INC.\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs13\b\qc HISTORICAL\plain\intbl\cf1\f52\fs13\b\qc MIND-NRG
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc JANUARY 1, 2014\plain\intbl\cf1\f52\fs13\b\qc TO
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc FEBRUARY 11,\plain\intbl\cf1\f52\fs13\b\qc 2014\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc PRO FORMA
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc COMBINED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc FOR MIND-NRG
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs13\b\qc ACQUISITION\cell\pard\plain\intbl\cf1\f52\fs13\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1533\clvertalb\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3609\clvertalb\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5649\clvertalb\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7689\clvertalb\cellx8369\trrh1034\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh345
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\b\ql Statement of\plain\intbl\li154\cf1\f52\fs13\b\ql Operations Data:\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh345\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh172
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql Expenses\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh172\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh345
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql Research and\plain\intbl\li154\cf1\f52\fs13\ql development\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 586\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 151\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr 737\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh345\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh345
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql General and\plain\intbl\li154\cf1\f52\fs13\ql administrative\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 2,037\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 302\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 2,339\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh345\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh32
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh32\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh215
\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh215\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh172
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql Total expenses\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 2,623\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 453\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 3,076\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh172\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh517
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql Foreign exchange\plain\intbl\li154\cf1\f52\fs13\ql (gains)/losses and\plain\intbl\li154\cf1\f52\fs13\ql other, net\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 7\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 7\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh517\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh345
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql Interest expense\plain\intbl\li154\cf1\f52\fs13\ql (income), net\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 308\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 308\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh345\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh32
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh32\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh215
\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh215\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh172
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql Net loss\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr (2,938\cell\pard\plain\intbl\cf1\f52\fs13\ql )\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr (453\cell\pard\plain\intbl\cf1\f52\fs13\ql )\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr (3,391\cell\pard\plain\intbl\cf1\f52\fs13\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh172\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh32
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh32\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh215
\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh215\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh215
\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs17\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh215\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh32
\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell\pard\plain\intbl\cf1\f52\fs2\qr \~\cell\pard\plain\intbl\cf1\f52\fs2\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh32\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh172
\pard\plain\intbl\li198\fi-154\cf1\f52\fs13\b\ql Per Share Data:\plain\intbl\li198\cf1\f52\fs10\b\ql (1)\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh172\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh517
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql Net loss per\plain\intbl\li154\cf1\f52\fs13\ql share\~\u8212? basic\plain\intbl\li154\cf1\f52\fs13\ql and diluted\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr (0.43\cell\pard\plain\intbl\cf1\f52\fs13\ql )\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr $\cell\pard\plain\intbl\cf1\f52\fs13\qr (0.45\cell\pard\plain\intbl\cf1\f52\fs13\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1533\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2213\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2911\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3609\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4289\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4969\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5649\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6329\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7009\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7689\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8369\trrh517\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh689
\pard\plain\intbl\li154\fi-132\cf1\f52\fs13\ql Weighted average\plain\intbl\li154\cf1\f52\fs13\ql shares\plain\intbl\li154\cf1\f52\fs13\ql outstanding\~\u8212?\plain\intbl\li154\cf1\f52\fs13\ql basic and diluted\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 6,902,910\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell\pard\plain\intbl\cf1\f52\fs13\qr 7,594,321\cell\pard\plain\intbl\cf1\f52\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2213\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2911\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3609\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4289\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4969\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5649\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6329\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7009\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7689\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8369\trrh689\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\li440\ri220\sb220\sa220\cf1\f52\fs16\i\ql (1)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql Per share data excludes 926,604 shares of non-vested common stock held by one of our stockholders that are not considered\plain\li440\ri220\cf1\f52\fs16\ql outstanding for accounting purposes for the periods presented. See "Management's Discussion and Analysis\~\u8212? Share Repurchase\plain\li440\ri220\cf1\f52\fs16\ql in Settlement of Nonrecourse Notes."\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 63\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dk48001_1_64}{\*\bkmkend gmnh1page_dk48001_1_64}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql MINERVA NEUROSCIENCES, INC\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql 1. Basis of Presentation and Description of Transactions\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The historical Minerva statement of operations data for the year ended December\~31, 2013 are derived from our audited financial statements\plain\cf1\f52\fs16\ql included elsewhere in this prospectus. The historical Minerva statement of operations data for the three months ended March\~31, 2014 are\plain\cf1\f52\fs16\ql derived from our unaudited financial statements included elsewhere in this prospectus.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql Effective November\~12, 2013, we acquired all of the outstanding shares of Sonkei in the Sonkei Merger, a transaction\plain\cf1\f52\fs16\ql accounted for as a business combination, which was financed through the issuance of 2,423,368 shares of common\plain\cf1\f52\fs16\ql stock. Since the balance sheet of Sonkei is already included in our balance sheet at March\~31, 2014, there is no pro\plain\cf1\f52\fs16\ql forma balance sheet presentation applicable. However, the unaudited pro forma condensed combined statement of\plain\cf1\f52\fs16\ql operations for the year ended December\~31, 2013 reflects the accounts of Sonkei prior to the Sonkei Merger.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql In February 2014, we acquired all of the outstanding common and preferred stock of Mind-NRG in the Mind-NRG\plain\cf1\f52\fs16\ql Acquisition, a transaction accounted for as a business combination, which was financed through the issuance of\plain\cf1\f52\fs16\ql 1,481,583 shares of our common stock (which includes 148,160 shares held in escrow until the expiration of the hold\plain\cf1\f52\fs16\ql back period, February\~11, 2015). See Note\~3 to our March\~31, 2014 consolidated financial statements included elsewhere\plain\cf1\f52\fs16\ql in this prospectus. Since the balance sheet of Mind-NRG is already included in our balance sheet of March\~31, 2014,\plain\cf1\f52\fs16\ql there is no pro forma balance sheet presentation applicable. However, the unaudited pro forma condensed combined\plain\cf1\f52\fs16\ql statement of operations for the year ended December\~31, 2013 and the three months ended March\~31, 2014 reflect the\plain\cf1\f52\fs16\ql accounts of Mind-NRG prior to the Mind-NRG Acquisition.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The unaudited pro forma condensed combined financial information also does not give effect to the potential impact of current financial\plain\cf1\f52\fs16\ql conditions, any anticipated synergies, operating efficiencies or cost savings that may result from the above transactions. Further, the\plain\cf1\f52\fs16\ql unaudited pro forma condensed combined financial information does not include any other transactions since March\~31, 2014 or transactions\plain\cf1\f52\fs16\ql that will occur in connection with the closing of this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql 2. Unaudited Pro Forma Condensed Combined Statement of Operations for the Sonkei Merger\~\u8212? Period from January\~1, 2013\plain\cf1\f52\fs16\b\ql to November\~12, 2013\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The historical results of operations required no purchase accounting adjustments to be reflected as if the Sonkei Merger occurred on\plain\cf1\f52\fs16\ql January\~1, 2013 since, based upon our assessment of the assets acquired in the transaction, there were no amortizable intangible assets\plain\cf1\f52\fs16\ql acquired, and there are no other transactions where the fair value was different from the carrying value of the Sonkei assets and liabilities.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Prior to the merger, Sonkei recognized a non-recurring stock-based compensation expense related to a modification of options in\plain\cf1\f52\fs16\ql contemplation of the merger of approximately $1.1\~million. The modification related to common stock held by a consultant (subject to a\plain\cf1\f52\fs16\ql non-recourse promissory note) that is accounted for as a stock option. A change in control provision that would have resulted in the vesting\plain\cf1\f52\fs16\ql of the option was waived by the consultant in contemplation of the Sonkei Merger. The stock-based compensation charge of $1.1\~million\plain\cf1\f52\fs16\ql was recorded in the 2013 results for Sonkei, and represents the value the consultant would have been entitled to if Sonkei and the\plain\cf1\f52\fs16\ql consultant had not waived the change of control provision in the original agreement. Since the pro forma results of operations reflects the\plain\cf1\f52\fs16\ql Sonkei Merger as if it occurred on January\~1, 2013, the charge is adjusted for in the "Adjustment" column and effectively removed from the\plain\cf1\f52\fs16\ql 2013 pro forma condensed combined statement of operations data.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 64\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dk48001_1_65}{\*\bkmkend gmnh1page_dk48001_1_65}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The historical Sonkei results of operations are summarized are follows:\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx834\clvertalc\cellx1312\clvertalc\cellx1790\clvertalc\cellx2268\clvertalc\cellx2746\clvertalc\cellx3224\clvertalc\cellx3702\clvertalc\cellx4180\clvertalc\cellx4658\clvertalc\cellx5136\clvertalc\cellx5614\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx834\clvertalc\cellx1312\clvertalc\cellx1790\clvertalc\cellx2268\clvertalc\cellx2746\clvertalc\cellx3224\clvertalc\cellx3702\clvertalc\cellx4180\clvertalc\cellx4658\clvertalc\cellx5136\clvertalc\cellx5614\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx834\clvertalb\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2269\clvertalb\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3704\clvertalb\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5139\clvertalb\cellx5617\trrh970
\pard\plain\intbl\cf1\f52\fs10\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs9\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs9\b\qc HISTORICAL\plain\intbl\cf1\f52\fs9\b\qc SONKEI FOR\plain\intbl\cf1\f52\fs9\b\qc PERIOD
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs9\b\qc JANUARY\~1, 2013\plain\intbl\cf1\f52\fs9\b\qc TO
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs9\b\qc NOVEMBER\~12,\plain\intbl\cf1\f52\fs9\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs9\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs9\b\qc ADJUSTMENT\cell\pard\plain\intbl\cf1\f52\fs9\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs9\b\qc HISTORICAL\plain\intbl\cf1\f52\fs9\b\qc SONKEI
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs9\b\qc ADJUSTED FOR\plain\intbl\cf1\f52\fs9\b\qc THE PERIOD
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs9\b\qc JANUARY\~1, 2013\plain\intbl\cf1\f52\fs9\b\qc TO
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs9\b\qc NOVEMBER\~12,\plain\intbl\cf1\f52\fs9\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs9\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx834\clvertalb\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2269\clvertalb\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\cellx3704\clvertalb\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5139\clvertalb\cellx5617\trrh970\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1790\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2268\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2746\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3224\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4180\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5136\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5614\trrh126
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\b\ql Expenses\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1790\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2268\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2746\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3224\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4180\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5136\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5614\trrh126\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh253
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Research and\plain\intbl\li198\cf1\f52\fs10\ql development\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr 1,497\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (1,126\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr 371\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh253\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1790\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2268\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2746\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3224\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4180\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5136\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5614\trrh253
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql General and\plain\intbl\li198\cf1\f52\fs10\ql administrative\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 233\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 233\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1790\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2268\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2746\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3224\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4180\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5136\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5614\trrh253\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2269\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5139\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5617\trrh23
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2269\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5139\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5617\trrh23\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh152
\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh152\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh126
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Total expenses\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 1,730\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr (1,126\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 604\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh126\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1790\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2268\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2746\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3224\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4180\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5136\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5614\trrh505
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Foreign\plain\intbl\li198\cf1\f52\fs10\ql exchange\plain\intbl\li198\cf1\f52\fs10\ql (gains)/losses\plain\intbl\li198\cf1\f52\fs10\ql and other, net\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr (4\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr (4\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1790\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2268\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2746\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3224\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4180\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5136\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5614\trrh505\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh253
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Interest expense\plain\intbl\li198\cf1\f52\fs10\ql (income), net\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 15\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr 15\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh253\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2269\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5139\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5617\trrh23
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2269\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5139\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5617\trrh23\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh152
\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh152\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1790\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2268\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2746\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3224\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4180\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5136\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5614\trrh126
\pard\plain\intbl\li198\fi-110\cf1\f52\fs10\ql Net loss\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (1,741\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr 1,126\cell\pard\plain\intbl\cf1\f52\fs10\ql \~\cell\pard\plain\intbl\cf1\f52\fs10\qr $\cell\pard\plain\intbl\cf1\f52\fs10\qr (615\cell\pard\plain\intbl\cf1\f52\fs10\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1790\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2268\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2746\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3224\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3702\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4180\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4658\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5136\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5614\trrh126\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2269\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5139\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5617\trrh23
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2269\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5139\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5617\trrh23\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh152
\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh152\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh152
\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs12\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1790\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2268\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2746\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3224\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3702\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4180\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4658\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5136\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5614\trrh152\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2269\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5139\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5617\trrh23
\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell\pard\plain\intbl\cf1\f52\fs1\qr \~\cell\pard\plain\intbl\cf1\f52\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2269\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2747\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3704\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4182\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5139\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5617\trrh23\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\sa220\cf1\f52\fs16\b\ql 3. Unaudited Pro Forma Condensed Combined Statement of Operations for the Mind-NRG Acquisition\~\u8212? year ended\plain\cf1\f52\fs16\b\ql December\~31, 2013 and three months ended March\~31, 2014\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The historical results of operations did not require purchase accounting adjustments to be reflected as if the Mind-NRG Acquisition occurred\plain\cf1\f52\fs16\ql on January\~1, 2013 since, based upon our assessment of the assets acquired in the transaction, there were no amortizable intangible assets\plain\cf1\f52\fs16\ql acquired, and there are no other transactions where the fair value was different from the carrying value of the Mind-NRG assets and\plain\cf1\f52\fs16\ql liabilities.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The results of operations for the year ended December\~31, 2013 have been translated from the historical financial statements from Euros to\plain\cf1\f52\fs16\ql dollars using average monthly exchange rates of 1.328. Mind-NRG has historically reported its financial results in Euros. As a result of the\plain\cf1\f52\fs16\ql acquisition of Mind-NRG by us in February 2014, the functional currency of Mind-NRG changed to the U.S. Dollar and exchange rate gains\plain\cf1\f52\fs16\ql and losses have been included in the results of operations.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 65\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_66}{\*\bkmkend gmnh1page_dm48001_1_66}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}{\*\bkmkstart dm48001_management_s_discussion_}{\*\bkmkend dm48001_management_s_discussion_}{\*\bkmkstart toc_dm48001_1}{\*\bkmkend toc_dm48001_1}
\par\pard\plain\fs16{\*\bkmkstart item_1_3_6}{\*\bkmkend item_1_3_6}\pard\plain\cf1\f52\fs16\b\qc MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs16\i\ql You should read the following discussion and analysis of our financial condition and results of operations together with "Selected Historical\plain\cf1\f52\fs16\i\ql Financial Data," "Unaudited Pro Forma Condensed Combined Financial Statements" and with the financial statements and related notes\plain\cf1\f52\fs16\i\ql appearing at the end of this prospectus. In addition to historical and pro forma information, some of the information in this discussion and\plain\cf1\f52\fs16\i\ql analysis contains forward-looking statements reflecting our current expectations and involves risk and uncertainties. For example, statements\plain\cf1\f52\fs16\i\ql regarding our expectations as to our plans and strategy for our business, future financial performance, expense levels and liquidity sources\plain\cf1\f52\fs16\i\ql are forward-looking statements. Our actual results and the timing of events could differ materially from those discussed in our\plain\cf1\f52\fs16\i\ql forward-looking statements as a result of many factors, including those set forth under the "Risk Factors" section and elsewhere in this\plain\cf1\f52\fs16\i\ql prospectus. Please also see the section entitled "Special Note Regarding Forward-Looking Statements."\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Overview\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates\plain\cf1\f52\fs16\ql to treat patients suffering from central nervous system, or CNS, diseases. Leveraging our domain expertise, we have acquired or in-licensed\plain\cf1\f52\fs16\ql four development-stage proprietary compounds that we believe have innovative mechanisms of action with potentially positive therapeutic\plain\cf1\f52\fs16\ql profiles. Our lead product candidates are MIN-101, a compound we are developing for the treatment of patients with schizophrenia, and\plain\cf1\f52\fs16\ql MIN-117, a compound we are developing for the treatment of patients suffering from major depressive disorder, or MDD. In addition, our\plain\cf1\f52\fs16\ql portfolio includes MIN-202, a compound we are co-developing for the treatment of patients suffering from primary and secondary insomnia,\plain\cf1\f52\fs16\ql and MIN-301, a compound we are developing for the treatment of patients suffering from Parkinson's disease. We believe our innovative\plain\cf1\f52\fs16\ql product candidates have significant potential to transform the lives of a large number of affected patients and their families who are currently\plain\cf1\f52\fs16\ql not well-served by available therapies in each of their respective indications.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We exclusively licensed MIN-101 from Mitsubishi Tanabe Pharma Corporation, or MTPC, in 2007 with the rights to develop, sell and import\plain\cf1\f52\fs16\ql MIN-101 globally, excluding most of Asia. In November 2013, we merged with Sonkei Pharmaceuticals\~Inc., or Sonkei, a clinical-stage\plain\cf1\f52\fs16\ql biopharmaceutical company and, in February 2014, we acquired Mind-NRG\~SA, or Mind-NRG, a pre-clinical-stage biopharmaceutical\plain\cf1\f52\fs16\ql company. We refer to these transactions as the Sonkei Merger and Mind-NRG Acquisition, respectively. Sonkei licensed MIN-117 from\plain\cf1\f52\fs16\ql MTPC in 2008 with the rights to develop, sell and import MIN-117 globally, excluding most of Asia. With the acquisition of Mind-NRG, we\plain\cf1\f52\fs16\ql obtained exclusive rights to develop and commercialize MIN-301. We have also entered into a co-development and license agreement with\plain\cf1\f52\fs16\ql Janssen for the exclusive rights to develop and commercialize MIN-202 in the European Union, subject to royalty payments to Janssen, and\plain\cf1\f52\fs16\ql royalty rights for any sales outside the European Union, and will obtain such rights upon the closing of this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have not received regulatory approvals to sell any of our product candidates, and we have not generated any revenue from the sales or\plain\cf1\f52\fs16\ql license of our product candidates. We have incurred significant operating losses since inception. In addition, neither Sonkei nor Mind-NRG\plain\cf1\f52\fs16\ql have received any regulatory approvals to sell any product candidates and have also incurred significant operating losses since their\plain\cf1\f52\fs16\ql respective inceptions in 2008 and 2010.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have financed our operations, including the development of MIN-101, through the sale of common stock and convertible promissory\plain\cf1\f52\fs16\ql notes. Likewise, Sonkei raised capital to fund the development of MIN-117 through the sale of common stock and convertible promissory\plain\cf1\f52\fs16\ql notes. Funds managed by Care Capital and Index Ventures are our principal investors, and were the principal investors of Sonkei, and\plain\cf1\f52\fs16\ql collectively owned approximately 76% of our capital stock at March\~31, 2014. The operations of Mind-NRG were financed through the sale\plain\cf1\f52\fs16\ql of preferred stock. Funds managed by Index Ventures were among the investors in Mind-NRG.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 66\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_67}{\*\bkmkend gmnh1page_dm48001_1_67}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql For the year ended December\~31, 2013, we reported a net loss of $3.3\~million and a combined pro forma net loss of $5.5\~million, after giving\plain\cf1\f52\fs16\ql effect to the Sonkei Merger and the Mind-NRG Acquisition as if such transactions occurred on January\~1, 2013. For the three months ended\plain\cf1\f52\fs16\ql March\~31, 2014, we reported a net loss of $2.9\~million and a combined pro forma net loss of $3.4\~million after giving effect to the Mind-NRG\plain\cf1\f52\fs16\ql Acquisition as if it occurred on January\~1, 2013. For a description of the combined pro forma adjustments described above, see "Unaudited\plain\cf1\f52\fs16\ql Pro Forma Condensed Combined Financial Statements." We expect to incur net losses and negative cash flow from operating activities for\plain\cf1\f52\fs16\ql the foreseeable future in connection with the clinical development and the potential regulatory approval, infrastructure development and\plain\cf1\f52\fs16\ql commercialization of our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The board of directors managed our company from our inception through November 2013, when we hired our Chief Executive Officer.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Financial Overview\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Presentation\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our results of operations include the accounts of Sonkei from November\~12, 2013 to March\~31, 2014 reflecting the Sonkei Merger which was\plain\cf1\f52\fs16\ql accounted for using the acquisition method. The purchase price of approximately $18.9\~million was primarily assigned to in-process research\plain\cf1\f52\fs16\ql and development of $19.0\~million and goodwill of $7.9\~million, offset by a deferred tax liability of $7.6\~million. On the effective date of the\plain\cf1\f52\fs16\ql Sonkei Merger, Sonkei had no employees and minimal clinical activity.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Our results also include the accounts of Mind-NRG from February\~12, 2014 to March\~31, 2014, reflecting the Mind-NRG Acquisition, which\plain\cf1\f52\fs16\ql was effective on February\~11, 2014 and accounted for using the acquisition method. The purchase price of approximately $16.5\~million was\plain\cf1\f52\fs16\ql primarily assigned to in-process research and development of $15.2\~million and goodwill of $7.2\~million, offset by a deferred tax liability of\plain\cf1\f52\fs16\ql $6.1\~million. On the effective date of the acquisition, Mind-NRG had no employees and minimal clinical activity.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Revenue\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql None of our product candidates have been approved for commercialization and we have not received any revenue in connection with the\plain\cf1\f52\fs16\ql sale or license of our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Research and Development Expense\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Research and development expense consists of costs incurred in connection with the development of our product candidates, including:\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql fees paid to consultants and clinical research organizations, or CROs, including in connection with our non-clinical and\plain\cf1\f52\fs16\ql clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical\plain\cf1\f52\fs16\ql trial database management, clinical trial material management and statistical compilation and analysis;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql licensing fees;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql costs related to acquiring clinical trial materials;
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql costs related to compliance with regulatory requirements; and
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\cf1\f52\fs20\i\ql \u8226?\par\pard\plain\cf1\f52\fs16\ql costs related to salaries, bonuses and stock-based compensation granted to consultants in research and development\plain\cf1\f52\fs16\ql functions.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 67\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_68}{\*\bkmkend gmnh1page_dm48001_1_68}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We expense research and development costs as they are incurred, and Sonkei and Mind-NRG also expensed research and development\plain\cf1\f52\fs16\ql costs as incurred. The historic costs relating to each of our product candidates are summarized as follows:\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1034\clvertalc\cellx1427\clvertalc\cellx1834\clvertalc\cellx2727\clvertalc\cellx3134\clvertalc\cellx3541\clvertalc\cellx4574\clvertalc\cellx4967\clvertalc\cellx5310\clvertalc\cellx6143\clvertalc\cellx6536\clvertalc\cellx6879\clvertalc\cellx7712\clvertalc\cellx8105\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1034\clvertalc\cellx1427\clvertalc\cellx1834\clvertalc\cellx2727\clvertalc\cellx3134\clvertalc\cellx3541\clvertalc\cellx4574\clvertalc\cellx4967\clvertalc\cellx5310\clvertalc\cellx6143\clvertalc\cellx6536\clvertalc\cellx6879\clvertalc\cellx7712\clvertalc\cellx8105\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1034\clvertalb\cellx1427\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4575\clvertalb\cellx4968\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7715\clvertalb\cellx8108\trrh396
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc YEARS ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc DECEMBER\~31,\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc THREE MONTHS ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc MARCH\~31,\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1034\clvertalb\cellx1427\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4575\clvertalb\cellx4968\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7715\clvertalb\cellx8108\trrh396\row}}}
{\trowd\trqc\clvertalb\cellx1034\clvertalb\cellx1427\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2727\clvertalb\cellx3134\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4574\clvertalb\cellx4967\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6143\clvertalb\cellx6536\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7712\clvertalb\cellx8105\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2012\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2014\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1034\clvertalb\cellx1427\clbrdrb\brdrs\brdrcf1\clvertalb\cellx2727\clvertalb\cellx3134\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4574\clvertalb\cellx4967\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6143\clvertalb\cellx6536\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7712\clvertalb\cellx8105\trrh248\row}}}
{\trowd\trqc\clvertalb\cellx1034\clvertalb\cellx1427\clvertalb\cellx7716\clvertalb\cellx8109\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc (dollars in thousands)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1034\clvertalb\cellx1427\clvertalb\cellx7716\clvertalb\cellx8109\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1034\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1427\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2727\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3134\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3541\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4574\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4967\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5310\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6143\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6536\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6879\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8105\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\b\ql MIN-101\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 550\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 706\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 104\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 81\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1034\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1427\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2727\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3134\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3541\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4574\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4967\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5310\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6143\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6536\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6879\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8105\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1034\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1427\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2727\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3134\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3541\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4574\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4967\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5310\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6143\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6536\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6879\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8105\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\b\ql MIN-117\plain\intbl\li198\cf1\f52\fs11\b\ql\super (1)\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 486\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 472\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 43\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 232\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1034\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1427\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1834\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2727\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3134\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3541\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4574\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4967\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5310\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6143\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6536\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6879\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7712\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx8105\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1034\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1427\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2727\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3134\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3541\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4574\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4967\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5310\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6143\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6536\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6879\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8105\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\b\ql MIN-301\plain\intbl\li198\cf1\f52\fs11\b\ql\super (2)\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 635\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 1,218\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 188\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 381\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1034\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1427\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1834\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2727\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3134\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3541\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4574\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4967\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5310\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6143\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6536\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6879\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7712\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8105\trrh206\row}}}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\li440\ri220\sb220\sa220\cf1\f52\fs12\i\ql (1)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql The research and development expense for MIN-117 for the year ended December\~31, 2012 was derived from Sonkei's\plain\li440\ri220\cf1\f52\fs16\ql historical audited financial statements. The expense for the three months ended March\~31, 2013 was derived from\plain\li440\ri220\cf1\f52\fs16\ql Sonkei's unaudited financial statements. The expense for the year ended December\~31, 2013 was derived from a\plain\li440\ri220\cf1\f52\fs16\ql combination of Sonkei's unaudited financial statements up to the date of the Sonkei Merger, and our financial statements\plain\li440\ri220\cf1\f52\fs16\ql subsequent to the Sonkei Merger. The expense for the three months ended March\~31, 2014 is from our unaudited\plain\li440\ri220\cf1\f52\fs16\ql financial statements for the three months ended March\~31, 2014.
\par\pard\plain\fs16
\par\pard\plain\fs16\par\pard\plain\li440\ri220\cf1\f52\fs12\i\ql (2)\par\pard\plain\li440\ri220\cf1\f52\fs16\ql The research and development expense for MIN-301 for the years ended December\~31, 2012 and 2013 was derived from\plain\li440\ri220\cf1\f52\fs16\ql the Mind-NRG audited financial statements included elsewhere in this prospectus, as converted in U.S. dollars using the\plain\li440\ri220\cf1\f52\fs16\ql average exchange rate over the periods presented, which was 1.2858 and 1.328 for the years ended December\~31, 2012\plain\li440\ri220\cf1\f52\fs16\ql and 2013, respectively. Mind-NRG has historically reported its financial results in Euros. As a result of the acquisition of\plain\li440\ri220\cf1\f52\fs16\ql Mind-NRG by us in February 2014, the functional currency of Mind-NRG changed to the U.S. Dollar and exchange rate\plain\li440\ri220\cf1\f52\fs16\ql gains and losses have been included in the results of operations. The expense for the three months ended March\~31,\plain\li440\ri220\cf1\f52\fs16\ql 2013 was derived from Mind-NRG's unaudited financial statements, as converted in U.S. dollars using the average\plain\li440\ri220\cf1\f52\fs16\ql exchange rate over the period presented, which was 1.0752. The expense for the three months ended March\~31, 2014\plain\li440\ri220\cf1\f52\fs16\ql was derived from a combination of Mind-NRG's unaudited financial statements up to the date of the Mind-NRG\plain\li440\ri220\cf1\f52\fs16\ql Acquisition, as converted in U.S. dollars using the average exchange rate of 1.1076, and our financial statements\plain\li440\ri220\cf1\f52\fs16\ql subsequent to the Mind-NRG Acquisition.\par\pard\plain\f0\fs16\par\pard\plain\sa220\cf1\f52\fs16\ql In the future, we expect research and development expense to consist of the items described above as well as expense incurred in\plain\cf1\f52\fs16\ql performing research and development activities, including compensation and benefits for full-time research and development employees,\plain\cf1\f52\fs16\ql facilities expenses and overhead expenses.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We expect research and development expense to be our largest category of operating expense and to increase as we continue our planned\plain\cf1\f52\fs16\ql pre-clinical and clinical trials for our product candidates, including MIN-202 (which we licensed from Janssen subject to the completion of\plain\cf1\f52\fs16\ql this offering). Please see "Business\~\u8212? Our Pipeline" for additional details regarding our current plan for progressing clinical trials of our\plain\cf1\f52\fs16\ql product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate we will\plain\cf1\f52\fs16\ql make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to\plain\cf1\f52\fs16\ql the scientific and clinical success or failure of each product candidate, as well as an ongoing assessment as to each product candidate's\plain\cf1\f52\fs16\ql commercial potential. We will need to raise additional capital or may seek additional product collaborations in the future in order to complete\plain\cf1\f52\fs16\ql the development and commercialization of our product candidates.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql General and Administrative Expenses\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql General and administrative expenses consist principally of consulting and professional services costs for functions in executive, finance,\plain\cf1\f52\fs16\ql business development, legal, auditing and taxes. Historically, substantially all of these services were provided by third party consultants, as\plain\cf1\f52\fs16\ql none of the three companies had employees in 2011 through October 2013. Our general and administrative expense in 2012, 2013 and\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 68\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_69}{\*\bkmkend gmnh1page_dm48001_1_69}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql 2014 also includes stock-based compensation expense with respect to option and warrant grants to such consultants and employees hired\plain\cf1\f52\fs16\ql and directors who joined our board subsequent to October 2013.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In the future, we expect general and administrative expenses to consist primarily of salaries and related benefits, including stock-based\plain\cf1\f52\fs16\ql compensation, related to our executive, finance and support functions. Other general and administrative expenses include allocated\plain\cf1\f52\fs16\ql facility-related costs not otherwise included in research and development expenses, travel expenses and professional fees for auditing, tax\plain\cf1\f52\fs16\ql and legal services.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We expect that general and administrative expenses will increase as a result of merging with Sonkei, the acquisition of Mind-NRG and\plain\cf1\f52\fs16\ql licensing MIN-202 from Janssen. In addition, we anticipate that following the completion of this offering, we expect to incur greater expenses\plain\cf1\f52\fs16\ql relating to our operations as a public reporting company, including increased payroll and increased consulting, legal and compliance,\plain\cf1\f52\fs16\ql accounting, insurance and investor relations costs.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Foreign Exchange (Gains)/Losses and Other, Net\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Foreign exchange (gains)/losses and other, net has been primarily comprised of interest income and foreign currency exchange gains or\plain\cf1\f52\fs16\ql losses resulting from clinical trial expenses denominated in Euros. We will incur interest expense on our outstanding convertible promissory\plain\cf1\f52\fs16\ql notes issued by us in November 2013 and assumed by us in the Sonkei Merger as well as our outstanding debt assumed in connection\plain\cf1\f52\fs16\ql with the Mind-NRG Acquisition. These notes and the accrued interest will convert into common stock upon the closing of this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Other than general and administrative expenses and interest expense, we have incurred certain expenses in Euros, which includes, research\plain\cf1\f52\fs16\ql and development expenses. Since our initial planned clinical trials are expected to be in Europe, we expect to continue to incur expenses in\plain\cf1\f52\fs16\ql Euros. We record expenses in U.S. dollars at the time the liability is incurred. Changes in the applicable foreign currency rate between the\plain\cf1\f52\fs16\ql date an expense is recorded and the payment date is recorded as a foreign currency gain or loss.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Net Operating Losses and Tax Carryforwards\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql As of December\~31, 2013, we had approximately $16.0\~million of federal net operating loss carryforwards. These federal net operating loss\plain\cf1\f52\fs16\ql carryforwards will begin to expire at various dates beginning in\~2028, if not utilized. As of December\~31, 2013, we had approximately\plain\cf1\f52\fs16\ql $11.0\~million of state net operating loss carryforwards. These state net operating loss carryforwards will begin to expire at various dates\plain\cf1\f52\fs16\ql beginning in 2014, if not utilized.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The Internal Revenue Code, or IRC, limits the amounts of net operating loss carryforwards that a company may use in any one year in the\plain\cf1\f52\fs16\ql event of certain cumulative changes in ownership over a three-year period as described in Section\~382 of the IRC. We do not believe an\plain\cf1\f52\fs16\ql ownership change had occurred through December\~31, 2013. We have not performed a detailed analysis to determine whether an ownership\plain\cf1\f52\fs16\ql change occurred upon consummation of the merger between us and Sonkei or the acquisition of Mind-NRG. However, as a result of these\plain\cf1\f52\fs16\ql transactions and the shares to be issued to JJDC or shareholders of Mind-NRG in concurrent private placements in connection with this\plain\cf1\f52\fs16\ql offering, it is likely that an ownership change would occur or has occurred and such an ownership change could also be triggered by\plain\cf1\f52\fs16\ql subsequent sales of securities by us or our stockholders. Such a change in ownership would limit the utilization of our net operating losses.\plain\cf1\f52\fs16\ql As a result, we may not be able to take full advantage of these tax carryforwards for federal tax purposes.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Costs Associated with the Acquisitions and Financings\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We incurred legal and other professional fees associated with the acquisition of Sonkei and Mind-NRG, which costs are expensed as\plain\cf1\f52\fs16\ql incurred. We also incurred professional fees associated with entering into the co-development and licensing agreement with Janssen,\plain\cf1\f52\fs16\ql engaging valuation specialists, and preparing this registration statement to support such activities. Through March\~31, 2014, such costs were\plain\cf1\f52\fs16\ql approximately $3.6\~million. Such costs are expected to significantly increase for us for the three month period ending June\~30, 2014.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 69\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_70}{\*\bkmkend gmnh1page_dm48001_1_70}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql On November\~12, 2013, Cyrenaic Pharmaceuticals, Inc., or Cyrenaic, merged with Sonkei, with Cyrenaic being the surviving company, which\plain\cf1\f52\fs16\ql was renamed Minerva. In the merger, each share of Sonkei common stock was converted into 0.383 shares of Cyrenaic common stock,\plain\cf1\f52\fs16\ql resulting in the issuance of 2,423,368 shares of Cyrenaic common stock to the former Sonkei stockholders. Although there were certain\plain\cf1\f52\fs16\ql venture funds that were common stockholders of each of Sonkei and Cyrenaic, since the underlying investors in the venture funds were not\plain\cf1\f52\fs16\ql "substantially similar", the merger was accounted for a business combination with Cyrenaic being treated as the acquirer. The results of\plain\cf1\f52\fs16\ql Sonkei are included in our accompanying financial statements commencing November\~12, 2013. We merged with Sonkei in order to acquire\plain\cf1\f52\fs16\ql Sonkei's lead product candidate, MIN-117.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql At the date of the merger, a Sonkei consultant held 1,112,500 shares of Sonkei common stock with a nonrecourse note due to Sonkei,\plain\cf1\f52\fs16\ql which was being treated as a stock option for accounting purposes. In connection with the merger, we issued 426,176 shares of common\plain\cf1\f52\fs16\ql stock to this consultant (discussed further in Note\~8\~\u8212? Stockholders' Equity to our December\~31, 2013 financial statements appearing\plain\cf1\f52\fs16\ql elsewhere in this prospectus) in order to replace the holder's common stock in Sonkei. Due to the nonrecourse note, these shares are\plain\cf1\f52\fs16\ql treated as stock options for accounting purposes and the holder of the option could only vest in the stock options if the holder continues to\plain\cf1\f52\fs16\ql provide services to us through the time of a change in control. As a change in control was not deemed probable as of the merger date, the\plain\cf1\f52\fs16\ql value of the options have not been included as part of the consideration transferred in the merger for accounting purposes. Rather, we will\plain\cf1\f52\fs16\ql recognize all of the compensation expense for these stock options in our statement of operations upon the closing of this offering. The\plain\cf1\f52\fs16\ql merger accounting purchase price was therefore determined based upon the remaining 1,997,192 shares of common stock issued in the\plain\cf1\f52\fs16\ql merger at a valuation of $9.49 per share for a total purchase price of approximately $18.9\~million. Merger expenses of $14\~thousand were\plain\cf1\f52\fs16\ql included in general and administrative expenses for the year ended December\~31, 2013.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The fair value of our common stock issued in the merger was determined based on a number of objective and subjective factors, including\plain\cf1\f52\fs16\ql external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event,\plain\cf1\f52\fs16\ql such as an initial public offering of common stock or our sale. Substantially all of the purchase price was allocated to in-process research\plain\cf1\f52\fs16\ql and development and goodwill. As part of the acquisition, we also assumed \u8364?0.5\~million (or $0.7\~million, as converted) of convertible\plain\cf1\f52\fs16\ql notes, which have a stated interest rate of 8%. Upon completion of this offering, the outstanding principal balance of the notes and accrued\plain\cf1\f52\fs16\ql but unpaid interest thereon will convert into common stock at a conversion price equal to the price per share set forth on the cover of this\plain\cf1\f52\fs16\ql prospectus.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We acquired Mind-NRG in February 2014, and the fair value of the 1,481,583 shares of common stock issued to the stockholders of\plain\cf1\f52\fs16\ql Mind-NRG was approximately $16.5\~million. The fair value of the common shares issued and the allocation of the purchase price was based\plain\cf1\f52\fs16\ql upon our valuation of our common stock as approved by our board of directors. Substantially all of the purchase price was allocated to\plain\cf1\f52\fs16\ql in-process research and development and goodwill. In connection with the acquisition, we entered into loan agreements for working capital\plain\cf1\f52\fs16\ql up to a maximum of $0.6\~million. The Mind-NRG loans have an interest rate of 8% per annum that is added to the principal. The\plain\cf1\f52\fs16\ql Mind-NRG loans, including accrued interest, were repaid in full in April 2014 for $0.5\~million. We subsequently entered into two loan\plain\cf1\f52\fs16\ql agreements for $0.6\~million and $1.0\~million, the April Bridge Loan and the May Bridge Loan, respectively. As part of the Mind-NRG\plain\cf1\f52\fs16\ql Acquisition, we have agreed to pay ProteoSys a final license payment of \u8364?0.5\~million (or $0.7\~million, as converted) upon the closing\plain\cf1\f52\fs16\ql of this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Results of Operations\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The following discussion relates to our results of operations without giving effect to the results of Sonkei prior to the Sonkei Merger, the\plain\cf1\f52\fs16\ql results of Mind-NRG prior to the Mind-NRG Acquisition or any of the transactions occurring at the closing of this offering. Please see\plain\cf1\f52\fs16\ql "Unaudited Pro Forma Condensed Consolidated Financial Statements" and the Sonkei and Mind-NRG financial statements included\plain\cf1\f52\fs16\ql elsewhere in this prospectus. The below results also exclude the accounting consequences of 926,604 shares of\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 70\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_71}{\*\bkmkend gmnh1page_dm48001_1_71}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql common stock that are considered non-vested stock for accounting purposes held by a consultant that will vest upon the closing of this\plain\cf1\f52\fs16\ql offering, for which we will incur a charge of approximately $10.5\~million for stock-based compensation upon the closing of this offering, equal\plain\cf1\f52\fs16\ql to 926,604 shares multiplied by the fair value per share on May\~1, 2014, the date the consultant became an employee, less previous\plain\cf1\f52\fs16\ql compensation expense recorded.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Comparison of the Years Ended December\~31, 2012 and December\~31, 2013\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1552\clvertalc\cellx2373\clvertalc\cellx3194\clvertalc\cellx4252\clvertalc\cellx5073\clvertalc\cellx5894\clvertalc\cellx6952\clvertalc\cellx7773\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1552\clvertalc\cellx2373\clvertalc\cellx3194\clvertalc\cellx4252\clvertalc\cellx5073\clvertalc\cellx5894\clvertalc\cellx6952\clvertalc\cellx7773\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1552\clvertalb\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6953\clvertalb\cellx7774\trrh396
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc YEARS ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc DECEMBER\~31,\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1552\clvertalb\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6953\clvertalb\cellx7774\trrh396\row}}}
{\trowd\trqc\clvertalb\cellx1552\clvertalb\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4252\clvertalb\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6952\clvertalb\cellx7773\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2012\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1552\clvertalb\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4252\clvertalb\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6952\clvertalb\cellx7773\trrh248\row}}}
{\trowd\trqc\clvertalb\cellx1552\clvertalb\cellx2373\clvertalb\cellx6953\clvertalb\cellx7774\trrh445
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc (dollars in
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc thousands)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1552\clvertalb\cellx2373\clvertalb\cellx6953\clvertalb\cellx7774\trrh445\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1552\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2373\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3194\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4252\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5073\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5894\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7773\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Expenses\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1552\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2373\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3194\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4252\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5073\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5894\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7773\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh412
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Research and\plain\intbl\li396\cf1\f52\fs16\ql development\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 550\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 708\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh412\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1552\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2373\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3194\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4252\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5073\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5894\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7773\trrh412
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql General and\plain\intbl\li396\cf1\f52\fs16\ql administrative\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 1,031\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 2,467\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1552\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2373\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3194\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4252\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5073\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5894\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7773\trrh412\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Total expenses\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 1,581\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 3,175\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1552\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2373\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3194\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4252\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5073\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5894\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7773\trrh825
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Foreign\plain\intbl\li396\cf1\f52\fs16\ql exchange\plain\intbl\li396\cf1\f52\fs16\ql (gains)/losses\plain\intbl\li396\cf1\f52\fs16\ql and other, net\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 1\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 29\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1552\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2373\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3194\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4252\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5073\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5894\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7773\trrh825\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh413
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Interest expense,\plain\intbl\li396\cf1\f52\fs16\ql net\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 58\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh413\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1552\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2373\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3194\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4252\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5073\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5894\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7773\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Net loss\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr (1,582\cell\pard\plain\intbl\cf1\f52\fs16\ql )\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr (3,262\cell\pard\plain\intbl\cf1\f52\fs16\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1552\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2373\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3194\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4252\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5073\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5894\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7773\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3194\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5894\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1552\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2373\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4252\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5073\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6952\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7773\trrh37\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\cf1\f52\fs16\i\ql Research and Development Expenses\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Research and development expenses were $0.7\~million for the year ended December\~31, 2013 compared to $0.6\~million for the same period\plain\cf1\f52\fs16\ql in 2012, an increase of $0.1\~million, or 17%. This increase was principally attributable to higher costs paid to regulatory consultants in 2013\plain\cf1\f52\fs16\ql as compared to the 2012 period.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\ql General and Administrative Expenses\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql General and administrative expenses were $2.5\~million for the year ended December\~31, 2013 compared to $1.0\~million for the same period\plain\cf1\f52\fs16\ql in 2012, representing an increase of approximately $1.5\~million or 138%. The increase was due primarily to higher legal and professional\plain\cf1\f52\fs16\ql fees in 2013 related to: (i)\~the Sonkei Merger in November 2013, (ii)\~the Mind-NRG Acquisition in February 2014, (iii)\~legal fees associated\plain\cf1\f52\fs16\ql with the Janssen license agreement, (iv)\~intellectual property expenses and (v)\~costs associated with preparing for our operation as a public\plain\cf1\f52\fs16\ql reporting company.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\ql Foreign Exchange (Gains)/Losses and Other, Net\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Foreign exchange (gains)/losses and other, net was a loss of $29\~thousand for the year ended December\~31, 2013 compared to a loss of\plain\cf1\f52\fs16\ql $1\~thousand for the same period in\~2012. The increase in foreign currency loss was principally due to certain expenses of Sonkei and\plain\cf1\f52\fs16\ql certain clinical activities being denominated in Euros, with more negative currency movements in 2013.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\ql Interest Expense, net\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Interest expense, net was $58\~thousand of expense for the year ended December\~31, 2013. This expense relates to the interest expense for\plain\cf1\f52\fs16\ql the convertible promissory notes issued or assumed in November\~2013, including $36\~thousand for the amortization of the debt discount and\plain\cf1\f52\fs16\ql $23\~thousand in accrued interest expense.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 71\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_72}{\*\bkmkend gmnh1page_dm48001_1_72}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Comparison of the Three Months Ended March\~31, 2013 and March\~31, 2014\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1582\clvertalc\cellx2432\clvertalc\cellx3282\clvertalc\cellx4132\clvertalc\cellx4982\clvertalc\cellx5832\clvertalc\cellx6920\clvertalc\cellx7770\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx1582\clvertalc\cellx2432\clvertalc\cellx3282\clvertalc\cellx4132\clvertalc\cellx4982\clvertalc\cellx5832\clvertalc\cellx6920\clvertalc\cellx7770\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx1582\clvertalb\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6923\clvertalb\cellx7773\trrh396
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc THREE MONTHS ENDED
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf1\f52\fs16\b\qc MARCH 31,\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1582\clvertalb\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6923\clvertalb\cellx7773\trrh396\row}}}
{\trowd\trqc\clvertalb\cellx1582\clvertalb\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4133\clvertalb\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6922\clvertalb\cellx7772\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2013\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc 2014\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1582\clvertalb\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4133\clvertalb\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6922\clvertalb\cellx7772\trrh248\row}}}
{\trowd\trqc\clvertalb\cellx1582\clvertalb\cellx2432\clvertalb\cellx6923\clvertalb\cellx7773\trrh248
\pard\plain\intbl\cf1\f52\fs16\b\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell\pard\plain\intbl\cf1\f52\fs16\b\qc (dollars in thousands)
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f52\fs16\b\qc \~\cell{
{\trowd\trqc\clvertalb\cellx1582\clvertalb\cellx2432\clvertalb\cellx6923\clvertalb\cellx7773\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1582\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2432\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4982\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5832\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6920\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7770\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Expenses\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1582\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2432\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4982\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5832\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6920\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7770\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh412
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Research and\plain\intbl\li396\cf1\f52\fs16\ql development\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 104\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr 586\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh412\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1582\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2432\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4982\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5832\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6920\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7770\trrh412
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql General and\plain\intbl\li396\cf1\f52\fs16\ql administrative\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 167\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 2,037\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1582\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2432\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4982\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5832\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6920\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7770\trrh412\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4133\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7772\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4133\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7772\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Total expenses\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 271\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 2,623\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1582\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2432\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4982\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5832\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6920\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7770\trrh412
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Foreign exchange\plain\intbl\li396\cf1\f52\fs16\ql losses\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 6\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1582\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2432\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4982\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5832\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6920\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7770\trrh412\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh412
\pard\plain\intbl\li396\fi-198\cf1\f52\fs16\ql Interest expense,\plain\intbl\li396\cf1\f52\fs16\ql net\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr \u8212?\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr 309\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh412\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4133\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7772\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4133\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7772\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1582\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2432\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4982\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5832\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6920\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7770\trrh206
\pard\plain\intbl\li198\fi-198\cf1\f52\fs16\ql Net loss\cell\pard\plain\intbl\cf1\f52\fs16\ql \~\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr (271\cell\pard\plain\intbl\cf1\f52\fs16\ql )\cell\pard\plain\intbl\cf1\f52\fs16\qr $\cell\pard\plain\intbl\cf1\f52\fs16\qr (2,938\cell\pard\plain\intbl\cf1\f52\fs16\ql )\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx1582\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx2432\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4132\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4982\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5832\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6920\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7770\trrh206\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4133\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7772\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4133\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7772\trrh37\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh248
\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\qr \u8203?\cell\pard\plain\intbl\cf1\f52\fs20\ql \u8203?\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx3282\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4132\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4982\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx5832\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6920\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7770\trrh248\row}}}
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4133\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7772\trrh37
\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell\pard\plain\intbl\cf1\f52\fs3\qr \~\cell\pard\plain\intbl\cf1\f52\fs3\ql \~\cell{
{\trowd\trqc\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx1582\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx2432\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4133\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx4983\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx6922\clvertalb\clshdng100\clcfpat7\clcbpat7\cellx7772\trrh37\row}}}\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\pard\plain\cf1\f52\fs16\i\ql Research and Development Expenses\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Research and development expenses were $0.6\~million for the three months ended March\~31, 2014 compared to $0.1\~million for the same\plain\cf1\f52\fs16\ql period in 2013, an increase of $0.5\~million. This increase was principally attributable to higher drug development program costs due to the\plain\cf1\f52\fs16\ql addition of MIN-117 as a result of the Sonkei Merger in November 2013 and the addition of MIN-301 as a result of the Mind-NRG\plain\cf1\f52\fs16\ql Acquisition in February 2014.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\ql General and Administrative Expenses\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql General and administrative expenses were $2.0\~million for the three months ended March\~31, 2014 compared to $0.2\~million for the same\plain\cf1\f52\fs16\ql period in 2013, representing an increase of approximately $1.9\~million. The increase was due primarily to higher legal and professional fees\plain\cf1\f52\fs16\ql in 2014 related to\~the Mind-NRG Acquisition in February 2014, the Janssen license agreement, intellectual property matters and preparing\plain\cf1\f52\fs16\ql for our operation as a public reporting company.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\ql Foreign Exchange Losses\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Foreign exchange losses were $7\~thousand for the three months ended March\~31, 2014 compared to $0 for the same period in 2013. The\plain\cf1\f52\fs16\ql increase in foreign exchange loss was principally due to certain expenses of Mind-NRG and certain clinical activities being denominated in\plain\cf1\f52\fs16\ql Euros, with more negative currency movements in 2014.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\ql Interest Expense, net\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql Interest expense was $0.3\~million for the three months ended March\~31, 2014 compared to $0 for the same period in 2013. This expense\plain\cf1\f52\fs16\ql relates to the interest expense for the convertible promissory notes associated with the beneficial conversion feature of the convertible\plain\cf1\f52\fs16\ql promissory notes issued and assumed in November 2013, including $275\~thousand for the amortization of the debt discount and\plain\cf1\f52\fs16\ql $39\~thousand in accrued interest expense.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The convertible promissory notes contain a beneficial conversion feature which allows noteholders to convert the notes and accrued interest\plain\cf1\f52\fs16\ql into shares of our common stock at a conversion price of $3.50 per common share at any time after April\~30, 2014. On April\~25, 2014, the\plain\cf1\f52\fs16\ql convertible promissory notes were amended to provide for conversion only after September\~30, 2014. The notes will convert into common\plain\cf1\f52\fs16\ql stock at a conversion price equal to the price per share set forth on the cover of this prospectus. The intrinsic value of the beneficial\plain\cf1\f52\fs16\ql conversion feature was calculated by measuring the difference between the effective conversion price and the fair value of the common\plain\cf1\f52\fs16\ql stock at initial recognition. We recorded a debt discount for the intrinsic value of the beneficial conversion feature which was limited to the\plain\cf1\f52\fs16\ql proceeds of the convertible promissory notes received of approximately $2.0\~million, with an offsetting increase to\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 72\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_73}{\*\bkmkend gmnh1page_dm48001_1_73}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql additional paid-in capital. The discount is being amortized to interest expense using the effective interest method through the notes' maturity\plain\cf1\f52\fs16\ql date of June\~30, 2014. This will result in noncash interest expense of approximately $2.0\~million in 2014.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\ql Liquidity and Capital Resources\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Sources of Liquidity\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have incurred losses and cumulative negative cash flows from operations since our inception in April 2007 and, as of March\~31, 2014,\plain\cf1\f52\fs16\ql we had an accumulated deficit of approximately $20.8\~million. We anticipate that we will continue to incur net losses for the foreseeable\plain\cf1\f52\fs16\ql future as we continue the development and potential commercialization of our product candidates and incur additional costs associated with\plain\cf1\f52\fs16\ql being a public company. At March\~31, 2014, we had $2.1\~million in cash and cash equivalents.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql We have raised capital to fund the development of MIN-101 primarily through common stock financings. From 2007 through 2013, we sold\plain\cf1\f52\fs16\ql shares of common stock at $3.50 per share over several closings to funds managed by Care Capital and Index Ventures in equal proportion\plain\cf1\f52\fs16\ql pursuant to a Stock Purchase Agreement among the stockholders. The stock purchase agreement provided for several closings of the stock\plain\cf1\f52\fs16\ql purchase depending on the success of clinical milestones. From 2007 through 2012 and from January\~1 through December\~31, 2013, we\plain\cf1\f52\fs16\ql raised approximately $12.1\~million and $1.9\~million, respectively, through the sale of shares of common stock.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\ql Convertible Promissory Notes\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql During November 2013, we issued convertible promissory notes for approximately $1.3\~million in aggregate to certain stockholders which are\plain\cf1\f52\fs16\ql payable by us on June\~30, 2014. The notes have a stated interest rate of 8% per annum. Upon completion of this offering, the outstanding\plain\cf1\f52\fs16\ql principal balance of the notes and accrued but unpaid interest thereon will convert into the common stock sold in this offering at a\plain\cf1\f52\fs16\ql conversion price equal to the price per share set forth on the cover of this prospectus.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql During November 2013, prior to the merger of Sonkei into us, Sonkei issued convertible promissory notes for \u8364?0.5\~million (or\plain\cf1\f52\fs16\ql $0.7\~million, as converted) in aggregate to certain stockholders which we assumed at the time of the merger with Sonkei and which are\plain\cf1\f52\fs16\ql payable by us on June\~30, 2014. The notes have a stated interest rate of 8% per annum. Upon completion of this offering, the outstanding\plain\cf1\f52\fs16\ql principal balance of the notes and accrued but unpaid interest thereon will convert into the common stock sold in this offering at a\plain\cf1\f52\fs16\ql conversion price equal to the price per share set forth on the cover of this prospectus.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\i\ql Working Capital Loans\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql In February 2014, we entered into loan agreements for working capital up to a maximum of $0.6\~million in connection with the Mind-NRG\plain\cf1\f52\fs16\ql Acquisition. As of March\~31, 2014, the balance outstanding under these loans was $0.5\~million, which were repaid in full with accrued\plain\cf1\f52\fs16\ql interest in April 2014.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql On April\~30, 2014 we entered into the April Bridge Loan with certain stockholders and their affiliates. The April Bridge Loan provides loan\plain\cf1\f52\fs16\ql facilities of $0.6\~million, of which we have drawn $0.6\~million, with an annual interest rate of 8% and is repayable at the time we complete\plain\cf1\f52\fs16\ql this offering or December\~1, 2015. The April Bridge Loan contains standard terms of default, under which the interest rate would increase to\plain\cf1\f52\fs16\ql 11% per annum. Any amount outstanding may be repaid at any time without penalty.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql On May\~22, 2014, we entered into the May Bridge Loan with certain stockholders and their affiliates. The May Bridge Loan provides loan\plain\cf1\f52\fs16\ql facilities up to a maximum of $1.0\~million, of which we have drawn $0.5\~million as of June\~10, 2014, at an annual interest rate of 8% and is\plain\cf1\f52\fs16\ql repayable at the time we complete this offering or December\~1, 2015. The May Bridge Loan contains standard terms of default, under which\plain\cf1\f52\fs16\ql the interest rate would increase to 11% per annum. Any amount outstanding may be repaid at any time without penalty. We expect to draw\plain\cf1\f52\fs16\ql down the remaining $0.5\~million prior to the closing of this offering.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\qc 73\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart gmnh1page_dm48001_1_74}{\*\bkmkend gmnh1page_dm48001_1_74}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "bg48001a_main_toc" }{\*\fldrslt\cf3\f52\fs16\ql Table of Contents}}\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Cash Flows\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\ql The tables below set forth our significant sources and uses of cash for the periods set forth below. The following table and discussion do\plain\cf1\f52\fs16\ql not give effect to any of the transactions occurring at the closing of this offering. Each of these events will occur after March\~31, 2014.\par\pard\plain\f0\fs16\par\pard\plain\cf1\f52\fs16\b\i\ql Comparison of the Years Ended December\~31, 2012 and December\~31, 2013\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\par\pard\plain
{\trowd\trqc\clvertalc\cellx1222\clvertalc\cellx2124\clvertalc\cellx3026\clvertalc\cellx3928\clvertalc\cellx4830\clvertalc\cellx5732\clvertalc\cellx6871\clvertalc\cellx7773\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\c